Landmark EU Vote Demands ‘Only Yes Means Yes’ Rape Law, Targeting Gaps in Survivor Care 01/05/2026 Felix Sassmannshausen Legislators Joanna Scheuring-Wielgus and Evin Incir present the parliament’s demand for a rape law based on an ‘only yes means yes’ principle. STRASBOURG – Amid a global backlash against sexual and reproductive rights, the European Parliament has taken a decisive stand by voting for a unified, human rights-based standard for sexual offences. This Europe-wide legislative push aims to overhaul the fragmented national laws that currently leave many survivors without access to justice or essential health support. The resolution formally urges the European Commission to draft binding laws that recognise rape is fundamentally defined by a lack of consent. This represents a stark departure from outdated national models that require victims to physically fight back or explicitly say no. Swedish lawmaker Evin Incir addresses the European Parliament. “It is both morally and legally unacceptable that women are not protected by ‘only yes means yes’ legislation across the EU,” leading lawmaker Evin Incir from the centre-left social democrats (S&D) declared following the plenary vote on Tuesday. Just hours earlier, the European Parliament had adopted a landmark report with 447 votes in favour, 160 votes against, and 43 abstentions, demanding a unified standard for sexual offences. The push for reform is driven by a societal reckoning, spurred by cases that have sparked international outrage, such as that of Gisèle Pelicot in France. During a high-profile 2024 trial, the public learned that Pelicot’s husband had covertly drugged and raped her over a decade, also inviting dozens of men to rape her while she was unconscious. Human rights baseline: only yes means yes Comparison between outdated force-based legal requirements and the Parliament’s proposed standard of affirmative, voluntary consent. At the core of the European debate is the push for an ‘only yes means yes’ principle to ensure that any sexual act without freely given consent is legally classified as a crime. While a clear verbal “yes” is the most direct method, legal experts emphasise that consent can be expressed in any voluntary and unambiguous way, meaning affirmative gestures or reciprocal actions, depending on the specific context of the relationship. Establishing legislation focused on the lack of consent is widely viewed as the necessary next step to implement the Istanbul Convention. Opened for signature in 2011 and ratified or acceded to by 39 parties, Article 36 of this comprehensive international treaty explicitly requires member states to criminalise all non-consensual sexual acts, setting a clear human rights baseline. A unified legal definition is essential for health policy, as it directly impacts how survivors access emergency contraception, trauma counselling, and forensic medical care. Recognising the health sector’s critical role in this recovery process, the WHO Regional Office for Europe provides health system baseline assessments to help stakeholders monitor member states’ compliance with the Istanbul Convention. The latest comprehensive EU gender-based violence survey reveals that a staggering 30.7% of women across the bloc have experienced physical or sexual violence, which aligns with global data. Crucially, 8.4% of women report being raped while under coercion or being unable to refuse, nearly double the 4.8% who experienced overt physical force. Despite this high prevalence, systemic barriers continue to suppress official reporting and hinder access to post-rape care. Only 13.9% of victims ever contact the police, frequently citing embarrassment, fear of retaliation, or a belief that law enforcement cannot help them as their primary reasons for silence. Acknowledging trauma and fear responses Neurobiological evidence from the Karolinska Institute shows 70% of survivors experience paralysis, supporting calls for an ‘only yes means yes’ approach. A critical aspect of focusing on the lack of consent involves officially recognising the physiological realities of trauma. Medical experts and victim advocates continuously stress that a lack of physical resistance does not equate to a voluntary agreement. Co-rapporteur Joanna Scheuring-Wielgus during the plenary debate. Legislators underscored the neurobiological “freeze” response, where a victim perceives overwhelming danger, and the body is rendered completely paralysed. “It’s important to understand that a victim may not always have the strength to fight, to say no,” Polish co-rapporteur Joanna Scheuring-Wielgus explained at the press conference. While some victims might actively fight back, others can also freeze or faint. A 2017 Swedish study from the Karolinska Institute found that 70% of sexual assault survivors experience significant “tonic immobility,” an involuntary, temporary state of motor inhibition triggered by intense fear. Current legal systems in several member states routinely dismiss cases where victims experienced this involuntary physiological paralysis, which the European Parliament notes causes severe secondary victimisation. Furthermore, victim support networks like Women Against Violence in Europe (WAVE) warn that failing to provide trauma-informed, gender-specific responses deters survivors from seeking essential medical and psychological support. Implementing laws based on an ‘only yes means yes’ principle would mandate that judges and law enforcement officials understand these complex trauma responses. Policy analysts argue this shift is vital for building trust in public institutions and ensuring that victims feel safe enough to access specialised healthcare services. Fractured legal landscape leaves survivors vulnerable German legal barriers create a stark gap between rising rape reports and actual criminal convictions. The contrast between different national models highlights why European lawmakers are demanding unified rules. In Germany, the current framework dictates that a victim must signal refusal, meaning perpetrators often escape conviction if the victim remains passive due to fear. According to recently published data from the Federal Criminal Police, 14,454 rapes were reported in Germany in 2025, an 8.5% increase that officials attribute primarily to a growing willingness among victims to come forward. However, the consequences of the current legal framework are still reflected in extremely low conviction rates, with the women’s rights organisation Terre des Femmes estimating that only one in one hundred rapes ultimately results in a conviction. Legal practitioners, including the German Women Lawyers Association, argue that this standard protects perpetrators rather than victims by shifting the responsibility of communication onto the assaulted person. They maintain that establishing the lack of consent as the legal threshold is the necessary next step to enable more victims to seek justice. Conversely, countries such as Sweden and Spain have recently reformed their penal codes to ensure that sexual relations must be affirmatively agreed upon. While Sweden has already recorded a subsequent rise in convictions due to broadened evidence admissibility, monitors note that Spain’s groundbreaking 2022 law has yet to translate into similar statistical increases. Political tide is changing in Europe After tough negotiations, the European Parliament voted for a unified legal standard based on an ‘only yes means yes’ principle on Tuesday. The road to a unified standard has been fraught with conflict. During the 2024 negotiations for the EU’s first Directive on violence against women, a blocking minority led by France, Germany, and Hungary successfully stripped rape from the final text. Rapporteur Evin Incir reminded the public of the “unholy alliance” of leaders – including Viktor Orbán and Emmanuel Macron – who formed this blocking minority. These national leaders had argued that the European Union lacked the legal competence to harmonise criminal laws on sexual violence. Only US Votes Against Women’s Rights Document at UN Commission However, the political winds are shifting. Mounting public pressure has forced national governments to reconsider, with countries like France now actively revising their own criminal codes to align with an ‘only yes means yes’-based model. Despite the momentum, the proposal faces fierce opposition from far-right factions who frame the initiative as an ideological overreach. During the Strasbourg debate, an MEP from the Patriots for Europe group argued that “human relationships do not unfold through formalized steps or legal checklists,” claiming the law would amount to morally policing intimate desire. Other right-wing voices attempted to pivot the debate toward anti-immigrant narratives, suggesting lawmakers should “protect the streets, not the bedrooms”. Progressive lawmakers swiftly rejected this framing, citing data that proves the vast majority of sexual assaults are committed by perpetrators known to the victim, underscoring the systemic, domestic nature of the crisis. More than judicial reform needed The proposed European standard combines legal reform with mandatory education and trauma-informed training for law enforcement. Establishing the ‘only yes means yes’ principle as the legal threshold for rape demands a fundamental re-evaluation of how European societies view sexual availability and interpersonal power dynamics. The core premise is that sexual partners must actively communicate their desires and mutually negotiate the boundaries of their intimacy. However, reforming the penal code to reflect the lack of consent is only one part of the broader societal transformation envisioned by the European Parliament. Lawmakers are heavily emphasising the need for mandatory, comprehensive sexuality and relationship education across all member states. To ensure these legal reforms are effectively applied, parliamentarians are also demanding mandatory, trauma-sensitive education for law enforcement officers to prevent secondary victimisation during police investigations. “Why in 2026 should it be controversial that we demand that it should be mandatory for those who are working to support these women and girls who are victims?” rapporteur Incir asked, pointing to the tough negotiations with conservative co-legislators. The European Commission has signalled its readiness to support this cultural shift by mapping the current legal landscape across the Union to identify further legislative action. However, it could take years before an EU-wide law takes effect: after the Commission proposes a legal framework, the parliament and EU member states have to negotiate their positions and find a compromise. Image Credits: Felix Sassmannshausen/HPW. Energy Transition ‘Past Point of No Return,’ 57 Nations Declare at First Fossil Fuel Phase-Out Summit 01/05/2026 Stefan Anderson Coalition launches first sustained diplomatic push to phase out oil, gas and coal as war in the Middle East exposes the costs of fossil fuel dependence. The first international conference on phasing out the oil, gas and coal igniting the climate crisis ended with 57 governments representing every continent and a third of the global economy declaring the transition away from fossil fuels is now irreversible. “Actions taken to date prove that the energy transition is past its point of no return,” the coalition declared in its closing document, affirming all members were “ready to advance their transition away from fossil fuels.” The momentum is partly driven by concern for the planet, but also by a strategic desire for the energy independence that renewables could provide in an era of geopolitical instability – a case sharpened by the havoc the war in the Middle East was wreaking on the global economy as delegates gathered on Colombia’s Caribbean coast. “In a time that has been marked by fragmentation, that has been affected by war, by mistrust and the climate crisis, to sit here together and talk about the challenges, talk about the taboos, it’s a deep transformation of policy,” Irene Vélez Torres, Colombia’s environment minister and conference co-chair, said in her closing remarks in Santa Marta. Conference co-chairs Irene Vélez Torres, Colombia’s environment minister, and Stientje van Veldhoven, the Dutch climate minister, celebrate at the closing plenary. “When they look back at us from the future, they will remember that we were there, working on the challenges of our time,” Vélez Torres added. “That we decided not to focus on an economy built on war and destruction — we decided instead that it was necessary to prioritise life, security, certainty, sovereignty and solidarity.” The conference produced no binding commitments, no finance pledges, no promises of emissions cuts — that wasn’t the point. Instead, organisers pitched the summit as a “safe space” for countries already committed to phasing out fossil fuels to speak frankly. No negotiations, no consensus text to be watered down, no red lines passed down from governments to throw a wrench into discussions. A space free of the fossil fuel lobbyists who fill the corridors of UN climate summits by the thousands, both openly and embedded in petrostate delegations, often outnumbering full national delegation teams. “The fact we didn’t have negotiations here makes for such a different dynamic,” said Stientje van Veldhoven, the Dutch climate minister and co-chair alongside Vélez Torres. “The psychology of the Santa Marta process is something that we will definitely make sure to carry forward.” A coalition born of frustration Two weeks of negotiations in Belém, Brazil, failed to address a phase-out plan for coal, oil and gas as more than 100 nations blocked language on the fossil fuels at the root of the climate crisis. Three years on from the COP28 breakthrough in Dubai, where nearly 200 countries agreed to “transition away from fossil fuels,” efforts to translate the pledge into concrete action have hit a wall. Negotiations to agree a phase-out roadmap at COP30 in Brazil last November were torpedoed by a coalition of petrostates led by Saudi Arabia, which drew over half of the nations in attendance to its side in opposing the plan. The final text in Belém contained no reference to “fossil fuels” at all, a marked step backwards for the UN climate process. Without that failure, the Santa Marta conference would not exist. Conceived in the hours after COP30 collapsed, the new process was born of frustration with the gridlock of consensus-based UN climate diplomacy. But its architects stressed that it is meant to be complementary to mainstream COPs, not to replace them. “It’s very important that we agree on the fact that we want this conference, this process, to be like an accelerator for what we want to do in the context of UNFCCC,” van Veldhoven said, adding that the chairs have already been in touch with the COP31 presidency. Alongside government ministers, the conference included nearly 3,000 representatives of subnational governments, trade unions, scientists, civil society groups, Indigenous Peoples, women’s organisations and youth representatives, all named in the closing document as equal participants rather than observers, the title they hold in UN negotiations. “A new reality is taking shape: this is no longer a one-off moment, but the foundation of an ongoing international process dedicated to phasing out fossil fuels,” said Kumi Naidoo, president of the Fossil Fuel Treaty Initiative. “What is emerging is a process that can finally match climate diplomacy to the scale of the crisis.” Countries will attempt to carry the momentum forward at the next phase-out conference, confirmed in the closing hours to be held in 2027 on the Pacific island of Tuvalu and co-hosted by Ireland, pairing a wealthy European island with one across the globe at risk of disappearing under sea-level rise. “We are making history. We have proven, in the words of our youth, that another way is possible,” Tuvalu’s representative said. “The world is in a fossil fuel crisis, of climate breakdown, of conflict, of instability. But here in Santa Marta, we have planted a seed of solutions.” The tailwind from Hormuz Roughly a fifth of the world’s oil passes through the Strait of Hormuz, where wartime disruptions have driven prices to their highest level in years and exposed how much the global economy still depends on fossil fuels. Running through the conference was the war between Israel, the United States and Iran, which has disrupted shipping through the Strait of Hormuz, tightening gas supplies across Europe and Asia and skyrocketing oil prices to their highest level in years. On the same day delegates closed proceedings, US President Donald Trump told reporters Iran would have to “cry uncle” before he lifted what he called his “genius” blockade. Brent crude hit $126 a barrel hours later, approaching the spike that followed Russia’s invasion of Ukraine in 2022. For the three-quarters of the world that depends on fossil fuel imports, the message of the past five days was hard to miss: their energy costs, inflation rates, fiscal stability and the prices their citizens pay for food and fuel are tied to decisions made by a handful of leaders in Washington, Moscow and Riyadh – none of whom were in Santa Marta. The coalition’s closing document named the Hormuz crisis directly, calling the disruptions a demonstration “that reducing fossil fuel dependencies is critical” to “keep our planet livable, to safeguard energy security, and to build economic resilience to volatile fossil fuel markets.” “Destructive oil wars, widening fuel and food shocks, and a mounting climate crisis only bolster the conviction that breaking free from the fossil fuel system is not a matter of magical realism but of radical realism, in line with science and the law,” said Nikki Reisch, director of climate and energy at the Centre for International Environmental Law. Van Veldhoven framed the crisis as part of the case for moving faster. “If these countries significantly reduce their dependency on fossil fuels, it means they’ll be investing in their own economy instead of importing fossil fuels from abroad,” she told Bloomberg. “It means they’ll be investing in clean technologies, but it also means they’ll be shielding their economies against the kind of price shocks we’re seeing currently.” Santa Marta: Key outcomes from first summit on ‘transitioning away’ from fossil fuels | @daisydunnesci Read here: https://t.co/YGUgQR5BTg pic.twitter.com/1nZuILSPO7 — Carbon Brief (@CarbonBrief) May 1, 2026 France became the first major economy to act on that argument at scale during the conference, releasing a national roadmap to eliminate fossil fuels from its energy mix by 2050. The plan does not introduce new pledges but consolidates existing French climate and energy targets under a single explicit goal: ending the use of oil, gas and coal for energy purposes by 2050. Globally, the picture is mixed. Fossil fuels remain responsible for more than 75% of greenhouse gas emissions, but new renewable capacity in 2025 is nearly 50% higher than in 2023, and renewables are meeting nearly all new energy demand, according to the International Energy Agency. Investment in the energy transition reached a record $2.4 trillion in 2024, more than double 2019 levels, though it is concentrated in advanced economies and China, IRENA found. “This momentum is not yet enough to deliver the needed breakthrough,” said Bronwen Tucker, public finance lead at Oil Change International. “The richest polluting countries must take immediate action to accelerate their transitions at home and show up with meaningful international economic cooperation.” Coalition of the self-aware For all its ambition, the coalition openly admitted the limits of its own reach. The outcome document released in Santa Marta lays out in candid detail the shortcomings of the coalition in Colombia, and the distance all nations still have to go to achieve the transition away from fossil fuels. Chief among these admissions is the degree to which most nations in attendance continue to be dependent on oil, gas or coal for the public revenues that fund health, infrastructure and other government functions, and ensure energy security. Until governments find a way to replace that funding, walking away from fossil fuel production remains off the table. “The countries present in Santa Marta still have structural dependencies to overcome, including fiscal dependencies, debt constraints, the dependence of the financial architecture on fossil fuels,” the outcome paper states. “Transitioning away from fossil fuels is more than replacing one energy source with another … the transition itself is complex.” Many others simply do not have the financial headroom to invest in renewables due to looming debt payments and empty balance sheets. “We must confront economic dependence on fossil fuels that shape the realities we face,” Tuvalu’s delegate said. “Unsustainable debt, reliance on fossil fuel revenues, and a global financial system that was not built for us, and too often fails us.” The coalition also recognised the limits of its own power. While the alliance contains a meaningful contingent of major fossil fuel producers – Norway, Canada, Australia, the United Kingdom, Brazil, Mexico, Nigeria, Angola and Colombia itself – what it does not contain is a critical mass of global fossil fuel supply or demand. The 57 countries present make up about a fifth of global fossil fuel production, a third of oil and gas demand, and the same share of world economic output. The five biggest fossil fuel producers – the United States, China, Russia, India and Saudi Arabia – were all absent. Together, they control nearly half the world economy, and pump about 45% of the world’s oil, half its natural gas and three-quarters of its coal, far outstripping the heft of the Santa Marta coalition on all fronts. “We are here with an immense group, and yet it is still too small a group for what our ambition actually is,” van Veldhoven said. “Let’s make sure that we continue to drive this process as an open coalition. That means we have to ensure visibility of the outcomes and use that as an invitation to others to join us.” Rockstars to the rescue Attendees gather for the launch of the Science Panel for the Global Energy Transition (SPGET) in Santa Marta. A concrete outcome of the summit is the creation of a new scientific panel to advise nations on the practice and policy of the fossil fuel phase-out, an idea born in the halls of COP30, which Vélez Torres pitched as a sort of climate scientists’ Avengers team of “rock star academics”. “This panel not only repairs a historical debt of an organisation dedicated, finally and for the first time, to overcoming fossil fuels in the energy matrix,” she said, “it will also tell us about other types of challenges regarding the social and economic limitations of being able to carry out this transition as quickly as possible.” The Science Panel for the Global Energy Transition (SPGET) will unite over 100 scientists and academics to guide nations in policymaking and emissions pathway analysis with the goal of keeping the 1.5°C warming target enshrined in the Paris Agreement alive. The independent panel will focus on mapping policy options, green technologies and financial mechanisms that can be harnessed by countries to reduce emissions and fossil fuel dependence. Johan Rockström, director of the Potsdam Institute for Climate Impact Research and co-lead of SPGET, said it will operate as a “scientific service” to governments, helping them figure out the balance of energy supply and demand with a “scientifically aligned, just and orderly phase out of fossil fuels.” “[The panel] will also enable us to have feedback into the COP process so that we can keep the fossil fuel phase-out discussions in plenary at the COP meeting alive,” Rockström said. “Now is the moment to tip the scales, to not allow anymore that a few actors at the COP meetings always block the most important discussion of them all: the phase-out of coal, oil and gas.” The hard the work begins Delegates arrive for high-level ministerial sessions in Santa Marta, Colombia. The final agreement struck at Santa Marta establishes three “workstreams”: working groups of countries, experts and civil society that will meet between now and the next conference to develop policy options on the thorniest questions of the phase-out. The first will focus on national emissions roadmaps, taking specific aim at what Vélez Torres called the “punto ciego,” or blind spot, in the Paris Agreement: exported emissions. Under the Nationally Determined Contributions (NDCs) mandated in the Paris Accords, countries report emissions on a territorial basis, but not the emissions from fossil fuels they extract and sell to other countries. For major exporters, the effect on emissions calculations is enormous. Norway’s exported emissions from oil and gas are roughly ten times its territorial emissions. Saudi Arabia’s full emissions footprint rises to two and a half times its reported emissions, closing in on 5% of global CO2 on its own. “We are not making clear commitments about how we are going to control the emissions that are exported from producing countries,” said Vélez Torres, whose country, Colombia, sees its emissions more than double when its coal and oil exports are counted. “We want to be very clear, very honest about how to transition away from production as well.” Winding down production is one of the most complex questions in the phase-out debate. If demand falls first, producer countries face collapsing revenues and an economic crisis. If supply falls first, importers face energy shortages. A complementary workstream announced in Santa Marta, backed by the OECD, will look at how exporters and importers can coordinate their wind-downs so the two declines move in step, avoiding a scenario where one side pulls back faster than the other, leaving producers without buyers or importers without fuel before clean alternatives can fill the gap. Money traps, and future hopes Indigenous Peoples’ representatives played a central role in the Santa Marta phase-out talks. The final workstream, supported by the International Institute for Sustainable Development, takes on what the co-hosts called the three “traps” holding states back from moving faster on fossil fuel phase-outs: finance, debt and subsidies. It is, in many ways, the hardest of the three. Without alternative revenues lined up, governments cannot turn off the tap on production that pays their bills. The constraint tightens further as interest payments squeeze public budgets and credit ratings for developing nations render borrowing exceedingly expensive, leaving fossil fuel revenue indispensable and crowding out renewables investment. Then there are the subsidies. Governments worldwide handed roughly $1.3 trillion in direct support to fossil fuel producers and consumers in 2022 to keep pump and power prices low, according to the IMF, and as much as $7 trillion once the unpriced costs of pollution and climate damage are factored in. The direct figure alone is more than half the $2.4 trillion the world invested in the entire energy transition the same year, tilting the market against cheaper renewables as subsidies keep expensive fossil fuels price-competitive. In Ghana, the financial realities of fossil fuel dependence remain too steep to overcome, its delegate told the conference, despite the country supporting the phase-out goal. “In Ghana, fossil fuels remain deeply tied to government revenues that fund essential public services and to our broader energy systems,” he said. “We need a fossil fuel treaty that creates the necessary architecture for a just transition.” Ten-year-old Paula Pedro from Colombia speaks at the closing of the Santa Marta conference. That the coalition is willing to talk openly about the financial dependency at the heart of the phase-out is, for many participants, the most encouraging signal to come out of Santa Marta. Whether it can build bridges and expand its membership as the climate crisis accelerates is the question that will loom over COP31 in Antalya later this year, and in the run-up to Tuvalu in 2027. With the workstreams set and the next conference scheduled, it fell to a 10-year-old from Colombia to remind the room what the diplomacy was for. “Of the 12 million children we have in Colombia, eight out of ten of us are affected by fossil fuels and weather changes,” Paula Pedro, representing the Colombian children and youth coalition, told the assembly. “What we need, for the children, is that the people in this room do the math, but not only on paper, but accomplish change as a matter of fact.” “We’re not only the future,” Pedro said. “We are the present and beyond.” Image Credits: Colombian Environment Ministry, Colombian Environment Ministry, COP30, ColomColombian Environment Ministrybian Ministry o, Colombian Environment Ministry, Colombian Environment Ministry, Colombian Environment Ministry. Heartbroken Families Face Huge Structural Barriers When Trying to Prove Medical Negligence in India 01/05/2026 Arsalan Bukhari & Naila Tabassum Indian families face a huge struggle to get timely access to medical records of loved ones who have died in Indian health facilities, while the police can only lay a charge against a doctor if an independent medical expert first confirms negligence. NEW DELHI – India faces thousands of medical negligence cases every year, but structural problems make it extremely difficult for patients’ families to find out what has happened to their loved ones – let alone win compensation when treatment has been botched. “A shadow of death is looming over us,” Ashwini Bajaj, a Haryana-based businessman, told Health Policy Watch, recalling the treatment of his 24-year-old son, Deshbandhu, more than a year after his death. In December 2024, Deshbandhu, an MBA student at Punjab University and Bajaj’s only son, developed a fever that lasted more than two days. On 26 December, he visited a hospital near his university in Chandigarh, where he was prescribed medicines and given a series of tests, including a liver function test (LFT). By the time the results came out later that evening, Deshbandhu had returned to his parents’ home in Hisar, around 200 kilometres away. The next day, he went to a private hospital there, but his condition deteriorated rapidly. His oxygen saturation dropped to 65%, and doctors warned of acute liver failure. “We were told his condition was very critical and that the hospital did not have the resources to treat him,” Bajaj said. “We were asked to take him to a super-speciality hospital. It felt as if the ground beneath our feet had slipped away.” Deshbandhu was shifted to a major private hospital in Gurugram. “My son was there for over three weeks. His condition kept deteriorating. He went with jaundice, and he developed intestinal obstruction, kidney stress, and pneumonia,” Bajaj said. A few days after his 24th birthday, which was on 20 January 2025, Deshbandhu died. Bajaj says he has been unable to return to work. His case reflects broader systemic gaps in India’s healthcare system, where delays in critical care, weak referral systems, and limited transparency can have life-threatening consequences — and the lack of updated national data continues to hamper accountability. Transparency in treatment Deshbandhu Bajaj (24), a mountaineer and an MBA student who died in January 2025. His father, Ashwini Bajaj, alleges medical negligence. “Initially, I thought the doctors tried hard to save my child, but when I obtained all the medical reports, which took three to four months to obtain, I realised much time was lost before the actual treatment started,” Bajaj said. “When I made a day-by-day chart, I realised that, for at least four days, my son didn’t get the treatment he should have. “Every evening, I used to get payment requests promptly on my WhatsApp. If they could send payment requests, why can’t they share procedural updates the same way?” Rujhan Dhawan, a lawyer at the Punjab and Haryana High Court, told Health Policy Watch such opacity is a major barrier to accountability. “A patient, once admitted, is entirely dependent on the institution not only for treatment but also for truthful disclosure,” he said. “Critical information about procedures and complications is often not readily accessible to families.” Bajaj’s family spent over ₹30 lakh ($33,000) on treatment. He says he is not seeking compensation, but a legal framework that mandates transparency. Not an isolated case Deshbandhu’s case is not an isolated one. According to the 18th Annual MedLegal Review, 65,000 medical negligence cases were filed in India in 2025 alone. Radha Sharma (49), a resident of Rajasthan’s capital city Jaipur, died days after being given a TB drugs although she had been diagnosed with a liver-related illness. In Jaipar, around 270 kilometres from Gurugram, 55-year-old tax consultant Kishan Kumar Sharma is fighting a case linked to the death of his wife, Radha. On 3 March 2025, she developed mild jaundice and was admitted to a private hospital. A test suggested Budd-Chiari syndrome, a rare liver disorder. However, despite a negative tuberculosis test, Radha was prescribed the TB drug, Isoniazid, said Sharma. Isoniazid should not be prescribed to patients with liver disease who have bilirubin levels over 4 mg/dL, according to World Health Organization (WHO) guidelines. But Sharma says his wife’s liver disorder was overlooked. Radha’s condition deteriorated rapidly, and she died on 18 March. “I have a simple question,” Sharma said. “Why was my wife given Isoniazid? Was it part of any established protocol or something else?” The risks highlighted by such cases reflect a broader global problem. According to the WHO, an estimated 138 million patients are harmed every year due to unsafe medical care. Lack of dedicated investigative body Nishant Bharihoke, an advocate at the Delhi High Court who specialises in medical negligence cases, told Health Policy Watch the core issue lies in the absence of a dedicated independent investigative framework. “India does not have a dedicated body specifically tasked with investigating deaths or serious injuries caused by medical negligence,” he said. “When a patient dies, and the family suspects wrongdoing, there is no authority whose sole function is to find out what happened.” Complaints are typically routed through State Medical Councils, which may form inquiry committees. Their decisions can be appealed to the National Medical Commission, but Bharihoke argues that the system is structurally limited. “The National Medical Commission’s primary mandate is to regulate medical education. Its disciplinary board has no independent investigators and no power to enter hospitals and examine evidence,” he said. He also pointed to a legal loophole: since these proceedings are not strictly judicial, false statements made before such bodies do not result in perjury charges. For families like Bajaj’s and Sharma’s, he said, this gap deepens the sense of injustice. When cases turn criminal Simran Chhabra (21), a resident of Gurugram and MA student at Amity University, was suffering from a simple cough and cold. She died within minutes of being administered an intravenous injection. The family is fighting a medical negligence case in a Gurugram court. The gap becomes even wider when negligence overlaps with criminal allegations. One such case is the death of 21-year-old Simran Chhabra. On 21 January 2023, she visited a private hospital in Gurugram with symptoms of cough and cold. According to a prescription her brother, Sourabh Chhabra, shared with Health Policy Watch, she was administered an intravenous injection of Dynapar. This is usually used to treat pain and inflammation associated with arthritis or after surgery. “As soon as the injection was fully administered, Simran collapsed on the bed and froth began coming out of her mouth,” Sourabh said. “Everything happened within minutes. I had no time to understand what was going on.” She was referred to another hospital, where she was declared dead. According to Bharihoke, the family’s legal representative, the doctor later claimed that multiple emergency interventions were carried out, including five additional injections and cardiopulmonary resuscitation (CPR), using drugs typically administered in cases of severe allergic reactions. However, the post-mortem report reviewed by Health Policy Watch raises questions. It records only two puncture marks on her body, and there is no mention of a cannula (an intravenous tube) being used. If multiple injections were administered, the family asks why there is no corresponding physical evidence. In this case, they argue, the medical account and post-mortem findings do not align. “Forget conviction or arrest, even registering an FIR in such cases often requires court intervention,” Bharihoke said. A FIR is a First Information Report (FIR) in Indian medical negligence cases, a formal document prepared by police under Section 154 of the Criminal Procedure Code upon receiving information about alleged criminal negligence. Absence of a legal framework Several structural barriers insulate medical health practitioners against negligence cases, according to legal experts. “In India, police usually cannot even register a case against a doctor unless an independent medical expert first confirms negligence,” Bharihoke told Health Policy Watch. “In most cases, doctors are reluctant to give such opinions, especially against their peers.” The challenge is compounded by access to evidence. Hospitals retain control over key records, case files, prescriptions, nursing notes, and CCTV footage while families often receive only partial or delayed documentation. India also lacks a statutory system guaranteeing timely access to medical records for patients and their families. There is no clear legal mandate requiring investigators to immediately secure hospital evidence. Tanvi Dubey, a Supreme Court lawyer, told Health Policy Watch the legal framework itself raises the bar for accountability. “Criminal liability in medical negligence cases is limited to gross negligence, not simple errors of judgment,” Dubey said. “This significantly narrows the scope for prosecution.” Even initiating an investigation can be delayed: “Authorities are allowed to conduct preliminary inquiries before registering a case, which often means waiting for medical opinions and slows the process.” Dubey also pointed to the continued reliance on what is known in Indian law as the “Bolam principle,” where a doctor’s actions are judged against a body of medical opinion. “This makes expert testimony central. Unless a complainant can produce strong contrary evidence, it becomes very difficult to establish negligence,” she said. While multiple legal remedies exist, including consumer courts, civil litigation, and disciplinary proceedings, Dubey noted that each comes with limitations. “Criminal prosecution is rare, civil cases are slow and evidence-heavy, and disciplinary proceedings do not always ensure compensation or thorough fact-finding,” she said. Compared with Western peers, India faces two major policy gaps in patients’ treatment: the absence of a national electronic medical record (EMR) system, and the lack of a digital system connecting labs directly to the consulting doctor. Currently, India doesn’t have a mandatory EMR policy applicable to healthcare organisations. Even today, prescriptions, clinical notes, and drug administration records are still handwritten in the majority of hospitals and almost all smaller clinics. This makes them more vulnerable to tampering, loss and destruction. The absence of a nationwide electronic medical record system adds another layer of opacity. In many facilities, records remain handwritten and vulnerable to alteration; a gap Bharihoke alleges was evident in Simran’s case. Urgent reform is necessary India’s Minister of Health Jagat Prakash Nadda. Legal experts are calling on authorities to establish an independent statutory body to investigate medical negligence. Only families with the financial means and emotional capacity to pursue long legal battles are able to take up medical negligence cases. For many others, the burden becomes too heavy to carry. While the rules may appear neutral on paper, experts say their impact is deeply unequal. Legal and policy experts argue that the most urgent reform is structural, particularly the creation of an independent statutory body tasked solely with investigating patient safety incidents, particularly in cases involving death, permanent disability, or serious injury. Such a body should have the authority to enter hospital premises, access medical records, secure CCTV footage, and record statements. Its findings should be made public, while the evidence it collects remains protected from use in criminal or disciplinary proceedings. In England, the Health Services Safety Investigations Body (HSSIB), established in 2023, follows this approach by conducting independent investigations into patient safety incidents. Globally, different systems offer alternative approaches to accountability. In the United States, oversight is spread across multiple layers: state medical boards regulate conduct, a national database tracks malpractice records, hospitals report serious incidents, and patients can pursue civil litigation. China follows a three-tier system, allowing patients to first negotiate with hospitals, then seek mediation, and finally pursue civil lawsuits. In parts of Europe, including France and the Nordic countries, no-fault compensation systems allow patients to receive compensation without proving negligence, making the process more accessible and less adversarial. Aviation and rail safety investigations have long operated on similar principles, focusing on systemic failures rather than individual blame. For India, experts say the lesson is clear. Accountability frameworks do not have to rely solely on litigation. A system built on independent investigation, timely access to evidence, and patient-centric redress could help provide answers to families like the Bajajs and Sharmas. Image Credits: César Badilla Miranda/ Unsplash, Felix Sassmannshausen. No Pandemic Agreement Annex by World Health Assembly, Says Civil Society 30/04/2026 Kerry Cullinan (Left to right from top) Third World Network’s moderator and speakers Lauren Paremoer, KP Gopakumar and Tamara Prisenburg form AIDS Healthcare Foundation. The final missing piece of the Pandemic Agreement – a pathogen access and benefit-sharing (PABS) system – is unlikely to be agreed on by the World Health Assembly (WHA) later this month. This was the view of civil society observers of the talks taking place at the World Health Organisation (WHO) headquarters in Geneva, who briefed the media on Thursday. The sixth round of talks is scheduled to end late on Friday night (1 May). Earlier in the week, WHO Director General Dr Tedros Adhanom Ghebreyesus told a Geneva media briefing that “key differences remain on key issues”. “I still see a common will to reach consensus, which means I continue to believe there is a way to reach consensus,” Tedros added. Although the notion of a “hybrid” PABS system is being discussed informally, its proponent, the European Union (EU), has not presented any formal text, Third World Network’s (TWN) KM Gopakumar told the media briefing, which was hosted by TWN and the AIDS Healthcare Foundation. While Brazil and Botswana have apparently indicated that they might support a hybrid or “blended” compromise, the Africa Group is opposed to it, according to the civil society representatives. WHO member states are negotiating how to share both information about dangerous pathogens and some of the “benefits” that manufacturers may develop from that information – namely, vaccines, therapeutics and diagnostics (VTDs). The “hybrid” or “blended” proposal is a mix of mandatory and voluntary measures for sharing pathogen information and any benefits that flow from this information. It de-links information-sharing and benefit-sharing. Gopakumar said that, in terms of the blended agreements, countries that shared pathogens “will have the freedom to choose to attach certain conditions for sharing the data and the sample, including benefit sharing requirements” or share without any conditions. Kill the efficiency Shifting the choice to individual countries would undermine the efficiency of a single PABS system as users would need to negotiate with the individual countries instead of through a centralised system, he argued. “If you have a hybrid system, first of all, it kills the efficiency [of a single system], and second, it’s going to debase the access and benefit sharing norms set by the international instruments like the Convention on Biological Diversity and the Nagoya Protocol. Any attempt to dilute benefit-sharing obligations would be a “disaster” for equity, said AHF’s Tamara Prisenberg. Lauren Paremoer of the People’s Health Movement said that the blended model introduces “a two-track system for accessing pathogens” that violates access and benefit-sharing on an “equal footing” specified in Article 12 of the Pandemic Agreement. One track would allow anonymous users to access pathogen data without upfront commitments to benefit-sharing or legally binding contracts. The other was in line with Article 12, permitting access to pathogens through databases and laboratories that would require users to register and commit to specified benefit-sharing. Earlier in the day, the Intergovernmental Working Group (IGWG) briefed civil society on text-based negotiations, but very little of the text they shared had been “greened” to show agreement. EXCLUSIVE: WHO Opens Nominations for Next Director General; Germany May Advance Former Merkel Aide, Helge Braun 30/04/2026 Felix Sassmannshausen, Elaine Ruth Fletcher & Editorial team WHO DG Dr Tedros Adhanom Ghebreyesus issued a call for nominations for the DG elections. He recently travelled to Berlin, where he met with high-level politicians and the WHO’s Pandemic Intelligence team. As the World Health Organization (WHO) formally opens the nomination process for the next Director-General, Germany now appears likely to propose Helge Braun, Chief of Staff in former Chancellor Angela Merkel’s government, according to Berlin insiders. But after slashing its global health budget, sources question whether a German candidate can win wide support from other WHO member states. WHO Director-General Dr Tedros Adhanom Ghebreyesus has formally issued a call to WHO member states for nominations to the DG elections, scheduled for May 2027, in an invitation sent on 24 April to all WHO member states. WHO confirmed this in an email to Health Policy Watch. The invitations had been sent via private letters to countries’ Geneva missions. The period in which member states may nominate candidates will now run for six months, until 24 September. Contenders who have until now remained in the shadows are expected to begin coming forward publicly with their candidacies at the World Health Assembly in May. From the German perspective, Berlin wants its financial weight reflected in executive influence at the multilateral level as the largest global health donor following the US withdrawal from the WHO in January 2025. The withdrawal, combined with the US non-payment of dues owed, thrust WHO into a budget crisis, prompting layoffs of about 25% of the workforce in the past year. German Foreign Ministry neither confirms nor denies The German Foreign Ministry, formally responsible for the nomination, declined to confirm or comment on Braun’s potential candidacy when responding to a query by Health Policy Watch. Germany’s other potential candidates include the contested former Health Minister Karl Lauterbach and the lesser-known Paul Zubeil. In contrast, Braun’s dual profile as an accomplished politician, skilled financial manager, and trained physician and researcher who successfully built cross-party bridges offers a distinct advantage. But he is little known outside of Germany. Bridge-builder with executive and medical expertise Former Chair of the influential German Budget Committee, Helge Braun (right), and former French Chair of the Finance Committee, Claude Raynal (left), in the Bundestag. The current WHO leadership landscape demands a candidate capable of managing deep institutional fractures and uniting a divided global community. Despite him being largely unknown in the international community, Germany could be expected to emphasise Braun’s extensive fiscal and crisis management experience in any candidacy it mounts. As ‘Head of the Chancellery’, effectively Chief of Staff, in Angela Merkel’s last term as Chancellor, from 2018 to 2021, Braun operated at the nexus of scientific advice and political implementation during the COVID-19 pandemic, notably comparing the Chancellery to an intensive care unit where acute problems must be solved. Between 2021 and 2025, Braun then chaired the powerful Budget Committee of the German Bundestag (Parliament), overseeing the distribution and management of hundreds of billions of Euros with strict discipline This profound understanding of macroeconomic management, coupled with his pragmatic defence of Germany’s controversial debt ceiling alongside crisis-driven special funds, makes him an attractive prospect for donor nations currently demanding more financial accountability and restructuring at WHO in Geneva. Serving as a central mediator across government ministries, Braun built a reputation as a highly pragmatic problem solver whose past domestic political affiliations will not necessarily dictate his future approach to global health governance. This pragmatism complements his longstanding political advocacy for research into infectious diseases like Ebola and malaria. And unlike many career politicians, Braun’s foundational expertise lies in medicine, having worked for years as an intensive care physician and anaesthesiologist. He returned to these roots in April 2025 by assuming the presidency of the University of Lübeck, an institution renowned for its focus on life sciences and artificial intelligence. Why the candidacy might spark concerns WHO member states are currently negotiating a pathogen access and benefit-sharing (PABS) system in Geneva. While Braun championed early interventions and massive digitisation projects in his role as Merkel’s Head of the Chancellery during the COVID pandemic, severe bureaucratic delays hampered the rollout of vaccination campaigns and testing strategies. This tarnished his crisis management legacy just as he exited the federal government. His domestic political capital suffered further damage during the December 2021 Christian Democratic Union leadership election, where he lost heavily to conservative rival Friedrich Merz, now Chancellor. Party members largely rejected Braun as an establishment candidate, perceiving him as too closely aligned with the moderate legacy of former Chancellor Angela Merkel. Additionally, it is questionable whether Braun would wield the necessary diplomatic connections and familiarity with foreign health systems to be effective on Day One of a term as WHO head. The Director-General must immediately command trust and authority on the international stage, particularly when dealing with health ministries and stakeholders in the Global South. Most notably, the German government opposed the release of COVID-19 vaccine patents during his tenure, drawing sharp criticism from international health equity advocates. Defending this refusal in May 2021, Braun wrote in a guest article for the German newspaper Die Zeit that “patent protection as a driver of innovation is not the problem in this crisis, but an essential foundation for its solution.” In the Global South, this track record could thus reinforce the perception that Germany defends pharmaceutical interests over equitable technology transfer – especially in the face of current PABS Annex negotiations. Recent reports from Tagesspiegel Background indicating that the former minister was approached by Germany’s Association of Research-Based Pharmaceutical Companies to become their next president, when the post becomes vacant at the end of 2026, might further fuel these concerns. Finally, Germany has been cutting back its Official Development Assistance (ODA) in general, including contributions to the World Health Organization, where it has historically been the largest member state donor after the United States. On Wednesday, the Merz government announced its 2027 budget plans with further ODA cuts following last year’s drastic 17% reductions. The likelihood of Germany fulfilling its original 2024 financial pledge to WHO for the current biennium (2026-27) also remains in doubt. “They can put forward a candidate, but I don’t think it’s going to get a lot of traction from other member states,” said one informed WHO source. “At a time when Germany is reducing global health funding to member states, I don’t think they can go ahead and claim the top seat.” Step back and support allied candidates? Braun served as Head of Chancellery under then German Chancellor Angela Merkel, seen here with WHO Director General Dr Tedros in Berlin in 2021. Furthermore, domestic opinion remains highly divided on mounting a campaign amidst the geopolitical strains on Chancellor Friedrich Merz’s coalition and Tedros has reportedly urged Germany to back allied candidates instead. At the same time, the desire to seize more leadership in the UN system remains strong after Germany’s failed previous attempt to secure the top role at the UN High Commissioner for Refugees in 2025. Currently, Germany is also pushing for another attempt at a UN Security Council seat. Should Germany put forward a candidate, Foreign Minister Johann Wadephul, who will make the final decision, also faces a stark choice between Braun and the better-known Karl Lauterbach, as well as Paul Zubeil with his strong international health and technical background. Advancing a WHO outsider like Braun against established public health veterans is a highly calculated risk for Berlin, which must first convince other European countries to rally behind him. In case Berlin formally nominates Braun, the success of his candidacy will depend entirely on how effectively the government can reframe his perceived lack of field experience and global networks as delivery on fresh, badly needed fiscal expertise and perspectives. Grappling with WHO’s funding crisis As the race for the next Director-General opens for formal nominations, the names of over a dozen high-profile potential candidates are still circulating – from Indonesia to the United Kingdom. Want to Become the Next WHO Director-General? Get in Line And the list is still growing. Among the newer names being floated is that of Dr Hanan Mohamed al-Kuwari, who served as Qatar’s Minister of Public Health until November 2024 and chaired the 153rd Session of the WHO Executive Board. Before joining the Hamad Medical Corporation in 1996, where she ultimately rose to managing director, al-Kuwari worked for Reuters and as a freelance health reporter. Holding a PhD in healthcare management from Brunel University and bringing early career experience from the WHO, she represents a highly networked voice from the Arab world, celebrated for her crisis resilience and for shaping the WHO’s recent global work programme. Dr Maria Neira, WHO Director of Climate, Environment and Health Another candidate who has been mentioned is Spain’s Dr Maria Neira, who recently retired from WHO as the director of Climate, Environment and Health. An iconic spokesperson for the climate, environment and health movement, Neira is known as a telegenic personality and adroit politically. As a young medical doctor, she worked in emergency relief in Latin America and Africa, and later served as Spain’s Vice Minister of Health and Consumer Affairs as well as President of the Spanish Food Safety and Nutrition Agency. However, Spain also recently decided to nominate a candidate to head the UN Food and Agriculture Organization (FAO), when Qu Dongyu’s second term as Director General ends in July 2027, leaving doubts about whether it would want to mount yet another campaign, in parallel. Continuing decline in ODA and global health aid Drastic ODA cuts and reduced global health funding leave vulnerable populations in precarious conditions worldwide. Whoever is elected will have to continue grappling with the continuing long-term declines in donor-driven ODA, and particularly global health aid – directly to countries and to WHO. While WHO 2026-2027 $4.2 billion base budget is now 85% financed, according to Tedros’ comments on Wednesday, declines in ODA continue to cast uncertainty on how the remaining $630 million gap will be filled. It’s unlikely that the $260.6 million in assessed US contributions still due for years 2024-2025, before the withdrawal became official in January, will ever be repaid, conceded WHO’s Tedros at a Geneva press briefing on Wednesday. “We’re hoping to get the money, but no signals yet,” Tedros told journalists, adding: “No signals means maybe we may not be able to get the money. The likelihood could be not getting the money.” “We’re looking at nontraditional donors. We’re looking at international financial institutions and other ways to mobilize that 15%,” Tedros said, in terms of filling that gap. “It’s not that we won’t go to the traditional donors, but I think we’re expanding that donor base.” This article has been edited to reflect additional information regarding Dr Hanan Mohamed al-Kuwari’s early career as a freelance journalist. Image Credits: X/Dr Tedros, Deutscher Bundestag/Leon Kügeler, European Commission. African Leaders Declare End of Aid Era at Nairobi World Health Summit, But The Data Tell a More Complicated Story 29/04/2026 Stefan Anderson Delegates gather for the opening plenary of the World Health Summit Regional meeting in Nairobi, Kenya. African leaders opened the World Health Summit Regional Meeting at the United Nations complex in Nairobi this week with a unified declaration that two decades of dependence on foreign aid for health is over. “The challenge that I see is that many of the leaders in our continent believe that it is somebody else’s responsibility. It should be the World Health Organization, USAID, I don’t know who,” Kenyan President William Ruto told the summit. “The sooner we realise that it is our responsibility to raise especially domestic resources to fund our health, the better for all of us.” The Nairobi meeting, the first co-organised by the World Health Organization (WHO) and the World Health Summit, has positioned itself as the continent’s first high-level response to the collapse of official development assistance (ODA) for health, which fell by an estimated $31.1 billion in 2025, according to the Africa Centres for Disease Control and Prevention (Africa CDC). Over 2,000 delegates from more than 50 countries, including health and finance ministers from 17 nations, are convening in the Kenyan capital to coordinate a united African position ahead of next month’s World Health Assembly in Geneva. “I don’t want to see this continent being dependent. And we are dependent because we want it,” Ruto said. “Africa is manufacturing a number of products today, from Egypt, from Kenya, from South Africa, from a number of countries, but we are not buying our own product.” Africa carries more than 25% of the global disease burden but accounts for less than 3% of global health expenditure. The continent currently produces less than 2% of the medicines and vaccines it consumes, leaving its countries dependent on external supply chains for essential medical commodities. “Who’s asking us not to buy our own product, who’s asking us not to register to the African Medicines Agency for the regulatory aspect?” Ruto asked. “It’s not Germany, it’s not Europe, it’s ourselves. We need to change our mindset.” A break with the past African leaders led by Kenyan President William Ruto arrive in Nairobi for the summit. The urgency on display in Nairobi is driven by the most disruptive year for global health financing on record. For African governments, the pivot to self-reliance has become a fiscal necessity. The dismantling of the United States Agency for International Development (USAID), followed by aid cuts by the United Kingdom, Germany, France and the Netherlands, drove a 23.1% drop in total ODA from OECD donors in 2025. This is the largest single-year contraction since records began. The US, Germany, UK, Japan and France accounted for 95.7% of the total decline. The Boston University ImpactCounter estimates the US cuts have already led to more than 518,000 child and 263,000 adult deaths from preventable diseases such as HIV and tuberculosis. A further 14 million preventable deaths, including 4.5 million children, may occur by 2030 if USAID funding gaps are not filled, a major international study found. Africa CDC estimates the combined cuts from the US, UK, Germany and other major donors will kill an additional two to four million Africans annually. “The year 2025 marked the end of one era and the beginning of another,” Sulaiman Shahabuddin, President and Vice Chancellor of the Aga Khan University, told the opening plenary. “We are confronting a new reality, defined by funding constraints, the rise of technology and artificial intelligence, and a decisive shift towards local ownership.” “Climate change, chronic diseases, lack of financial resources, the digital divide, inequity and others are [challenges] we will have to overcome,” Shahabuddin added. What aid remains on the table increasingly comes with strings attached. Washington has begun rolling out bilateral “America First” global health agreements, with US President Donald Trump retaining the right to terminate any programme judged not to align with American interests. Conditionalities include sharing pathogen samples and genomic data with US authorities, prioritising faith-based health providers to prevent services such as abortions, channelling funding away from non-governmental organisations, and, in the case of Zambia, granting access to critical minerals in exchange for health funding. Lukoye Atwoli, Dean of the Aga Khan University Medical College East Africa and the summit’s international president, said this year’s gathering would mark a break with past meetings on African health. “Historically, meetings about Africa and Africa’s health have been about lamentations. Have been about framing the problems. Have been about basically begging and saying that we have a problem and we need help,” Atwoli told delegates. “This meeting will be different.” Reform body launched Africa CDC Director Dr Jean Kaseya speaking in Nairobi. On the sidelines of the summit, Africa CDC launched the African High-Level Ministerial Committee on Global Health Architecture Reform. The body brings together health and finance ministers from across the continent to coordinate African positions ahead of the World Health Assembly and broader UN reform processes. Convening both portfolios in the same room is a long-standing demand of global health advocates, who have struggled for decades to make the economic case for health investment to treasuries that hold the purse strings. The committee, chaired by former Liberian president Ellen Johnson Sirleaf, will produce coordinated African position papers on health architecture reform and a 2026–2030 reform roadmap focused on five axes: governance, financial sovereignty, data sovereignty, local manufacturing, and pandemic preparedness. “The old model is no longer fit for purpose. Africa cannot continue to be a passive recipient of global health decisions,” said Africa CDC Director General Dr Jean Kaseya. “We welcome our partners, but on a new basis: not as donors and recipients, but as equal partners aligned with Africa’s priorities.” Aspiration meets evidence Official development assistance fell by a historic 23.1% in 2025. African nations are among the hardest hit. The data on whether Africa can deliver on the vision laid out in Nairobi tell a more complicated story. A Centre for Global Development (CGD) audit of 442 government actions across all 54 African countries found a continental reaction to the historic aid cuts split in radically uneven ways, a story of inequality within Africa as much as between Africa and its donors. The countries that moved fastest are those with the deepest pockets and most diversified economies, including Nigeria, Ghana and Ethiopia. Lower-income, debt-burdened countries, many of which were the largest per-capita recipients of foreign assistance, have largely absorbed the loss in silence. “Governments with limited fiscal space and weaker administrative capacity have less room to cushion abrupt external shocks,” the analysis found. “What is slightly surprising is that they were not only doing little about the aid cuts, they are also saying little about them.” Global Health Leaders Urge Fewer Agencies Amid Funding Crisis A separate CGD study published in February examined the budget statements of 18 sub-Saharan African countries: among the world’s poorest, most heavily aid-dependent and exposed to the cuts. It found that only two, Tanzania and Sierra Leone, proposed new revenue measures to replace lost financing in their 2025 budgets. None reprioritised spending from other sectors to protect health. “With few exceptions, governments neither raised new revenues nor reallocated spending to compensate for lost external financing,” the analysis concluded. The burden of adjustment, it found, has instead fallen on the services patients receive, from disrupted HIV and tuberculosis treatment to delays in vaccination campaigns and the closure of clinics that depended on donor financing. “Health is not a cost, it is an investment,” Ruto said. “And it is important for us to invest.” Cascading crises Runaway climate change is colliding with constant economic shocks from war and the COVID-19 pandemic, shrinking Africa’s budgets and taking away the space to invest in health. The continent’s ability to absorb the aid shock and finance the pivot to support its own health systems is constrained by an unending sequence of external crises over the past decade that continue to batter government budgets, layered on top of the escalating climate crisis. The COVID-19 pandemic, during which wealthy nations hoarded vaccines, exposed Africa’s reliance on a foreign supply chain that produces 99% of the vaccines and 90% of the medical supplies it consumes. Pandemic response cost African governments an additional $154 billion in 2020 and 2021, according to the African Development Bank, pushing sub-Saharan public debt up by 8 percentage points of GDP in a single year. Russia’s invasion of Ukraine drove an inflationary spike that ballooned debt-service costs across the region, a pressure that has now snowballed into the global economic crisis triggered by the US-Israeli war on Iran, to which African economies are uniquely vulnerable. The closure of the Strait of Hormuz, a chokepoint for a fifth of the world’s oil and a third of its liquefied natural gas, is driving up fuel and fertiliser costs and deepening food insecurity across the continent. The resulting inflation, weaker currencies and tighter global financial conditions across Africa are inflating debt-servicing bills and forcing governments to divert money that could otherwise help absorb the aid shock. Climate change is compounding the pressure on every front. African countries are losing between 2% and 5% of GDP to climate extremes, the World Meteorological Organization estimates, with some governments diverting up to 9% of national budgets to respond. Health systems will bear a growing share of that cost. The World Bank estimates climate change could drive at least $21 trillion in excess health costs in low- and middle-income countries by 2050, with sub-Saharan Africa among the regions hit hardest. “What was considered reliable for decades is turning out to be fragile,” said Birgit Pickel, Director-General for Global Health at Germany’s Federal Ministry for Economic Cooperation and Development. “Cracks are appearing in the international order. Cracks that, in some cases, are already leading to its collapse.” Fiscal squeeze limits options African debt levels have more than doubled in the past decade, according to ONE Data figures. The cumulative damage has left African governments with little room to manoeuvre. Thirty-two African nations now spend more servicing external debt than funding healthcare. The continent paid almost $90 billion in external debt service in 2024 alone, with African governments now spending an average of 17% of state revenue on debt servicing, according to leading estimates. The IMF warned last week that more than a third of African countries are at high risk of, or already in, debt distress, with rising interest bills “crowding out essential development spending, healthcare above all.” “Official funding will probably shrink, at least internationally. Domestic funding will hopefully move up,” Pickel said. “But there are innovative instruments out there to also meet urgent funding needs in the health sector, especially for heavily indebted countries.” Pickel proposed debt-for-health swaps, an instrument under which creditor nations cancel debt in exchange for redirected health spending, as a route to fiscal space for highly indebted countries. Germany issued €100 million in such swaps last year, channelled to the Global Fund. The figure is substantial as a signal, but negligible against the scale of the African external debt service crisis. The IMF’s Africa Director, Abebe Selassie, told the Fund’s Spring Meetings in Washington this month that the 2025 foreign aid contraction marks a structural break – and the money is unlikely to come back. “Past aid shocks were largely cyclical; donors cut back and then returned. What we are seeing now appears more structural,” Selassie said. “And it is falling hardest on the region’s most vulnerable countries: fragile states and low-income economies that depend on aid not as a supplement, but as a critical source of budget financing, healthcare, and food assistance.” The summit runs through Wednesday, with the African Union expected to publish a position paper on global health architecture reform at its close. Image Credits: ONE Data. Ghana Rebuffs US Health Deal – But South Africa and Zambia Struggle Without Aid 29/04/2026 Kerry Cullinan US Ambassador to the UN Mike Waltz (left) at the launch of the ‘Trade over Aid’ event at the New York Stock Exchange this week. Ghana has become the latest African country to reject the United States’ terms for bilateral health assistance, particularly the requirement to share sensitive health data, according to Reuters. Late last year, Zimbabwe rejected US terms for health assistance, particularly the demand to share pathogen data without any “corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data,” according to government spokesperson Nick Mangwana. Zambia has until 30 April to decide on whether to avail its minerals – primarily copper, cobalt and lithium – to US companies in exchange for health assistance. US aid supported antiretroviral treatment for an estimated 1,3 million Zambians. In the wake of disruptions since President Donald Trump assumed office last January, some Zambian hospitals are seeing an increase in AIDS cases, according to the New York Times. Back in December, the US announced Zambia had committed to a plan to unlock “a substantial grant package of US support in exchange for collaboration in the mining sector and clear business sector reforms that will drive economic growth and commercial investment that benefits both the United States and Zambia”. But this has never materialised amid renewed US pressure on Zambia to open its mineral wealth to the US. Meanwhile, South Africa has been frozen out of health aid by the Trump administration – in the main, for charging Israel with genocide at the International Criminal Court and for policies aimed at addressing apartheid-era discrimination that the US claims are anti-white. The loss of US funding has “damaged critical health services, dismantled HIV prevention programs, and disrupted world-class South Africa-U.S. research collaboration,” according to a report published last week by Physicians for Human Rights (PHR), Advocates for the Prevention of HIV in South Africa (APHA), and Emthonjeni Counselling and Training. ‘Trade over aid’ The terms of the Memorandums of Understanding (MOU) that the US is seeking with key countries, as part of its “America First Global Health Strategy” (AFGHSD), are overwhelmingly transactional. This week, the US entrenched this approach at the launch of its ‘Trade over Aid’ initiative at the New York Stock Exchange, asserting that the free market is the “surest route to economic prosperity” Ghana is Africa’s largest gold producer. It is unclear whether the US tried to use its aid offer to extract minerals, as it has in other countries. However, this is unlikely to have gone down well as Ghana is clamping down on foreign mining operations. In the past few weeks, the country’s Minerals Commission has given three international firms until the end of the year to transfer their gold mining operations to locals. Ghanaian President John Mahama is also championing the “Accra Reset”, launched last year to encourage African countries to invest more of their domestic budgets in their health and depend less on aid. At the same time, Ghana is heavily indebted and recently held off paying newly recruited nurses as it lacked the finances. US role in DRC conflict? President Donald Trump meets with DRC President Felix Tshisekedi and President Paul Kagame of the Republic of Rwanda, in the Oval Office in December 2025. The US held off signing an MOU with the DRC on 5 December, when it signed deals with Rwanda and Kenya on the sidelines of a peace accord between the DRC and Rwanda, allegedly the sponsor of the M23 rebels waging war inside the DRC. Instead, the US and DRC first signed a “strategic partnership agreement” to “promote secure, reliable, and mutually beneficial critical mineral flows for commercial and defense purposes”, according to the US State Department. The health MOU followed on 26 February. The DRC is one of the world’s most important sources of rare earth minerals, but China has dominated the purchasing and processing of its minerals. Following the agreement, the DRC offered US investors stakes in state-owned mineral assets. In late March, a US company, Virtus, bought a cobalt mine. Recently, it emerged that the DRC has offered mining opportunities to US companies in Rubaya, currently held by M23 rebels, indicating that the US would need to play a role in maintaining peace if it wants access to rare minerals. This week, the DRC announced the formation of a $100 million initiative to establish “mining guards” to secure mines, with investment from the US and the United Arab Emirates. However, lawyers in the DRC have challenged the MOU in court, while part of Kenya’s MOU has been suspended by a High Court in the face of an ongoing court challenge. South Africa in the cold South African HIV scientist Prof Linda-Gail Bekker received a standing ovation at the International AIDS Conference in 2022 when she announced the results of the lenacapavir clinical trial. South Africa has the biggest HIV population in the world, and was the largest international recipient of US National Institutes of Health (NIH) research funds, as well as getting funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR). “Our report illustrates what an ‘America First’ approach to global health looks like: Lifesaving programs shuttered, world-class research jettisoned, decades of progress against HIV/AIDS jeopardized. All to the harm of, not only South Africans, but to Americans and the global public as well,” said Thomas McHale, director of public health at PHR and a report co-author. Co-author Emily Bass warned: “Short-sighted, sudden withdrawal of funds for critical components of the HIV response will cause long-term harm to infants, children, adolescent girls and young women, and other groups at the highest risk of HIV.” The report mentions two scientific breakthroughs that came from US-South African research partnerships, namely the clinical trial of lenacapavir, an injectable pre-exposure prophylaxis (PrEP) that is almost 100% effective in preventing HIV, and updated global guidelines for treating drug-resistant tuberculosis (TB). These breakthroughs “directly benefit Americans”, the authors argue. “By freezing research funding to South Africa, the Trump administration is sabotaging the United States’ own future health and national security.” The report is based on interviews with South African doctors, researchers, people living with HIV, and others involved in South Africa’s HIV response efforts. Image Credits: Daniel Torok/ White House , Kerry Cullinan. Record European Heatwaves Shrink Glaciers and Diminish Snow Cover in 2025 29/04/2026 Disha Shetty Europe experienced record extremes in 2025, according to WMO’s latest assessment. Around 95% of Europe experienced above-average temperatures in 2025, with record heatwaves from the Mediterranean to the Arctic region. This caused rapid loss of glacier mass and snow cover, according to the latest State of the European Climate report by the World Meteorological Organization (WMO) released on Thursday. All of Europe’s glaciers saw a net mass loss, with Iceland recording its second-largest glacier loss on record. The continent experienced dangerously high air temperatures, drought, heatwaves and record ocean temperatures. This has translated into economic and biodiversity loss affecting countries and ecosystems across the continent. “Europe is the fastest-warming continent, and the impacts are already severe. Almost the whole region has seen above-average annual temperatures,” said Florian Pappenberger, Director-General of the European Centre for Medium-Range Weather Forecasts (ECMWF), an inter-governmental organisation that contributed to the report along with WMO. Also read: Europe is World’s Fastest Warming Continent With Record Temperatures in 2024 Europe is warming twice as fast as the global average Europe is now the fastest-warming continent, warming twice as fast as the global average. The impact of the temperature increases is most visible in the coldest regions, such as the Arctic and the Alps. Snow and ice play a critical role in slowing climate change by reflecting sunlight into space in what is known as the albedo effect. “In 2025, sub-Arctic Norway, Sweden and Finland recorded their worst heatwave on record with 21 straight days and temperatures exceeding 30°C within the Arctic Circle itself,” Pappenberger of ECMWF said. This also pushed up temperatures within and adjacent to the Arctic Circle to over 30°C, peaking at 34.9°C in Frosta, Norway. Ironically, low levels of air pollution in Europe allow more solar radiation to reach the surface, leading to a higher rate of warming. The number of cold stress days when temperatures drop below normal is also reducing. Nearly 90% of the continent experienced fewer cold stress days than average, and minimum temperatures remained above average for most of the year. Hot, dry conditions resulted in more wildfires. A record total area of around 1,034,000 hectares was burnt across Europe – an area larger than Cyprus. Spain, Cyprus, the United Kingdom, the Netherlands, and Germany recorded their highest wildfire emissions on record in 2025. Record loss of glacier mass Glaciers across Europe lost mass in 2025, with the highest loss recorded in Iceland. The Greenland Ice Sheet, which is the largest ice mass in the northern hemisphere and covers 80% of Greenland, lost 139 gigatonnes (139 billion tonnes) of ice. This is equivalent to 1.5 times the volume stored in all glaciers in the European Alps. Such ice loss contributes to rising global sea levels, with every centimetre increase exposing an additional six million people to coastal flooding. Overall, snow cover was 31% below average, affecting 1.32 million square kilometres, which is equivalent to the combined area of France, Italy, Germany, Switzerland, and Austria. “The ESOTC 2025 paints a stark picture: the pace of climate change demands more urgent action. With rising temperatures, and widespread wildfires and drought, the evidence is unequivocal; climate change is not a future threat, it is our present reality,” Samantha Burgess, Strategic Lead for Climate at ECMWF said. Rising ocean heat, reducing river flow Nearly 86% of European waters saw strong marine heatwaves in 2025. Oceans absorb 90% of the atmosphere’s excess heat due to the burning of fossil fuels. In 2025, Europe’s sea surface temperature was the highest on record. Around 86% of the region experienced strong marine heatwaves, disrupting fish and the ocean plants. Changes in rainfall and snowfall patterns have also affected the flow in 70% of Europe’s rivers. In May 2025, around half of Europe (53%) was affected by drought conditions. “Maintaining our own state-of-the-art, reliable data records of our Earth system is vital for making informed policy decisions in our rapidly changing climate. Copernicus is pivotal to help us preserve our sovereignty, our environment, food systems, safety, and economy,” said Mauro Facchini, Head of the European Commission’s Copernicus, is the European Union’s Earth Observation Programme. Renewable growth and actionable items for policymakers The share of renewables in Europe’s energy mix has gone up, supported by the growth in solar energy. A silver lining in the report is the growth of renewable energy, which in 2025 supplied nearly half (46.4%) of Europe’s electricity. Solar power contributed around 12.5% of this, a new regional record. Countries have begun to see energy security as a national security issue, and that appears to be one of the reasons driving the growth of renewables, including the adoption of nuclear energy at a higher rate compared to recent decades. Another positive was that by the end of 2025, around half of the European Biodiversity Strategy 2030’s recommended actions were in place or completed. The strategy is a European Union plan to restore the continent’s biodiversity. The report highlighted initiatives like Ireland’s network of marine protected areas, Armenia’s biodiversity finance plan, and Iceland’s funding to assist in recovering wetlands as examples of policy interventions that can help arrest biodiversity loss. Image Credits: Unsplash/Jochen Bückers, WMO. Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Energy Transition ‘Past Point of No Return,’ 57 Nations Declare at First Fossil Fuel Phase-Out Summit 01/05/2026 Stefan Anderson Coalition launches first sustained diplomatic push to phase out oil, gas and coal as war in the Middle East exposes the costs of fossil fuel dependence. The first international conference on phasing out the oil, gas and coal igniting the climate crisis ended with 57 governments representing every continent and a third of the global economy declaring the transition away from fossil fuels is now irreversible. “Actions taken to date prove that the energy transition is past its point of no return,” the coalition declared in its closing document, affirming all members were “ready to advance their transition away from fossil fuels.” The momentum is partly driven by concern for the planet, but also by a strategic desire for the energy independence that renewables could provide in an era of geopolitical instability – a case sharpened by the havoc the war in the Middle East was wreaking on the global economy as delegates gathered on Colombia’s Caribbean coast. “In a time that has been marked by fragmentation, that has been affected by war, by mistrust and the climate crisis, to sit here together and talk about the challenges, talk about the taboos, it’s a deep transformation of policy,” Irene Vélez Torres, Colombia’s environment minister and conference co-chair, said in her closing remarks in Santa Marta. Conference co-chairs Irene Vélez Torres, Colombia’s environment minister, and Stientje van Veldhoven, the Dutch climate minister, celebrate at the closing plenary. “When they look back at us from the future, they will remember that we were there, working on the challenges of our time,” Vélez Torres added. “That we decided not to focus on an economy built on war and destruction — we decided instead that it was necessary to prioritise life, security, certainty, sovereignty and solidarity.” The conference produced no binding commitments, no finance pledges, no promises of emissions cuts — that wasn’t the point. Instead, organisers pitched the summit as a “safe space” for countries already committed to phasing out fossil fuels to speak frankly. No negotiations, no consensus text to be watered down, no red lines passed down from governments to throw a wrench into discussions. A space free of the fossil fuel lobbyists who fill the corridors of UN climate summits by the thousands, both openly and embedded in petrostate delegations, often outnumbering full national delegation teams. “The fact we didn’t have negotiations here makes for such a different dynamic,” said Stientje van Veldhoven, the Dutch climate minister and co-chair alongside Vélez Torres. “The psychology of the Santa Marta process is something that we will definitely make sure to carry forward.” A coalition born of frustration Two weeks of negotiations in Belém, Brazil, failed to address a phase-out plan for coal, oil and gas as more than 100 nations blocked language on the fossil fuels at the root of the climate crisis. Three years on from the COP28 breakthrough in Dubai, where nearly 200 countries agreed to “transition away from fossil fuels,” efforts to translate the pledge into concrete action have hit a wall. Negotiations to agree a phase-out roadmap at COP30 in Brazil last November were torpedoed by a coalition of petrostates led by Saudi Arabia, which drew over half of the nations in attendance to its side in opposing the plan. The final text in Belém contained no reference to “fossil fuels” at all, a marked step backwards for the UN climate process. Without that failure, the Santa Marta conference would not exist. Conceived in the hours after COP30 collapsed, the new process was born of frustration with the gridlock of consensus-based UN climate diplomacy. But its architects stressed that it is meant to be complementary to mainstream COPs, not to replace them. “It’s very important that we agree on the fact that we want this conference, this process, to be like an accelerator for what we want to do in the context of UNFCCC,” van Veldhoven said, adding that the chairs have already been in touch with the COP31 presidency. Alongside government ministers, the conference included nearly 3,000 representatives of subnational governments, trade unions, scientists, civil society groups, Indigenous Peoples, women’s organisations and youth representatives, all named in the closing document as equal participants rather than observers, the title they hold in UN negotiations. “A new reality is taking shape: this is no longer a one-off moment, but the foundation of an ongoing international process dedicated to phasing out fossil fuels,” said Kumi Naidoo, president of the Fossil Fuel Treaty Initiative. “What is emerging is a process that can finally match climate diplomacy to the scale of the crisis.” Countries will attempt to carry the momentum forward at the next phase-out conference, confirmed in the closing hours to be held in 2027 on the Pacific island of Tuvalu and co-hosted by Ireland, pairing a wealthy European island with one across the globe at risk of disappearing under sea-level rise. “We are making history. We have proven, in the words of our youth, that another way is possible,” Tuvalu’s representative said. “The world is in a fossil fuel crisis, of climate breakdown, of conflict, of instability. But here in Santa Marta, we have planted a seed of solutions.” The tailwind from Hormuz Roughly a fifth of the world’s oil passes through the Strait of Hormuz, where wartime disruptions have driven prices to their highest level in years and exposed how much the global economy still depends on fossil fuels. Running through the conference was the war between Israel, the United States and Iran, which has disrupted shipping through the Strait of Hormuz, tightening gas supplies across Europe and Asia and skyrocketing oil prices to their highest level in years. On the same day delegates closed proceedings, US President Donald Trump told reporters Iran would have to “cry uncle” before he lifted what he called his “genius” blockade. Brent crude hit $126 a barrel hours later, approaching the spike that followed Russia’s invasion of Ukraine in 2022. For the three-quarters of the world that depends on fossil fuel imports, the message of the past five days was hard to miss: their energy costs, inflation rates, fiscal stability and the prices their citizens pay for food and fuel are tied to decisions made by a handful of leaders in Washington, Moscow and Riyadh – none of whom were in Santa Marta. The coalition’s closing document named the Hormuz crisis directly, calling the disruptions a demonstration “that reducing fossil fuel dependencies is critical” to “keep our planet livable, to safeguard energy security, and to build economic resilience to volatile fossil fuel markets.” “Destructive oil wars, widening fuel and food shocks, and a mounting climate crisis only bolster the conviction that breaking free from the fossil fuel system is not a matter of magical realism but of radical realism, in line with science and the law,” said Nikki Reisch, director of climate and energy at the Centre for International Environmental Law. Van Veldhoven framed the crisis as part of the case for moving faster. “If these countries significantly reduce their dependency on fossil fuels, it means they’ll be investing in their own economy instead of importing fossil fuels from abroad,” she told Bloomberg. “It means they’ll be investing in clean technologies, but it also means they’ll be shielding their economies against the kind of price shocks we’re seeing currently.” Santa Marta: Key outcomes from first summit on ‘transitioning away’ from fossil fuels | @daisydunnesci Read here: https://t.co/YGUgQR5BTg pic.twitter.com/1nZuILSPO7 — Carbon Brief (@CarbonBrief) May 1, 2026 France became the first major economy to act on that argument at scale during the conference, releasing a national roadmap to eliminate fossil fuels from its energy mix by 2050. The plan does not introduce new pledges but consolidates existing French climate and energy targets under a single explicit goal: ending the use of oil, gas and coal for energy purposes by 2050. Globally, the picture is mixed. Fossil fuels remain responsible for more than 75% of greenhouse gas emissions, but new renewable capacity in 2025 is nearly 50% higher than in 2023, and renewables are meeting nearly all new energy demand, according to the International Energy Agency. Investment in the energy transition reached a record $2.4 trillion in 2024, more than double 2019 levels, though it is concentrated in advanced economies and China, IRENA found. “This momentum is not yet enough to deliver the needed breakthrough,” said Bronwen Tucker, public finance lead at Oil Change International. “The richest polluting countries must take immediate action to accelerate their transitions at home and show up with meaningful international economic cooperation.” Coalition of the self-aware For all its ambition, the coalition openly admitted the limits of its own reach. The outcome document released in Santa Marta lays out in candid detail the shortcomings of the coalition in Colombia, and the distance all nations still have to go to achieve the transition away from fossil fuels. Chief among these admissions is the degree to which most nations in attendance continue to be dependent on oil, gas or coal for the public revenues that fund health, infrastructure and other government functions, and ensure energy security. Until governments find a way to replace that funding, walking away from fossil fuel production remains off the table. “The countries present in Santa Marta still have structural dependencies to overcome, including fiscal dependencies, debt constraints, the dependence of the financial architecture on fossil fuels,” the outcome paper states. “Transitioning away from fossil fuels is more than replacing one energy source with another … the transition itself is complex.” Many others simply do not have the financial headroom to invest in renewables due to looming debt payments and empty balance sheets. “We must confront economic dependence on fossil fuels that shape the realities we face,” Tuvalu’s delegate said. “Unsustainable debt, reliance on fossil fuel revenues, and a global financial system that was not built for us, and too often fails us.” The coalition also recognised the limits of its own power. While the alliance contains a meaningful contingent of major fossil fuel producers – Norway, Canada, Australia, the United Kingdom, Brazil, Mexico, Nigeria, Angola and Colombia itself – what it does not contain is a critical mass of global fossil fuel supply or demand. The 57 countries present make up about a fifth of global fossil fuel production, a third of oil and gas demand, and the same share of world economic output. The five biggest fossil fuel producers – the United States, China, Russia, India and Saudi Arabia – were all absent. Together, they control nearly half the world economy, and pump about 45% of the world’s oil, half its natural gas and three-quarters of its coal, far outstripping the heft of the Santa Marta coalition on all fronts. “We are here with an immense group, and yet it is still too small a group for what our ambition actually is,” van Veldhoven said. “Let’s make sure that we continue to drive this process as an open coalition. That means we have to ensure visibility of the outcomes and use that as an invitation to others to join us.” Rockstars to the rescue Attendees gather for the launch of the Science Panel for the Global Energy Transition (SPGET) in Santa Marta. A concrete outcome of the summit is the creation of a new scientific panel to advise nations on the practice and policy of the fossil fuel phase-out, an idea born in the halls of COP30, which Vélez Torres pitched as a sort of climate scientists’ Avengers team of “rock star academics”. “This panel not only repairs a historical debt of an organisation dedicated, finally and for the first time, to overcoming fossil fuels in the energy matrix,” she said, “it will also tell us about other types of challenges regarding the social and economic limitations of being able to carry out this transition as quickly as possible.” The Science Panel for the Global Energy Transition (SPGET) will unite over 100 scientists and academics to guide nations in policymaking and emissions pathway analysis with the goal of keeping the 1.5°C warming target enshrined in the Paris Agreement alive. The independent panel will focus on mapping policy options, green technologies and financial mechanisms that can be harnessed by countries to reduce emissions and fossil fuel dependence. Johan Rockström, director of the Potsdam Institute for Climate Impact Research and co-lead of SPGET, said it will operate as a “scientific service” to governments, helping them figure out the balance of energy supply and demand with a “scientifically aligned, just and orderly phase out of fossil fuels.” “[The panel] will also enable us to have feedback into the COP process so that we can keep the fossil fuel phase-out discussions in plenary at the COP meeting alive,” Rockström said. “Now is the moment to tip the scales, to not allow anymore that a few actors at the COP meetings always block the most important discussion of them all: the phase-out of coal, oil and gas.” The hard the work begins Delegates arrive for high-level ministerial sessions in Santa Marta, Colombia. The final agreement struck at Santa Marta establishes three “workstreams”: working groups of countries, experts and civil society that will meet between now and the next conference to develop policy options on the thorniest questions of the phase-out. The first will focus on national emissions roadmaps, taking specific aim at what Vélez Torres called the “punto ciego,” or blind spot, in the Paris Agreement: exported emissions. Under the Nationally Determined Contributions (NDCs) mandated in the Paris Accords, countries report emissions on a territorial basis, but not the emissions from fossil fuels they extract and sell to other countries. For major exporters, the effect on emissions calculations is enormous. Norway’s exported emissions from oil and gas are roughly ten times its territorial emissions. Saudi Arabia’s full emissions footprint rises to two and a half times its reported emissions, closing in on 5% of global CO2 on its own. “We are not making clear commitments about how we are going to control the emissions that are exported from producing countries,” said Vélez Torres, whose country, Colombia, sees its emissions more than double when its coal and oil exports are counted. “We want to be very clear, very honest about how to transition away from production as well.” Winding down production is one of the most complex questions in the phase-out debate. If demand falls first, producer countries face collapsing revenues and an economic crisis. If supply falls first, importers face energy shortages. A complementary workstream announced in Santa Marta, backed by the OECD, will look at how exporters and importers can coordinate their wind-downs so the two declines move in step, avoiding a scenario where one side pulls back faster than the other, leaving producers without buyers or importers without fuel before clean alternatives can fill the gap. Money traps, and future hopes Indigenous Peoples’ representatives played a central role in the Santa Marta phase-out talks. The final workstream, supported by the International Institute for Sustainable Development, takes on what the co-hosts called the three “traps” holding states back from moving faster on fossil fuel phase-outs: finance, debt and subsidies. It is, in many ways, the hardest of the three. Without alternative revenues lined up, governments cannot turn off the tap on production that pays their bills. The constraint tightens further as interest payments squeeze public budgets and credit ratings for developing nations render borrowing exceedingly expensive, leaving fossil fuel revenue indispensable and crowding out renewables investment. Then there are the subsidies. Governments worldwide handed roughly $1.3 trillion in direct support to fossil fuel producers and consumers in 2022 to keep pump and power prices low, according to the IMF, and as much as $7 trillion once the unpriced costs of pollution and climate damage are factored in. The direct figure alone is more than half the $2.4 trillion the world invested in the entire energy transition the same year, tilting the market against cheaper renewables as subsidies keep expensive fossil fuels price-competitive. In Ghana, the financial realities of fossil fuel dependence remain too steep to overcome, its delegate told the conference, despite the country supporting the phase-out goal. “In Ghana, fossil fuels remain deeply tied to government revenues that fund essential public services and to our broader energy systems,” he said. “We need a fossil fuel treaty that creates the necessary architecture for a just transition.” Ten-year-old Paula Pedro from Colombia speaks at the closing of the Santa Marta conference. That the coalition is willing to talk openly about the financial dependency at the heart of the phase-out is, for many participants, the most encouraging signal to come out of Santa Marta. Whether it can build bridges and expand its membership as the climate crisis accelerates is the question that will loom over COP31 in Antalya later this year, and in the run-up to Tuvalu in 2027. With the workstreams set and the next conference scheduled, it fell to a 10-year-old from Colombia to remind the room what the diplomacy was for. “Of the 12 million children we have in Colombia, eight out of ten of us are affected by fossil fuels and weather changes,” Paula Pedro, representing the Colombian children and youth coalition, told the assembly. “What we need, for the children, is that the people in this room do the math, but not only on paper, but accomplish change as a matter of fact.” “We’re not only the future,” Pedro said. “We are the present and beyond.” Image Credits: Colombian Environment Ministry, Colombian Environment Ministry, COP30, ColomColombian Environment Ministrybian Ministry o, Colombian Environment Ministry, Colombian Environment Ministry, Colombian Environment Ministry. Heartbroken Families Face Huge Structural Barriers When Trying to Prove Medical Negligence in India 01/05/2026 Arsalan Bukhari & Naila Tabassum Indian families face a huge struggle to get timely access to medical records of loved ones who have died in Indian health facilities, while the police can only lay a charge against a doctor if an independent medical expert first confirms negligence. NEW DELHI – India faces thousands of medical negligence cases every year, but structural problems make it extremely difficult for patients’ families to find out what has happened to their loved ones – let alone win compensation when treatment has been botched. “A shadow of death is looming over us,” Ashwini Bajaj, a Haryana-based businessman, told Health Policy Watch, recalling the treatment of his 24-year-old son, Deshbandhu, more than a year after his death. In December 2024, Deshbandhu, an MBA student at Punjab University and Bajaj’s only son, developed a fever that lasted more than two days. On 26 December, he visited a hospital near his university in Chandigarh, where he was prescribed medicines and given a series of tests, including a liver function test (LFT). By the time the results came out later that evening, Deshbandhu had returned to his parents’ home in Hisar, around 200 kilometres away. The next day, he went to a private hospital there, but his condition deteriorated rapidly. His oxygen saturation dropped to 65%, and doctors warned of acute liver failure. “We were told his condition was very critical and that the hospital did not have the resources to treat him,” Bajaj said. “We were asked to take him to a super-speciality hospital. It felt as if the ground beneath our feet had slipped away.” Deshbandhu was shifted to a major private hospital in Gurugram. “My son was there for over three weeks. His condition kept deteriorating. He went with jaundice, and he developed intestinal obstruction, kidney stress, and pneumonia,” Bajaj said. A few days after his 24th birthday, which was on 20 January 2025, Deshbandhu died. Bajaj says he has been unable to return to work. His case reflects broader systemic gaps in India’s healthcare system, where delays in critical care, weak referral systems, and limited transparency can have life-threatening consequences — and the lack of updated national data continues to hamper accountability. Transparency in treatment Deshbandhu Bajaj (24), a mountaineer and an MBA student who died in January 2025. His father, Ashwini Bajaj, alleges medical negligence. “Initially, I thought the doctors tried hard to save my child, but when I obtained all the medical reports, which took three to four months to obtain, I realised much time was lost before the actual treatment started,” Bajaj said. “When I made a day-by-day chart, I realised that, for at least four days, my son didn’t get the treatment he should have. “Every evening, I used to get payment requests promptly on my WhatsApp. If they could send payment requests, why can’t they share procedural updates the same way?” Rujhan Dhawan, a lawyer at the Punjab and Haryana High Court, told Health Policy Watch such opacity is a major barrier to accountability. “A patient, once admitted, is entirely dependent on the institution not only for treatment but also for truthful disclosure,” he said. “Critical information about procedures and complications is often not readily accessible to families.” Bajaj’s family spent over ₹30 lakh ($33,000) on treatment. He says he is not seeking compensation, but a legal framework that mandates transparency. Not an isolated case Deshbandhu’s case is not an isolated one. According to the 18th Annual MedLegal Review, 65,000 medical negligence cases were filed in India in 2025 alone. Radha Sharma (49), a resident of Rajasthan’s capital city Jaipur, died days after being given a TB drugs although she had been diagnosed with a liver-related illness. In Jaipar, around 270 kilometres from Gurugram, 55-year-old tax consultant Kishan Kumar Sharma is fighting a case linked to the death of his wife, Radha. On 3 March 2025, she developed mild jaundice and was admitted to a private hospital. A test suggested Budd-Chiari syndrome, a rare liver disorder. However, despite a negative tuberculosis test, Radha was prescribed the TB drug, Isoniazid, said Sharma. Isoniazid should not be prescribed to patients with liver disease who have bilirubin levels over 4 mg/dL, according to World Health Organization (WHO) guidelines. But Sharma says his wife’s liver disorder was overlooked. Radha’s condition deteriorated rapidly, and she died on 18 March. “I have a simple question,” Sharma said. “Why was my wife given Isoniazid? Was it part of any established protocol or something else?” The risks highlighted by such cases reflect a broader global problem. According to the WHO, an estimated 138 million patients are harmed every year due to unsafe medical care. Lack of dedicated investigative body Nishant Bharihoke, an advocate at the Delhi High Court who specialises in medical negligence cases, told Health Policy Watch the core issue lies in the absence of a dedicated independent investigative framework. “India does not have a dedicated body specifically tasked with investigating deaths or serious injuries caused by medical negligence,” he said. “When a patient dies, and the family suspects wrongdoing, there is no authority whose sole function is to find out what happened.” Complaints are typically routed through State Medical Councils, which may form inquiry committees. Their decisions can be appealed to the National Medical Commission, but Bharihoke argues that the system is structurally limited. “The National Medical Commission’s primary mandate is to regulate medical education. Its disciplinary board has no independent investigators and no power to enter hospitals and examine evidence,” he said. He also pointed to a legal loophole: since these proceedings are not strictly judicial, false statements made before such bodies do not result in perjury charges. For families like Bajaj’s and Sharma’s, he said, this gap deepens the sense of injustice. When cases turn criminal Simran Chhabra (21), a resident of Gurugram and MA student at Amity University, was suffering from a simple cough and cold. She died within minutes of being administered an intravenous injection. The family is fighting a medical negligence case in a Gurugram court. The gap becomes even wider when negligence overlaps with criminal allegations. One such case is the death of 21-year-old Simran Chhabra. On 21 January 2023, she visited a private hospital in Gurugram with symptoms of cough and cold. According to a prescription her brother, Sourabh Chhabra, shared with Health Policy Watch, she was administered an intravenous injection of Dynapar. This is usually used to treat pain and inflammation associated with arthritis or after surgery. “As soon as the injection was fully administered, Simran collapsed on the bed and froth began coming out of her mouth,” Sourabh said. “Everything happened within minutes. I had no time to understand what was going on.” She was referred to another hospital, where she was declared dead. According to Bharihoke, the family’s legal representative, the doctor later claimed that multiple emergency interventions were carried out, including five additional injections and cardiopulmonary resuscitation (CPR), using drugs typically administered in cases of severe allergic reactions. However, the post-mortem report reviewed by Health Policy Watch raises questions. It records only two puncture marks on her body, and there is no mention of a cannula (an intravenous tube) being used. If multiple injections were administered, the family asks why there is no corresponding physical evidence. In this case, they argue, the medical account and post-mortem findings do not align. “Forget conviction or arrest, even registering an FIR in such cases often requires court intervention,” Bharihoke said. A FIR is a First Information Report (FIR) in Indian medical negligence cases, a formal document prepared by police under Section 154 of the Criminal Procedure Code upon receiving information about alleged criminal negligence. Absence of a legal framework Several structural barriers insulate medical health practitioners against negligence cases, according to legal experts. “In India, police usually cannot even register a case against a doctor unless an independent medical expert first confirms negligence,” Bharihoke told Health Policy Watch. “In most cases, doctors are reluctant to give such opinions, especially against their peers.” The challenge is compounded by access to evidence. Hospitals retain control over key records, case files, prescriptions, nursing notes, and CCTV footage while families often receive only partial or delayed documentation. India also lacks a statutory system guaranteeing timely access to medical records for patients and their families. There is no clear legal mandate requiring investigators to immediately secure hospital evidence. Tanvi Dubey, a Supreme Court lawyer, told Health Policy Watch the legal framework itself raises the bar for accountability. “Criminal liability in medical negligence cases is limited to gross negligence, not simple errors of judgment,” Dubey said. “This significantly narrows the scope for prosecution.” Even initiating an investigation can be delayed: “Authorities are allowed to conduct preliminary inquiries before registering a case, which often means waiting for medical opinions and slows the process.” Dubey also pointed to the continued reliance on what is known in Indian law as the “Bolam principle,” where a doctor’s actions are judged against a body of medical opinion. “This makes expert testimony central. Unless a complainant can produce strong contrary evidence, it becomes very difficult to establish negligence,” she said. While multiple legal remedies exist, including consumer courts, civil litigation, and disciplinary proceedings, Dubey noted that each comes with limitations. “Criminal prosecution is rare, civil cases are slow and evidence-heavy, and disciplinary proceedings do not always ensure compensation or thorough fact-finding,” she said. Compared with Western peers, India faces two major policy gaps in patients’ treatment: the absence of a national electronic medical record (EMR) system, and the lack of a digital system connecting labs directly to the consulting doctor. Currently, India doesn’t have a mandatory EMR policy applicable to healthcare organisations. Even today, prescriptions, clinical notes, and drug administration records are still handwritten in the majority of hospitals and almost all smaller clinics. This makes them more vulnerable to tampering, loss and destruction. The absence of a nationwide electronic medical record system adds another layer of opacity. In many facilities, records remain handwritten and vulnerable to alteration; a gap Bharihoke alleges was evident in Simran’s case. Urgent reform is necessary India’s Minister of Health Jagat Prakash Nadda. Legal experts are calling on authorities to establish an independent statutory body to investigate medical negligence. Only families with the financial means and emotional capacity to pursue long legal battles are able to take up medical negligence cases. For many others, the burden becomes too heavy to carry. While the rules may appear neutral on paper, experts say their impact is deeply unequal. Legal and policy experts argue that the most urgent reform is structural, particularly the creation of an independent statutory body tasked solely with investigating patient safety incidents, particularly in cases involving death, permanent disability, or serious injury. Such a body should have the authority to enter hospital premises, access medical records, secure CCTV footage, and record statements. Its findings should be made public, while the evidence it collects remains protected from use in criminal or disciplinary proceedings. In England, the Health Services Safety Investigations Body (HSSIB), established in 2023, follows this approach by conducting independent investigations into patient safety incidents. Globally, different systems offer alternative approaches to accountability. In the United States, oversight is spread across multiple layers: state medical boards regulate conduct, a national database tracks malpractice records, hospitals report serious incidents, and patients can pursue civil litigation. China follows a three-tier system, allowing patients to first negotiate with hospitals, then seek mediation, and finally pursue civil lawsuits. In parts of Europe, including France and the Nordic countries, no-fault compensation systems allow patients to receive compensation without proving negligence, making the process more accessible and less adversarial. Aviation and rail safety investigations have long operated on similar principles, focusing on systemic failures rather than individual blame. For India, experts say the lesson is clear. Accountability frameworks do not have to rely solely on litigation. A system built on independent investigation, timely access to evidence, and patient-centric redress could help provide answers to families like the Bajajs and Sharmas. Image Credits: César Badilla Miranda/ Unsplash, Felix Sassmannshausen. No Pandemic Agreement Annex by World Health Assembly, Says Civil Society 30/04/2026 Kerry Cullinan (Left to right from top) Third World Network’s moderator and speakers Lauren Paremoer, KP Gopakumar and Tamara Prisenburg form AIDS Healthcare Foundation. The final missing piece of the Pandemic Agreement – a pathogen access and benefit-sharing (PABS) system – is unlikely to be agreed on by the World Health Assembly (WHA) later this month. This was the view of civil society observers of the talks taking place at the World Health Organisation (WHO) headquarters in Geneva, who briefed the media on Thursday. The sixth round of talks is scheduled to end late on Friday night (1 May). Earlier in the week, WHO Director General Dr Tedros Adhanom Ghebreyesus told a Geneva media briefing that “key differences remain on key issues”. “I still see a common will to reach consensus, which means I continue to believe there is a way to reach consensus,” Tedros added. Although the notion of a “hybrid” PABS system is being discussed informally, its proponent, the European Union (EU), has not presented any formal text, Third World Network’s (TWN) KM Gopakumar told the media briefing, which was hosted by TWN and the AIDS Healthcare Foundation. While Brazil and Botswana have apparently indicated that they might support a hybrid or “blended” compromise, the Africa Group is opposed to it, according to the civil society representatives. WHO member states are negotiating how to share both information about dangerous pathogens and some of the “benefits” that manufacturers may develop from that information – namely, vaccines, therapeutics and diagnostics (VTDs). The “hybrid” or “blended” proposal is a mix of mandatory and voluntary measures for sharing pathogen information and any benefits that flow from this information. It de-links information-sharing and benefit-sharing. Gopakumar said that, in terms of the blended agreements, countries that shared pathogens “will have the freedom to choose to attach certain conditions for sharing the data and the sample, including benefit sharing requirements” or share without any conditions. Kill the efficiency Shifting the choice to individual countries would undermine the efficiency of a single PABS system as users would need to negotiate with the individual countries instead of through a centralised system, he argued. “If you have a hybrid system, first of all, it kills the efficiency [of a single system], and second, it’s going to debase the access and benefit sharing norms set by the international instruments like the Convention on Biological Diversity and the Nagoya Protocol. Any attempt to dilute benefit-sharing obligations would be a “disaster” for equity, said AHF’s Tamara Prisenberg. Lauren Paremoer of the People’s Health Movement said that the blended model introduces “a two-track system for accessing pathogens” that violates access and benefit-sharing on an “equal footing” specified in Article 12 of the Pandemic Agreement. One track would allow anonymous users to access pathogen data without upfront commitments to benefit-sharing or legally binding contracts. The other was in line with Article 12, permitting access to pathogens through databases and laboratories that would require users to register and commit to specified benefit-sharing. Earlier in the day, the Intergovernmental Working Group (IGWG) briefed civil society on text-based negotiations, but very little of the text they shared had been “greened” to show agreement. EXCLUSIVE: WHO Opens Nominations for Next Director General; Germany May Advance Former Merkel Aide, Helge Braun 30/04/2026 Felix Sassmannshausen, Elaine Ruth Fletcher & Editorial team WHO DG Dr Tedros Adhanom Ghebreyesus issued a call for nominations for the DG elections. He recently travelled to Berlin, where he met with high-level politicians and the WHO’s Pandemic Intelligence team. As the World Health Organization (WHO) formally opens the nomination process for the next Director-General, Germany now appears likely to propose Helge Braun, Chief of Staff in former Chancellor Angela Merkel’s government, according to Berlin insiders. But after slashing its global health budget, sources question whether a German candidate can win wide support from other WHO member states. WHO Director-General Dr Tedros Adhanom Ghebreyesus has formally issued a call to WHO member states for nominations to the DG elections, scheduled for May 2027, in an invitation sent on 24 April to all WHO member states. WHO confirmed this in an email to Health Policy Watch. The invitations had been sent via private letters to countries’ Geneva missions. The period in which member states may nominate candidates will now run for six months, until 24 September. Contenders who have until now remained in the shadows are expected to begin coming forward publicly with their candidacies at the World Health Assembly in May. From the German perspective, Berlin wants its financial weight reflected in executive influence at the multilateral level as the largest global health donor following the US withdrawal from the WHO in January 2025. The withdrawal, combined with the US non-payment of dues owed, thrust WHO into a budget crisis, prompting layoffs of about 25% of the workforce in the past year. German Foreign Ministry neither confirms nor denies The German Foreign Ministry, formally responsible for the nomination, declined to confirm or comment on Braun’s potential candidacy when responding to a query by Health Policy Watch. Germany’s other potential candidates include the contested former Health Minister Karl Lauterbach and the lesser-known Paul Zubeil. In contrast, Braun’s dual profile as an accomplished politician, skilled financial manager, and trained physician and researcher who successfully built cross-party bridges offers a distinct advantage. But he is little known outside of Germany. Bridge-builder with executive and medical expertise Former Chair of the influential German Budget Committee, Helge Braun (right), and former French Chair of the Finance Committee, Claude Raynal (left), in the Bundestag. The current WHO leadership landscape demands a candidate capable of managing deep institutional fractures and uniting a divided global community. Despite him being largely unknown in the international community, Germany could be expected to emphasise Braun’s extensive fiscal and crisis management experience in any candidacy it mounts. As ‘Head of the Chancellery’, effectively Chief of Staff, in Angela Merkel’s last term as Chancellor, from 2018 to 2021, Braun operated at the nexus of scientific advice and political implementation during the COVID-19 pandemic, notably comparing the Chancellery to an intensive care unit where acute problems must be solved. Between 2021 and 2025, Braun then chaired the powerful Budget Committee of the German Bundestag (Parliament), overseeing the distribution and management of hundreds of billions of Euros with strict discipline This profound understanding of macroeconomic management, coupled with his pragmatic defence of Germany’s controversial debt ceiling alongside crisis-driven special funds, makes him an attractive prospect for donor nations currently demanding more financial accountability and restructuring at WHO in Geneva. Serving as a central mediator across government ministries, Braun built a reputation as a highly pragmatic problem solver whose past domestic political affiliations will not necessarily dictate his future approach to global health governance. This pragmatism complements his longstanding political advocacy for research into infectious diseases like Ebola and malaria. And unlike many career politicians, Braun’s foundational expertise lies in medicine, having worked for years as an intensive care physician and anaesthesiologist. He returned to these roots in April 2025 by assuming the presidency of the University of Lübeck, an institution renowned for its focus on life sciences and artificial intelligence. Why the candidacy might spark concerns WHO member states are currently negotiating a pathogen access and benefit-sharing (PABS) system in Geneva. While Braun championed early interventions and massive digitisation projects in his role as Merkel’s Head of the Chancellery during the COVID pandemic, severe bureaucratic delays hampered the rollout of vaccination campaigns and testing strategies. This tarnished his crisis management legacy just as he exited the federal government. His domestic political capital suffered further damage during the December 2021 Christian Democratic Union leadership election, where he lost heavily to conservative rival Friedrich Merz, now Chancellor. Party members largely rejected Braun as an establishment candidate, perceiving him as too closely aligned with the moderate legacy of former Chancellor Angela Merkel. Additionally, it is questionable whether Braun would wield the necessary diplomatic connections and familiarity with foreign health systems to be effective on Day One of a term as WHO head. The Director-General must immediately command trust and authority on the international stage, particularly when dealing with health ministries and stakeholders in the Global South. Most notably, the German government opposed the release of COVID-19 vaccine patents during his tenure, drawing sharp criticism from international health equity advocates. Defending this refusal in May 2021, Braun wrote in a guest article for the German newspaper Die Zeit that “patent protection as a driver of innovation is not the problem in this crisis, but an essential foundation for its solution.” In the Global South, this track record could thus reinforce the perception that Germany defends pharmaceutical interests over equitable technology transfer – especially in the face of current PABS Annex negotiations. Recent reports from Tagesspiegel Background indicating that the former minister was approached by Germany’s Association of Research-Based Pharmaceutical Companies to become their next president, when the post becomes vacant at the end of 2026, might further fuel these concerns. Finally, Germany has been cutting back its Official Development Assistance (ODA) in general, including contributions to the World Health Organization, where it has historically been the largest member state donor after the United States. On Wednesday, the Merz government announced its 2027 budget plans with further ODA cuts following last year’s drastic 17% reductions. The likelihood of Germany fulfilling its original 2024 financial pledge to WHO for the current biennium (2026-27) also remains in doubt. “They can put forward a candidate, but I don’t think it’s going to get a lot of traction from other member states,” said one informed WHO source. “At a time when Germany is reducing global health funding to member states, I don’t think they can go ahead and claim the top seat.” Step back and support allied candidates? Braun served as Head of Chancellery under then German Chancellor Angela Merkel, seen here with WHO Director General Dr Tedros in Berlin in 2021. Furthermore, domestic opinion remains highly divided on mounting a campaign amidst the geopolitical strains on Chancellor Friedrich Merz’s coalition and Tedros has reportedly urged Germany to back allied candidates instead. At the same time, the desire to seize more leadership in the UN system remains strong after Germany’s failed previous attempt to secure the top role at the UN High Commissioner for Refugees in 2025. Currently, Germany is also pushing for another attempt at a UN Security Council seat. Should Germany put forward a candidate, Foreign Minister Johann Wadephul, who will make the final decision, also faces a stark choice between Braun and the better-known Karl Lauterbach, as well as Paul Zubeil with his strong international health and technical background. Advancing a WHO outsider like Braun against established public health veterans is a highly calculated risk for Berlin, which must first convince other European countries to rally behind him. In case Berlin formally nominates Braun, the success of his candidacy will depend entirely on how effectively the government can reframe his perceived lack of field experience and global networks as delivery on fresh, badly needed fiscal expertise and perspectives. Grappling with WHO’s funding crisis As the race for the next Director-General opens for formal nominations, the names of over a dozen high-profile potential candidates are still circulating – from Indonesia to the United Kingdom. Want to Become the Next WHO Director-General? Get in Line And the list is still growing. Among the newer names being floated is that of Dr Hanan Mohamed al-Kuwari, who served as Qatar’s Minister of Public Health until November 2024 and chaired the 153rd Session of the WHO Executive Board. Before joining the Hamad Medical Corporation in 1996, where she ultimately rose to managing director, al-Kuwari worked for Reuters and as a freelance health reporter. Holding a PhD in healthcare management from Brunel University and bringing early career experience from the WHO, she represents a highly networked voice from the Arab world, celebrated for her crisis resilience and for shaping the WHO’s recent global work programme. Dr Maria Neira, WHO Director of Climate, Environment and Health Another candidate who has been mentioned is Spain’s Dr Maria Neira, who recently retired from WHO as the director of Climate, Environment and Health. An iconic spokesperson for the climate, environment and health movement, Neira is known as a telegenic personality and adroit politically. As a young medical doctor, she worked in emergency relief in Latin America and Africa, and later served as Spain’s Vice Minister of Health and Consumer Affairs as well as President of the Spanish Food Safety and Nutrition Agency. However, Spain also recently decided to nominate a candidate to head the UN Food and Agriculture Organization (FAO), when Qu Dongyu’s second term as Director General ends in July 2027, leaving doubts about whether it would want to mount yet another campaign, in parallel. Continuing decline in ODA and global health aid Drastic ODA cuts and reduced global health funding leave vulnerable populations in precarious conditions worldwide. Whoever is elected will have to continue grappling with the continuing long-term declines in donor-driven ODA, and particularly global health aid – directly to countries and to WHO. While WHO 2026-2027 $4.2 billion base budget is now 85% financed, according to Tedros’ comments on Wednesday, declines in ODA continue to cast uncertainty on how the remaining $630 million gap will be filled. It’s unlikely that the $260.6 million in assessed US contributions still due for years 2024-2025, before the withdrawal became official in January, will ever be repaid, conceded WHO’s Tedros at a Geneva press briefing on Wednesday. “We’re hoping to get the money, but no signals yet,” Tedros told journalists, adding: “No signals means maybe we may not be able to get the money. The likelihood could be not getting the money.” “We’re looking at nontraditional donors. We’re looking at international financial institutions and other ways to mobilize that 15%,” Tedros said, in terms of filling that gap. “It’s not that we won’t go to the traditional donors, but I think we’re expanding that donor base.” This article has been edited to reflect additional information regarding Dr Hanan Mohamed al-Kuwari’s early career as a freelance journalist. Image Credits: X/Dr Tedros, Deutscher Bundestag/Leon Kügeler, European Commission. African Leaders Declare End of Aid Era at Nairobi World Health Summit, But The Data Tell a More Complicated Story 29/04/2026 Stefan Anderson Delegates gather for the opening plenary of the World Health Summit Regional meeting in Nairobi, Kenya. African leaders opened the World Health Summit Regional Meeting at the United Nations complex in Nairobi this week with a unified declaration that two decades of dependence on foreign aid for health is over. “The challenge that I see is that many of the leaders in our continent believe that it is somebody else’s responsibility. It should be the World Health Organization, USAID, I don’t know who,” Kenyan President William Ruto told the summit. “The sooner we realise that it is our responsibility to raise especially domestic resources to fund our health, the better for all of us.” The Nairobi meeting, the first co-organised by the World Health Organization (WHO) and the World Health Summit, has positioned itself as the continent’s first high-level response to the collapse of official development assistance (ODA) for health, which fell by an estimated $31.1 billion in 2025, according to the Africa Centres for Disease Control and Prevention (Africa CDC). Over 2,000 delegates from more than 50 countries, including health and finance ministers from 17 nations, are convening in the Kenyan capital to coordinate a united African position ahead of next month’s World Health Assembly in Geneva. “I don’t want to see this continent being dependent. And we are dependent because we want it,” Ruto said. “Africa is manufacturing a number of products today, from Egypt, from Kenya, from South Africa, from a number of countries, but we are not buying our own product.” Africa carries more than 25% of the global disease burden but accounts for less than 3% of global health expenditure. The continent currently produces less than 2% of the medicines and vaccines it consumes, leaving its countries dependent on external supply chains for essential medical commodities. “Who’s asking us not to buy our own product, who’s asking us not to register to the African Medicines Agency for the regulatory aspect?” Ruto asked. “It’s not Germany, it’s not Europe, it’s ourselves. We need to change our mindset.” A break with the past African leaders led by Kenyan President William Ruto arrive in Nairobi for the summit. The urgency on display in Nairobi is driven by the most disruptive year for global health financing on record. For African governments, the pivot to self-reliance has become a fiscal necessity. The dismantling of the United States Agency for International Development (USAID), followed by aid cuts by the United Kingdom, Germany, France and the Netherlands, drove a 23.1% drop in total ODA from OECD donors in 2025. This is the largest single-year contraction since records began. The US, Germany, UK, Japan and France accounted for 95.7% of the total decline. The Boston University ImpactCounter estimates the US cuts have already led to more than 518,000 child and 263,000 adult deaths from preventable diseases such as HIV and tuberculosis. A further 14 million preventable deaths, including 4.5 million children, may occur by 2030 if USAID funding gaps are not filled, a major international study found. Africa CDC estimates the combined cuts from the US, UK, Germany and other major donors will kill an additional two to four million Africans annually. “The year 2025 marked the end of one era and the beginning of another,” Sulaiman Shahabuddin, President and Vice Chancellor of the Aga Khan University, told the opening plenary. “We are confronting a new reality, defined by funding constraints, the rise of technology and artificial intelligence, and a decisive shift towards local ownership.” “Climate change, chronic diseases, lack of financial resources, the digital divide, inequity and others are [challenges] we will have to overcome,” Shahabuddin added. What aid remains on the table increasingly comes with strings attached. Washington has begun rolling out bilateral “America First” global health agreements, with US President Donald Trump retaining the right to terminate any programme judged not to align with American interests. Conditionalities include sharing pathogen samples and genomic data with US authorities, prioritising faith-based health providers to prevent services such as abortions, channelling funding away from non-governmental organisations, and, in the case of Zambia, granting access to critical minerals in exchange for health funding. Lukoye Atwoli, Dean of the Aga Khan University Medical College East Africa and the summit’s international president, said this year’s gathering would mark a break with past meetings on African health. “Historically, meetings about Africa and Africa’s health have been about lamentations. Have been about framing the problems. Have been about basically begging and saying that we have a problem and we need help,” Atwoli told delegates. “This meeting will be different.” Reform body launched Africa CDC Director Dr Jean Kaseya speaking in Nairobi. On the sidelines of the summit, Africa CDC launched the African High-Level Ministerial Committee on Global Health Architecture Reform. The body brings together health and finance ministers from across the continent to coordinate African positions ahead of the World Health Assembly and broader UN reform processes. Convening both portfolios in the same room is a long-standing demand of global health advocates, who have struggled for decades to make the economic case for health investment to treasuries that hold the purse strings. The committee, chaired by former Liberian president Ellen Johnson Sirleaf, will produce coordinated African position papers on health architecture reform and a 2026–2030 reform roadmap focused on five axes: governance, financial sovereignty, data sovereignty, local manufacturing, and pandemic preparedness. “The old model is no longer fit for purpose. Africa cannot continue to be a passive recipient of global health decisions,” said Africa CDC Director General Dr Jean Kaseya. “We welcome our partners, but on a new basis: not as donors and recipients, but as equal partners aligned with Africa’s priorities.” Aspiration meets evidence Official development assistance fell by a historic 23.1% in 2025. African nations are among the hardest hit. The data on whether Africa can deliver on the vision laid out in Nairobi tell a more complicated story. A Centre for Global Development (CGD) audit of 442 government actions across all 54 African countries found a continental reaction to the historic aid cuts split in radically uneven ways, a story of inequality within Africa as much as between Africa and its donors. The countries that moved fastest are those with the deepest pockets and most diversified economies, including Nigeria, Ghana and Ethiopia. Lower-income, debt-burdened countries, many of which were the largest per-capita recipients of foreign assistance, have largely absorbed the loss in silence. “Governments with limited fiscal space and weaker administrative capacity have less room to cushion abrupt external shocks,” the analysis found. “What is slightly surprising is that they were not only doing little about the aid cuts, they are also saying little about them.” Global Health Leaders Urge Fewer Agencies Amid Funding Crisis A separate CGD study published in February examined the budget statements of 18 sub-Saharan African countries: among the world’s poorest, most heavily aid-dependent and exposed to the cuts. It found that only two, Tanzania and Sierra Leone, proposed new revenue measures to replace lost financing in their 2025 budgets. None reprioritised spending from other sectors to protect health. “With few exceptions, governments neither raised new revenues nor reallocated spending to compensate for lost external financing,” the analysis concluded. The burden of adjustment, it found, has instead fallen on the services patients receive, from disrupted HIV and tuberculosis treatment to delays in vaccination campaigns and the closure of clinics that depended on donor financing. “Health is not a cost, it is an investment,” Ruto said. “And it is important for us to invest.” Cascading crises Runaway climate change is colliding with constant economic shocks from war and the COVID-19 pandemic, shrinking Africa’s budgets and taking away the space to invest in health. The continent’s ability to absorb the aid shock and finance the pivot to support its own health systems is constrained by an unending sequence of external crises over the past decade that continue to batter government budgets, layered on top of the escalating climate crisis. The COVID-19 pandemic, during which wealthy nations hoarded vaccines, exposed Africa’s reliance on a foreign supply chain that produces 99% of the vaccines and 90% of the medical supplies it consumes. Pandemic response cost African governments an additional $154 billion in 2020 and 2021, according to the African Development Bank, pushing sub-Saharan public debt up by 8 percentage points of GDP in a single year. Russia’s invasion of Ukraine drove an inflationary spike that ballooned debt-service costs across the region, a pressure that has now snowballed into the global economic crisis triggered by the US-Israeli war on Iran, to which African economies are uniquely vulnerable. The closure of the Strait of Hormuz, a chokepoint for a fifth of the world’s oil and a third of its liquefied natural gas, is driving up fuel and fertiliser costs and deepening food insecurity across the continent. The resulting inflation, weaker currencies and tighter global financial conditions across Africa are inflating debt-servicing bills and forcing governments to divert money that could otherwise help absorb the aid shock. Climate change is compounding the pressure on every front. African countries are losing between 2% and 5% of GDP to climate extremes, the World Meteorological Organization estimates, with some governments diverting up to 9% of national budgets to respond. Health systems will bear a growing share of that cost. The World Bank estimates climate change could drive at least $21 trillion in excess health costs in low- and middle-income countries by 2050, with sub-Saharan Africa among the regions hit hardest. “What was considered reliable for decades is turning out to be fragile,” said Birgit Pickel, Director-General for Global Health at Germany’s Federal Ministry for Economic Cooperation and Development. “Cracks are appearing in the international order. Cracks that, in some cases, are already leading to its collapse.” Fiscal squeeze limits options African debt levels have more than doubled in the past decade, according to ONE Data figures. The cumulative damage has left African governments with little room to manoeuvre. Thirty-two African nations now spend more servicing external debt than funding healthcare. The continent paid almost $90 billion in external debt service in 2024 alone, with African governments now spending an average of 17% of state revenue on debt servicing, according to leading estimates. The IMF warned last week that more than a third of African countries are at high risk of, or already in, debt distress, with rising interest bills “crowding out essential development spending, healthcare above all.” “Official funding will probably shrink, at least internationally. Domestic funding will hopefully move up,” Pickel said. “But there are innovative instruments out there to also meet urgent funding needs in the health sector, especially for heavily indebted countries.” Pickel proposed debt-for-health swaps, an instrument under which creditor nations cancel debt in exchange for redirected health spending, as a route to fiscal space for highly indebted countries. Germany issued €100 million in such swaps last year, channelled to the Global Fund. The figure is substantial as a signal, but negligible against the scale of the African external debt service crisis. The IMF’s Africa Director, Abebe Selassie, told the Fund’s Spring Meetings in Washington this month that the 2025 foreign aid contraction marks a structural break – and the money is unlikely to come back. “Past aid shocks were largely cyclical; donors cut back and then returned. What we are seeing now appears more structural,” Selassie said. “And it is falling hardest on the region’s most vulnerable countries: fragile states and low-income economies that depend on aid not as a supplement, but as a critical source of budget financing, healthcare, and food assistance.” The summit runs through Wednesday, with the African Union expected to publish a position paper on global health architecture reform at its close. Image Credits: ONE Data. Ghana Rebuffs US Health Deal – But South Africa and Zambia Struggle Without Aid 29/04/2026 Kerry Cullinan US Ambassador to the UN Mike Waltz (left) at the launch of the ‘Trade over Aid’ event at the New York Stock Exchange this week. Ghana has become the latest African country to reject the United States’ terms for bilateral health assistance, particularly the requirement to share sensitive health data, according to Reuters. Late last year, Zimbabwe rejected US terms for health assistance, particularly the demand to share pathogen data without any “corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data,” according to government spokesperson Nick Mangwana. Zambia has until 30 April to decide on whether to avail its minerals – primarily copper, cobalt and lithium – to US companies in exchange for health assistance. US aid supported antiretroviral treatment for an estimated 1,3 million Zambians. In the wake of disruptions since President Donald Trump assumed office last January, some Zambian hospitals are seeing an increase in AIDS cases, according to the New York Times. Back in December, the US announced Zambia had committed to a plan to unlock “a substantial grant package of US support in exchange for collaboration in the mining sector and clear business sector reforms that will drive economic growth and commercial investment that benefits both the United States and Zambia”. But this has never materialised amid renewed US pressure on Zambia to open its mineral wealth to the US. Meanwhile, South Africa has been frozen out of health aid by the Trump administration – in the main, for charging Israel with genocide at the International Criminal Court and for policies aimed at addressing apartheid-era discrimination that the US claims are anti-white. The loss of US funding has “damaged critical health services, dismantled HIV prevention programs, and disrupted world-class South Africa-U.S. research collaboration,” according to a report published last week by Physicians for Human Rights (PHR), Advocates for the Prevention of HIV in South Africa (APHA), and Emthonjeni Counselling and Training. ‘Trade over aid’ The terms of the Memorandums of Understanding (MOU) that the US is seeking with key countries, as part of its “America First Global Health Strategy” (AFGHSD), are overwhelmingly transactional. This week, the US entrenched this approach at the launch of its ‘Trade over Aid’ initiative at the New York Stock Exchange, asserting that the free market is the “surest route to economic prosperity” Ghana is Africa’s largest gold producer. It is unclear whether the US tried to use its aid offer to extract minerals, as it has in other countries. However, this is unlikely to have gone down well as Ghana is clamping down on foreign mining operations. In the past few weeks, the country’s Minerals Commission has given three international firms until the end of the year to transfer their gold mining operations to locals. Ghanaian President John Mahama is also championing the “Accra Reset”, launched last year to encourage African countries to invest more of their domestic budgets in their health and depend less on aid. At the same time, Ghana is heavily indebted and recently held off paying newly recruited nurses as it lacked the finances. US role in DRC conflict? President Donald Trump meets with DRC President Felix Tshisekedi and President Paul Kagame of the Republic of Rwanda, in the Oval Office in December 2025. The US held off signing an MOU with the DRC on 5 December, when it signed deals with Rwanda and Kenya on the sidelines of a peace accord between the DRC and Rwanda, allegedly the sponsor of the M23 rebels waging war inside the DRC. Instead, the US and DRC first signed a “strategic partnership agreement” to “promote secure, reliable, and mutually beneficial critical mineral flows for commercial and defense purposes”, according to the US State Department. The health MOU followed on 26 February. The DRC is one of the world’s most important sources of rare earth minerals, but China has dominated the purchasing and processing of its minerals. Following the agreement, the DRC offered US investors stakes in state-owned mineral assets. In late March, a US company, Virtus, bought a cobalt mine. Recently, it emerged that the DRC has offered mining opportunities to US companies in Rubaya, currently held by M23 rebels, indicating that the US would need to play a role in maintaining peace if it wants access to rare minerals. This week, the DRC announced the formation of a $100 million initiative to establish “mining guards” to secure mines, with investment from the US and the United Arab Emirates. However, lawyers in the DRC have challenged the MOU in court, while part of Kenya’s MOU has been suspended by a High Court in the face of an ongoing court challenge. South Africa in the cold South African HIV scientist Prof Linda-Gail Bekker received a standing ovation at the International AIDS Conference in 2022 when she announced the results of the lenacapavir clinical trial. South Africa has the biggest HIV population in the world, and was the largest international recipient of US National Institutes of Health (NIH) research funds, as well as getting funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR). “Our report illustrates what an ‘America First’ approach to global health looks like: Lifesaving programs shuttered, world-class research jettisoned, decades of progress against HIV/AIDS jeopardized. All to the harm of, not only South Africans, but to Americans and the global public as well,” said Thomas McHale, director of public health at PHR and a report co-author. Co-author Emily Bass warned: “Short-sighted, sudden withdrawal of funds for critical components of the HIV response will cause long-term harm to infants, children, adolescent girls and young women, and other groups at the highest risk of HIV.” The report mentions two scientific breakthroughs that came from US-South African research partnerships, namely the clinical trial of lenacapavir, an injectable pre-exposure prophylaxis (PrEP) that is almost 100% effective in preventing HIV, and updated global guidelines for treating drug-resistant tuberculosis (TB). These breakthroughs “directly benefit Americans”, the authors argue. “By freezing research funding to South Africa, the Trump administration is sabotaging the United States’ own future health and national security.” The report is based on interviews with South African doctors, researchers, people living with HIV, and others involved in South Africa’s HIV response efforts. Image Credits: Daniel Torok/ White House , Kerry Cullinan. Record European Heatwaves Shrink Glaciers and Diminish Snow Cover in 2025 29/04/2026 Disha Shetty Europe experienced record extremes in 2025, according to WMO’s latest assessment. Around 95% of Europe experienced above-average temperatures in 2025, with record heatwaves from the Mediterranean to the Arctic region. This caused rapid loss of glacier mass and snow cover, according to the latest State of the European Climate report by the World Meteorological Organization (WMO) released on Thursday. All of Europe’s glaciers saw a net mass loss, with Iceland recording its second-largest glacier loss on record. The continent experienced dangerously high air temperatures, drought, heatwaves and record ocean temperatures. This has translated into economic and biodiversity loss affecting countries and ecosystems across the continent. “Europe is the fastest-warming continent, and the impacts are already severe. Almost the whole region has seen above-average annual temperatures,” said Florian Pappenberger, Director-General of the European Centre for Medium-Range Weather Forecasts (ECMWF), an inter-governmental organisation that contributed to the report along with WMO. Also read: Europe is World’s Fastest Warming Continent With Record Temperatures in 2024 Europe is warming twice as fast as the global average Europe is now the fastest-warming continent, warming twice as fast as the global average. The impact of the temperature increases is most visible in the coldest regions, such as the Arctic and the Alps. Snow and ice play a critical role in slowing climate change by reflecting sunlight into space in what is known as the albedo effect. “In 2025, sub-Arctic Norway, Sweden and Finland recorded their worst heatwave on record with 21 straight days and temperatures exceeding 30°C within the Arctic Circle itself,” Pappenberger of ECMWF said. This also pushed up temperatures within and adjacent to the Arctic Circle to over 30°C, peaking at 34.9°C in Frosta, Norway. Ironically, low levels of air pollution in Europe allow more solar radiation to reach the surface, leading to a higher rate of warming. The number of cold stress days when temperatures drop below normal is also reducing. Nearly 90% of the continent experienced fewer cold stress days than average, and minimum temperatures remained above average for most of the year. Hot, dry conditions resulted in more wildfires. A record total area of around 1,034,000 hectares was burnt across Europe – an area larger than Cyprus. Spain, Cyprus, the United Kingdom, the Netherlands, and Germany recorded their highest wildfire emissions on record in 2025. Record loss of glacier mass Glaciers across Europe lost mass in 2025, with the highest loss recorded in Iceland. The Greenland Ice Sheet, which is the largest ice mass in the northern hemisphere and covers 80% of Greenland, lost 139 gigatonnes (139 billion tonnes) of ice. This is equivalent to 1.5 times the volume stored in all glaciers in the European Alps. Such ice loss contributes to rising global sea levels, with every centimetre increase exposing an additional six million people to coastal flooding. Overall, snow cover was 31% below average, affecting 1.32 million square kilometres, which is equivalent to the combined area of France, Italy, Germany, Switzerland, and Austria. “The ESOTC 2025 paints a stark picture: the pace of climate change demands more urgent action. With rising temperatures, and widespread wildfires and drought, the evidence is unequivocal; climate change is not a future threat, it is our present reality,” Samantha Burgess, Strategic Lead for Climate at ECMWF said. Rising ocean heat, reducing river flow Nearly 86% of European waters saw strong marine heatwaves in 2025. Oceans absorb 90% of the atmosphere’s excess heat due to the burning of fossil fuels. In 2025, Europe’s sea surface temperature was the highest on record. Around 86% of the region experienced strong marine heatwaves, disrupting fish and the ocean plants. Changes in rainfall and snowfall patterns have also affected the flow in 70% of Europe’s rivers. In May 2025, around half of Europe (53%) was affected by drought conditions. “Maintaining our own state-of-the-art, reliable data records of our Earth system is vital for making informed policy decisions in our rapidly changing climate. Copernicus is pivotal to help us preserve our sovereignty, our environment, food systems, safety, and economy,” said Mauro Facchini, Head of the European Commission’s Copernicus, is the European Union’s Earth Observation Programme. Renewable growth and actionable items for policymakers The share of renewables in Europe’s energy mix has gone up, supported by the growth in solar energy. A silver lining in the report is the growth of renewable energy, which in 2025 supplied nearly half (46.4%) of Europe’s electricity. Solar power contributed around 12.5% of this, a new regional record. Countries have begun to see energy security as a national security issue, and that appears to be one of the reasons driving the growth of renewables, including the adoption of nuclear energy at a higher rate compared to recent decades. Another positive was that by the end of 2025, around half of the European Biodiversity Strategy 2030’s recommended actions were in place or completed. The strategy is a European Union plan to restore the continent’s biodiversity. The report highlighted initiatives like Ireland’s network of marine protected areas, Armenia’s biodiversity finance plan, and Iceland’s funding to assist in recovering wetlands as examples of policy interventions that can help arrest biodiversity loss. Image Credits: Unsplash/Jochen Bückers, WMO. Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Heartbroken Families Face Huge Structural Barriers When Trying to Prove Medical Negligence in India 01/05/2026 Arsalan Bukhari & Naila Tabassum Indian families face a huge struggle to get timely access to medical records of loved ones who have died in Indian health facilities, while the police can only lay a charge against a doctor if an independent medical expert first confirms negligence. NEW DELHI – India faces thousands of medical negligence cases every year, but structural problems make it extremely difficult for patients’ families to find out what has happened to their loved ones – let alone win compensation when treatment has been botched. “A shadow of death is looming over us,” Ashwini Bajaj, a Haryana-based businessman, told Health Policy Watch, recalling the treatment of his 24-year-old son, Deshbandhu, more than a year after his death. In December 2024, Deshbandhu, an MBA student at Punjab University and Bajaj’s only son, developed a fever that lasted more than two days. On 26 December, he visited a hospital near his university in Chandigarh, where he was prescribed medicines and given a series of tests, including a liver function test (LFT). By the time the results came out later that evening, Deshbandhu had returned to his parents’ home in Hisar, around 200 kilometres away. The next day, he went to a private hospital there, but his condition deteriorated rapidly. His oxygen saturation dropped to 65%, and doctors warned of acute liver failure. “We were told his condition was very critical and that the hospital did not have the resources to treat him,” Bajaj said. “We were asked to take him to a super-speciality hospital. It felt as if the ground beneath our feet had slipped away.” Deshbandhu was shifted to a major private hospital in Gurugram. “My son was there for over three weeks. His condition kept deteriorating. He went with jaundice, and he developed intestinal obstruction, kidney stress, and pneumonia,” Bajaj said. A few days after his 24th birthday, which was on 20 January 2025, Deshbandhu died. Bajaj says he has been unable to return to work. His case reflects broader systemic gaps in India’s healthcare system, where delays in critical care, weak referral systems, and limited transparency can have life-threatening consequences — and the lack of updated national data continues to hamper accountability. Transparency in treatment Deshbandhu Bajaj (24), a mountaineer and an MBA student who died in January 2025. His father, Ashwini Bajaj, alleges medical negligence. “Initially, I thought the doctors tried hard to save my child, but when I obtained all the medical reports, which took three to four months to obtain, I realised much time was lost before the actual treatment started,” Bajaj said. “When I made a day-by-day chart, I realised that, for at least four days, my son didn’t get the treatment he should have. “Every evening, I used to get payment requests promptly on my WhatsApp. If they could send payment requests, why can’t they share procedural updates the same way?” Rujhan Dhawan, a lawyer at the Punjab and Haryana High Court, told Health Policy Watch such opacity is a major barrier to accountability. “A patient, once admitted, is entirely dependent on the institution not only for treatment but also for truthful disclosure,” he said. “Critical information about procedures and complications is often not readily accessible to families.” Bajaj’s family spent over ₹30 lakh ($33,000) on treatment. He says he is not seeking compensation, but a legal framework that mandates transparency. Not an isolated case Deshbandhu’s case is not an isolated one. According to the 18th Annual MedLegal Review, 65,000 medical negligence cases were filed in India in 2025 alone. Radha Sharma (49), a resident of Rajasthan’s capital city Jaipur, died days after being given a TB drugs although she had been diagnosed with a liver-related illness. In Jaipar, around 270 kilometres from Gurugram, 55-year-old tax consultant Kishan Kumar Sharma is fighting a case linked to the death of his wife, Radha. On 3 March 2025, she developed mild jaundice and was admitted to a private hospital. A test suggested Budd-Chiari syndrome, a rare liver disorder. However, despite a negative tuberculosis test, Radha was prescribed the TB drug, Isoniazid, said Sharma. Isoniazid should not be prescribed to patients with liver disease who have bilirubin levels over 4 mg/dL, according to World Health Organization (WHO) guidelines. But Sharma says his wife’s liver disorder was overlooked. Radha’s condition deteriorated rapidly, and she died on 18 March. “I have a simple question,” Sharma said. “Why was my wife given Isoniazid? Was it part of any established protocol or something else?” The risks highlighted by such cases reflect a broader global problem. According to the WHO, an estimated 138 million patients are harmed every year due to unsafe medical care. Lack of dedicated investigative body Nishant Bharihoke, an advocate at the Delhi High Court who specialises in medical negligence cases, told Health Policy Watch the core issue lies in the absence of a dedicated independent investigative framework. “India does not have a dedicated body specifically tasked with investigating deaths or serious injuries caused by medical negligence,” he said. “When a patient dies, and the family suspects wrongdoing, there is no authority whose sole function is to find out what happened.” Complaints are typically routed through State Medical Councils, which may form inquiry committees. Their decisions can be appealed to the National Medical Commission, but Bharihoke argues that the system is structurally limited. “The National Medical Commission’s primary mandate is to regulate medical education. Its disciplinary board has no independent investigators and no power to enter hospitals and examine evidence,” he said. He also pointed to a legal loophole: since these proceedings are not strictly judicial, false statements made before such bodies do not result in perjury charges. For families like Bajaj’s and Sharma’s, he said, this gap deepens the sense of injustice. When cases turn criminal Simran Chhabra (21), a resident of Gurugram and MA student at Amity University, was suffering from a simple cough and cold. She died within minutes of being administered an intravenous injection. The family is fighting a medical negligence case in a Gurugram court. The gap becomes even wider when negligence overlaps with criminal allegations. One such case is the death of 21-year-old Simran Chhabra. On 21 January 2023, she visited a private hospital in Gurugram with symptoms of cough and cold. According to a prescription her brother, Sourabh Chhabra, shared with Health Policy Watch, she was administered an intravenous injection of Dynapar. This is usually used to treat pain and inflammation associated with arthritis or after surgery. “As soon as the injection was fully administered, Simran collapsed on the bed and froth began coming out of her mouth,” Sourabh said. “Everything happened within minutes. I had no time to understand what was going on.” She was referred to another hospital, where she was declared dead. According to Bharihoke, the family’s legal representative, the doctor later claimed that multiple emergency interventions were carried out, including five additional injections and cardiopulmonary resuscitation (CPR), using drugs typically administered in cases of severe allergic reactions. However, the post-mortem report reviewed by Health Policy Watch raises questions. It records only two puncture marks on her body, and there is no mention of a cannula (an intravenous tube) being used. If multiple injections were administered, the family asks why there is no corresponding physical evidence. In this case, they argue, the medical account and post-mortem findings do not align. “Forget conviction or arrest, even registering an FIR in such cases often requires court intervention,” Bharihoke said. A FIR is a First Information Report (FIR) in Indian medical negligence cases, a formal document prepared by police under Section 154 of the Criminal Procedure Code upon receiving information about alleged criminal negligence. Absence of a legal framework Several structural barriers insulate medical health practitioners against negligence cases, according to legal experts. “In India, police usually cannot even register a case against a doctor unless an independent medical expert first confirms negligence,” Bharihoke told Health Policy Watch. “In most cases, doctors are reluctant to give such opinions, especially against their peers.” The challenge is compounded by access to evidence. Hospitals retain control over key records, case files, prescriptions, nursing notes, and CCTV footage while families often receive only partial or delayed documentation. India also lacks a statutory system guaranteeing timely access to medical records for patients and their families. There is no clear legal mandate requiring investigators to immediately secure hospital evidence. Tanvi Dubey, a Supreme Court lawyer, told Health Policy Watch the legal framework itself raises the bar for accountability. “Criminal liability in medical negligence cases is limited to gross negligence, not simple errors of judgment,” Dubey said. “This significantly narrows the scope for prosecution.” Even initiating an investigation can be delayed: “Authorities are allowed to conduct preliminary inquiries before registering a case, which often means waiting for medical opinions and slows the process.” Dubey also pointed to the continued reliance on what is known in Indian law as the “Bolam principle,” where a doctor’s actions are judged against a body of medical opinion. “This makes expert testimony central. Unless a complainant can produce strong contrary evidence, it becomes very difficult to establish negligence,” she said. While multiple legal remedies exist, including consumer courts, civil litigation, and disciplinary proceedings, Dubey noted that each comes with limitations. “Criminal prosecution is rare, civil cases are slow and evidence-heavy, and disciplinary proceedings do not always ensure compensation or thorough fact-finding,” she said. Compared with Western peers, India faces two major policy gaps in patients’ treatment: the absence of a national electronic medical record (EMR) system, and the lack of a digital system connecting labs directly to the consulting doctor. Currently, India doesn’t have a mandatory EMR policy applicable to healthcare organisations. Even today, prescriptions, clinical notes, and drug administration records are still handwritten in the majority of hospitals and almost all smaller clinics. This makes them more vulnerable to tampering, loss and destruction. The absence of a nationwide electronic medical record system adds another layer of opacity. In many facilities, records remain handwritten and vulnerable to alteration; a gap Bharihoke alleges was evident in Simran’s case. Urgent reform is necessary India’s Minister of Health Jagat Prakash Nadda. Legal experts are calling on authorities to establish an independent statutory body to investigate medical negligence. Only families with the financial means and emotional capacity to pursue long legal battles are able to take up medical negligence cases. For many others, the burden becomes too heavy to carry. While the rules may appear neutral on paper, experts say their impact is deeply unequal. Legal and policy experts argue that the most urgent reform is structural, particularly the creation of an independent statutory body tasked solely with investigating patient safety incidents, particularly in cases involving death, permanent disability, or serious injury. Such a body should have the authority to enter hospital premises, access medical records, secure CCTV footage, and record statements. Its findings should be made public, while the evidence it collects remains protected from use in criminal or disciplinary proceedings. In England, the Health Services Safety Investigations Body (HSSIB), established in 2023, follows this approach by conducting independent investigations into patient safety incidents. Globally, different systems offer alternative approaches to accountability. In the United States, oversight is spread across multiple layers: state medical boards regulate conduct, a national database tracks malpractice records, hospitals report serious incidents, and patients can pursue civil litigation. China follows a three-tier system, allowing patients to first negotiate with hospitals, then seek mediation, and finally pursue civil lawsuits. In parts of Europe, including France and the Nordic countries, no-fault compensation systems allow patients to receive compensation without proving negligence, making the process more accessible and less adversarial. Aviation and rail safety investigations have long operated on similar principles, focusing on systemic failures rather than individual blame. For India, experts say the lesson is clear. Accountability frameworks do not have to rely solely on litigation. A system built on independent investigation, timely access to evidence, and patient-centric redress could help provide answers to families like the Bajajs and Sharmas. Image Credits: César Badilla Miranda/ Unsplash, Felix Sassmannshausen. No Pandemic Agreement Annex by World Health Assembly, Says Civil Society 30/04/2026 Kerry Cullinan (Left to right from top) Third World Network’s moderator and speakers Lauren Paremoer, KP Gopakumar and Tamara Prisenburg form AIDS Healthcare Foundation. The final missing piece of the Pandemic Agreement – a pathogen access and benefit-sharing (PABS) system – is unlikely to be agreed on by the World Health Assembly (WHA) later this month. This was the view of civil society observers of the talks taking place at the World Health Organisation (WHO) headquarters in Geneva, who briefed the media on Thursday. The sixth round of talks is scheduled to end late on Friday night (1 May). Earlier in the week, WHO Director General Dr Tedros Adhanom Ghebreyesus told a Geneva media briefing that “key differences remain on key issues”. “I still see a common will to reach consensus, which means I continue to believe there is a way to reach consensus,” Tedros added. Although the notion of a “hybrid” PABS system is being discussed informally, its proponent, the European Union (EU), has not presented any formal text, Third World Network’s (TWN) KM Gopakumar told the media briefing, which was hosted by TWN and the AIDS Healthcare Foundation. While Brazil and Botswana have apparently indicated that they might support a hybrid or “blended” compromise, the Africa Group is opposed to it, according to the civil society representatives. WHO member states are negotiating how to share both information about dangerous pathogens and some of the “benefits” that manufacturers may develop from that information – namely, vaccines, therapeutics and diagnostics (VTDs). The “hybrid” or “blended” proposal is a mix of mandatory and voluntary measures for sharing pathogen information and any benefits that flow from this information. It de-links information-sharing and benefit-sharing. Gopakumar said that, in terms of the blended agreements, countries that shared pathogens “will have the freedom to choose to attach certain conditions for sharing the data and the sample, including benefit sharing requirements” or share without any conditions. Kill the efficiency Shifting the choice to individual countries would undermine the efficiency of a single PABS system as users would need to negotiate with the individual countries instead of through a centralised system, he argued. “If you have a hybrid system, first of all, it kills the efficiency [of a single system], and second, it’s going to debase the access and benefit sharing norms set by the international instruments like the Convention on Biological Diversity and the Nagoya Protocol. Any attempt to dilute benefit-sharing obligations would be a “disaster” for equity, said AHF’s Tamara Prisenberg. Lauren Paremoer of the People’s Health Movement said that the blended model introduces “a two-track system for accessing pathogens” that violates access and benefit-sharing on an “equal footing” specified in Article 12 of the Pandemic Agreement. One track would allow anonymous users to access pathogen data without upfront commitments to benefit-sharing or legally binding contracts. The other was in line with Article 12, permitting access to pathogens through databases and laboratories that would require users to register and commit to specified benefit-sharing. Earlier in the day, the Intergovernmental Working Group (IGWG) briefed civil society on text-based negotiations, but very little of the text they shared had been “greened” to show agreement. EXCLUSIVE: WHO Opens Nominations for Next Director General; Germany May Advance Former Merkel Aide, Helge Braun 30/04/2026 Felix Sassmannshausen, Elaine Ruth Fletcher & Editorial team WHO DG Dr Tedros Adhanom Ghebreyesus issued a call for nominations for the DG elections. He recently travelled to Berlin, where he met with high-level politicians and the WHO’s Pandemic Intelligence team. As the World Health Organization (WHO) formally opens the nomination process for the next Director-General, Germany now appears likely to propose Helge Braun, Chief of Staff in former Chancellor Angela Merkel’s government, according to Berlin insiders. But after slashing its global health budget, sources question whether a German candidate can win wide support from other WHO member states. WHO Director-General Dr Tedros Adhanom Ghebreyesus has formally issued a call to WHO member states for nominations to the DG elections, scheduled for May 2027, in an invitation sent on 24 April to all WHO member states. WHO confirmed this in an email to Health Policy Watch. The invitations had been sent via private letters to countries’ Geneva missions. The period in which member states may nominate candidates will now run for six months, until 24 September. Contenders who have until now remained in the shadows are expected to begin coming forward publicly with their candidacies at the World Health Assembly in May. From the German perspective, Berlin wants its financial weight reflected in executive influence at the multilateral level as the largest global health donor following the US withdrawal from the WHO in January 2025. The withdrawal, combined with the US non-payment of dues owed, thrust WHO into a budget crisis, prompting layoffs of about 25% of the workforce in the past year. German Foreign Ministry neither confirms nor denies The German Foreign Ministry, formally responsible for the nomination, declined to confirm or comment on Braun’s potential candidacy when responding to a query by Health Policy Watch. Germany’s other potential candidates include the contested former Health Minister Karl Lauterbach and the lesser-known Paul Zubeil. In contrast, Braun’s dual profile as an accomplished politician, skilled financial manager, and trained physician and researcher who successfully built cross-party bridges offers a distinct advantage. But he is little known outside of Germany. Bridge-builder with executive and medical expertise Former Chair of the influential German Budget Committee, Helge Braun (right), and former French Chair of the Finance Committee, Claude Raynal (left), in the Bundestag. The current WHO leadership landscape demands a candidate capable of managing deep institutional fractures and uniting a divided global community. Despite him being largely unknown in the international community, Germany could be expected to emphasise Braun’s extensive fiscal and crisis management experience in any candidacy it mounts. As ‘Head of the Chancellery’, effectively Chief of Staff, in Angela Merkel’s last term as Chancellor, from 2018 to 2021, Braun operated at the nexus of scientific advice and political implementation during the COVID-19 pandemic, notably comparing the Chancellery to an intensive care unit where acute problems must be solved. Between 2021 and 2025, Braun then chaired the powerful Budget Committee of the German Bundestag (Parliament), overseeing the distribution and management of hundreds of billions of Euros with strict discipline This profound understanding of macroeconomic management, coupled with his pragmatic defence of Germany’s controversial debt ceiling alongside crisis-driven special funds, makes him an attractive prospect for donor nations currently demanding more financial accountability and restructuring at WHO in Geneva. Serving as a central mediator across government ministries, Braun built a reputation as a highly pragmatic problem solver whose past domestic political affiliations will not necessarily dictate his future approach to global health governance. This pragmatism complements his longstanding political advocacy for research into infectious diseases like Ebola and malaria. And unlike many career politicians, Braun’s foundational expertise lies in medicine, having worked for years as an intensive care physician and anaesthesiologist. He returned to these roots in April 2025 by assuming the presidency of the University of Lübeck, an institution renowned for its focus on life sciences and artificial intelligence. Why the candidacy might spark concerns WHO member states are currently negotiating a pathogen access and benefit-sharing (PABS) system in Geneva. While Braun championed early interventions and massive digitisation projects in his role as Merkel’s Head of the Chancellery during the COVID pandemic, severe bureaucratic delays hampered the rollout of vaccination campaigns and testing strategies. This tarnished his crisis management legacy just as he exited the federal government. His domestic political capital suffered further damage during the December 2021 Christian Democratic Union leadership election, where he lost heavily to conservative rival Friedrich Merz, now Chancellor. Party members largely rejected Braun as an establishment candidate, perceiving him as too closely aligned with the moderate legacy of former Chancellor Angela Merkel. Additionally, it is questionable whether Braun would wield the necessary diplomatic connections and familiarity with foreign health systems to be effective on Day One of a term as WHO head. The Director-General must immediately command trust and authority on the international stage, particularly when dealing with health ministries and stakeholders in the Global South. Most notably, the German government opposed the release of COVID-19 vaccine patents during his tenure, drawing sharp criticism from international health equity advocates. Defending this refusal in May 2021, Braun wrote in a guest article for the German newspaper Die Zeit that “patent protection as a driver of innovation is not the problem in this crisis, but an essential foundation for its solution.” In the Global South, this track record could thus reinforce the perception that Germany defends pharmaceutical interests over equitable technology transfer – especially in the face of current PABS Annex negotiations. Recent reports from Tagesspiegel Background indicating that the former minister was approached by Germany’s Association of Research-Based Pharmaceutical Companies to become their next president, when the post becomes vacant at the end of 2026, might further fuel these concerns. Finally, Germany has been cutting back its Official Development Assistance (ODA) in general, including contributions to the World Health Organization, where it has historically been the largest member state donor after the United States. On Wednesday, the Merz government announced its 2027 budget plans with further ODA cuts following last year’s drastic 17% reductions. The likelihood of Germany fulfilling its original 2024 financial pledge to WHO for the current biennium (2026-27) also remains in doubt. “They can put forward a candidate, but I don’t think it’s going to get a lot of traction from other member states,” said one informed WHO source. “At a time when Germany is reducing global health funding to member states, I don’t think they can go ahead and claim the top seat.” Step back and support allied candidates? Braun served as Head of Chancellery under then German Chancellor Angela Merkel, seen here with WHO Director General Dr Tedros in Berlin in 2021. Furthermore, domestic opinion remains highly divided on mounting a campaign amidst the geopolitical strains on Chancellor Friedrich Merz’s coalition and Tedros has reportedly urged Germany to back allied candidates instead. At the same time, the desire to seize more leadership in the UN system remains strong after Germany’s failed previous attempt to secure the top role at the UN High Commissioner for Refugees in 2025. Currently, Germany is also pushing for another attempt at a UN Security Council seat. Should Germany put forward a candidate, Foreign Minister Johann Wadephul, who will make the final decision, also faces a stark choice between Braun and the better-known Karl Lauterbach, as well as Paul Zubeil with his strong international health and technical background. Advancing a WHO outsider like Braun against established public health veterans is a highly calculated risk for Berlin, which must first convince other European countries to rally behind him. In case Berlin formally nominates Braun, the success of his candidacy will depend entirely on how effectively the government can reframe his perceived lack of field experience and global networks as delivery on fresh, badly needed fiscal expertise and perspectives. Grappling with WHO’s funding crisis As the race for the next Director-General opens for formal nominations, the names of over a dozen high-profile potential candidates are still circulating – from Indonesia to the United Kingdom. Want to Become the Next WHO Director-General? Get in Line And the list is still growing. Among the newer names being floated is that of Dr Hanan Mohamed al-Kuwari, who served as Qatar’s Minister of Public Health until November 2024 and chaired the 153rd Session of the WHO Executive Board. Before joining the Hamad Medical Corporation in 1996, where she ultimately rose to managing director, al-Kuwari worked for Reuters and as a freelance health reporter. Holding a PhD in healthcare management from Brunel University and bringing early career experience from the WHO, she represents a highly networked voice from the Arab world, celebrated for her crisis resilience and for shaping the WHO’s recent global work programme. Dr Maria Neira, WHO Director of Climate, Environment and Health Another candidate who has been mentioned is Spain’s Dr Maria Neira, who recently retired from WHO as the director of Climate, Environment and Health. An iconic spokesperson for the climate, environment and health movement, Neira is known as a telegenic personality and adroit politically. As a young medical doctor, she worked in emergency relief in Latin America and Africa, and later served as Spain’s Vice Minister of Health and Consumer Affairs as well as President of the Spanish Food Safety and Nutrition Agency. However, Spain also recently decided to nominate a candidate to head the UN Food and Agriculture Organization (FAO), when Qu Dongyu’s second term as Director General ends in July 2027, leaving doubts about whether it would want to mount yet another campaign, in parallel. Continuing decline in ODA and global health aid Drastic ODA cuts and reduced global health funding leave vulnerable populations in precarious conditions worldwide. Whoever is elected will have to continue grappling with the continuing long-term declines in donor-driven ODA, and particularly global health aid – directly to countries and to WHO. While WHO 2026-2027 $4.2 billion base budget is now 85% financed, according to Tedros’ comments on Wednesday, declines in ODA continue to cast uncertainty on how the remaining $630 million gap will be filled. It’s unlikely that the $260.6 million in assessed US contributions still due for years 2024-2025, before the withdrawal became official in January, will ever be repaid, conceded WHO’s Tedros at a Geneva press briefing on Wednesday. “We’re hoping to get the money, but no signals yet,” Tedros told journalists, adding: “No signals means maybe we may not be able to get the money. The likelihood could be not getting the money.” “We’re looking at nontraditional donors. We’re looking at international financial institutions and other ways to mobilize that 15%,” Tedros said, in terms of filling that gap. “It’s not that we won’t go to the traditional donors, but I think we’re expanding that donor base.” This article has been edited to reflect additional information regarding Dr Hanan Mohamed al-Kuwari’s early career as a freelance journalist. Image Credits: X/Dr Tedros, Deutscher Bundestag/Leon Kügeler, European Commission. African Leaders Declare End of Aid Era at Nairobi World Health Summit, But The Data Tell a More Complicated Story 29/04/2026 Stefan Anderson Delegates gather for the opening plenary of the World Health Summit Regional meeting in Nairobi, Kenya. African leaders opened the World Health Summit Regional Meeting at the United Nations complex in Nairobi this week with a unified declaration that two decades of dependence on foreign aid for health is over. “The challenge that I see is that many of the leaders in our continent believe that it is somebody else’s responsibility. It should be the World Health Organization, USAID, I don’t know who,” Kenyan President William Ruto told the summit. “The sooner we realise that it is our responsibility to raise especially domestic resources to fund our health, the better for all of us.” The Nairobi meeting, the first co-organised by the World Health Organization (WHO) and the World Health Summit, has positioned itself as the continent’s first high-level response to the collapse of official development assistance (ODA) for health, which fell by an estimated $31.1 billion in 2025, according to the Africa Centres for Disease Control and Prevention (Africa CDC). Over 2,000 delegates from more than 50 countries, including health and finance ministers from 17 nations, are convening in the Kenyan capital to coordinate a united African position ahead of next month’s World Health Assembly in Geneva. “I don’t want to see this continent being dependent. And we are dependent because we want it,” Ruto said. “Africa is manufacturing a number of products today, from Egypt, from Kenya, from South Africa, from a number of countries, but we are not buying our own product.” Africa carries more than 25% of the global disease burden but accounts for less than 3% of global health expenditure. The continent currently produces less than 2% of the medicines and vaccines it consumes, leaving its countries dependent on external supply chains for essential medical commodities. “Who’s asking us not to buy our own product, who’s asking us not to register to the African Medicines Agency for the regulatory aspect?” Ruto asked. “It’s not Germany, it’s not Europe, it’s ourselves. We need to change our mindset.” A break with the past African leaders led by Kenyan President William Ruto arrive in Nairobi for the summit. The urgency on display in Nairobi is driven by the most disruptive year for global health financing on record. For African governments, the pivot to self-reliance has become a fiscal necessity. The dismantling of the United States Agency for International Development (USAID), followed by aid cuts by the United Kingdom, Germany, France and the Netherlands, drove a 23.1% drop in total ODA from OECD donors in 2025. This is the largest single-year contraction since records began. The US, Germany, UK, Japan and France accounted for 95.7% of the total decline. The Boston University ImpactCounter estimates the US cuts have already led to more than 518,000 child and 263,000 adult deaths from preventable diseases such as HIV and tuberculosis. A further 14 million preventable deaths, including 4.5 million children, may occur by 2030 if USAID funding gaps are not filled, a major international study found. Africa CDC estimates the combined cuts from the US, UK, Germany and other major donors will kill an additional two to four million Africans annually. “The year 2025 marked the end of one era and the beginning of another,” Sulaiman Shahabuddin, President and Vice Chancellor of the Aga Khan University, told the opening plenary. “We are confronting a new reality, defined by funding constraints, the rise of technology and artificial intelligence, and a decisive shift towards local ownership.” “Climate change, chronic diseases, lack of financial resources, the digital divide, inequity and others are [challenges] we will have to overcome,” Shahabuddin added. What aid remains on the table increasingly comes with strings attached. Washington has begun rolling out bilateral “America First” global health agreements, with US President Donald Trump retaining the right to terminate any programme judged not to align with American interests. Conditionalities include sharing pathogen samples and genomic data with US authorities, prioritising faith-based health providers to prevent services such as abortions, channelling funding away from non-governmental organisations, and, in the case of Zambia, granting access to critical minerals in exchange for health funding. Lukoye Atwoli, Dean of the Aga Khan University Medical College East Africa and the summit’s international president, said this year’s gathering would mark a break with past meetings on African health. “Historically, meetings about Africa and Africa’s health have been about lamentations. Have been about framing the problems. Have been about basically begging and saying that we have a problem and we need help,” Atwoli told delegates. “This meeting will be different.” Reform body launched Africa CDC Director Dr Jean Kaseya speaking in Nairobi. On the sidelines of the summit, Africa CDC launched the African High-Level Ministerial Committee on Global Health Architecture Reform. The body brings together health and finance ministers from across the continent to coordinate African positions ahead of the World Health Assembly and broader UN reform processes. Convening both portfolios in the same room is a long-standing demand of global health advocates, who have struggled for decades to make the economic case for health investment to treasuries that hold the purse strings. The committee, chaired by former Liberian president Ellen Johnson Sirleaf, will produce coordinated African position papers on health architecture reform and a 2026–2030 reform roadmap focused on five axes: governance, financial sovereignty, data sovereignty, local manufacturing, and pandemic preparedness. “The old model is no longer fit for purpose. Africa cannot continue to be a passive recipient of global health decisions,” said Africa CDC Director General Dr Jean Kaseya. “We welcome our partners, but on a new basis: not as donors and recipients, but as equal partners aligned with Africa’s priorities.” Aspiration meets evidence Official development assistance fell by a historic 23.1% in 2025. African nations are among the hardest hit. The data on whether Africa can deliver on the vision laid out in Nairobi tell a more complicated story. A Centre for Global Development (CGD) audit of 442 government actions across all 54 African countries found a continental reaction to the historic aid cuts split in radically uneven ways, a story of inequality within Africa as much as between Africa and its donors. The countries that moved fastest are those with the deepest pockets and most diversified economies, including Nigeria, Ghana and Ethiopia. Lower-income, debt-burdened countries, many of which were the largest per-capita recipients of foreign assistance, have largely absorbed the loss in silence. “Governments with limited fiscal space and weaker administrative capacity have less room to cushion abrupt external shocks,” the analysis found. “What is slightly surprising is that they were not only doing little about the aid cuts, they are also saying little about them.” Global Health Leaders Urge Fewer Agencies Amid Funding Crisis A separate CGD study published in February examined the budget statements of 18 sub-Saharan African countries: among the world’s poorest, most heavily aid-dependent and exposed to the cuts. It found that only two, Tanzania and Sierra Leone, proposed new revenue measures to replace lost financing in their 2025 budgets. None reprioritised spending from other sectors to protect health. “With few exceptions, governments neither raised new revenues nor reallocated spending to compensate for lost external financing,” the analysis concluded. The burden of adjustment, it found, has instead fallen on the services patients receive, from disrupted HIV and tuberculosis treatment to delays in vaccination campaigns and the closure of clinics that depended on donor financing. “Health is not a cost, it is an investment,” Ruto said. “And it is important for us to invest.” Cascading crises Runaway climate change is colliding with constant economic shocks from war and the COVID-19 pandemic, shrinking Africa’s budgets and taking away the space to invest in health. The continent’s ability to absorb the aid shock and finance the pivot to support its own health systems is constrained by an unending sequence of external crises over the past decade that continue to batter government budgets, layered on top of the escalating climate crisis. The COVID-19 pandemic, during which wealthy nations hoarded vaccines, exposed Africa’s reliance on a foreign supply chain that produces 99% of the vaccines and 90% of the medical supplies it consumes. Pandemic response cost African governments an additional $154 billion in 2020 and 2021, according to the African Development Bank, pushing sub-Saharan public debt up by 8 percentage points of GDP in a single year. Russia’s invasion of Ukraine drove an inflationary spike that ballooned debt-service costs across the region, a pressure that has now snowballed into the global economic crisis triggered by the US-Israeli war on Iran, to which African economies are uniquely vulnerable. The closure of the Strait of Hormuz, a chokepoint for a fifth of the world’s oil and a third of its liquefied natural gas, is driving up fuel and fertiliser costs and deepening food insecurity across the continent. The resulting inflation, weaker currencies and tighter global financial conditions across Africa are inflating debt-servicing bills and forcing governments to divert money that could otherwise help absorb the aid shock. Climate change is compounding the pressure on every front. African countries are losing between 2% and 5% of GDP to climate extremes, the World Meteorological Organization estimates, with some governments diverting up to 9% of national budgets to respond. Health systems will bear a growing share of that cost. The World Bank estimates climate change could drive at least $21 trillion in excess health costs in low- and middle-income countries by 2050, with sub-Saharan Africa among the regions hit hardest. “What was considered reliable for decades is turning out to be fragile,” said Birgit Pickel, Director-General for Global Health at Germany’s Federal Ministry for Economic Cooperation and Development. “Cracks are appearing in the international order. Cracks that, in some cases, are already leading to its collapse.” Fiscal squeeze limits options African debt levels have more than doubled in the past decade, according to ONE Data figures. The cumulative damage has left African governments with little room to manoeuvre. Thirty-two African nations now spend more servicing external debt than funding healthcare. The continent paid almost $90 billion in external debt service in 2024 alone, with African governments now spending an average of 17% of state revenue on debt servicing, according to leading estimates. The IMF warned last week that more than a third of African countries are at high risk of, or already in, debt distress, with rising interest bills “crowding out essential development spending, healthcare above all.” “Official funding will probably shrink, at least internationally. Domestic funding will hopefully move up,” Pickel said. “But there are innovative instruments out there to also meet urgent funding needs in the health sector, especially for heavily indebted countries.” Pickel proposed debt-for-health swaps, an instrument under which creditor nations cancel debt in exchange for redirected health spending, as a route to fiscal space for highly indebted countries. Germany issued €100 million in such swaps last year, channelled to the Global Fund. The figure is substantial as a signal, but negligible against the scale of the African external debt service crisis. The IMF’s Africa Director, Abebe Selassie, told the Fund’s Spring Meetings in Washington this month that the 2025 foreign aid contraction marks a structural break – and the money is unlikely to come back. “Past aid shocks were largely cyclical; donors cut back and then returned. What we are seeing now appears more structural,” Selassie said. “And it is falling hardest on the region’s most vulnerable countries: fragile states and low-income economies that depend on aid not as a supplement, but as a critical source of budget financing, healthcare, and food assistance.” The summit runs through Wednesday, with the African Union expected to publish a position paper on global health architecture reform at its close. Image Credits: ONE Data. Ghana Rebuffs US Health Deal – But South Africa and Zambia Struggle Without Aid 29/04/2026 Kerry Cullinan US Ambassador to the UN Mike Waltz (left) at the launch of the ‘Trade over Aid’ event at the New York Stock Exchange this week. Ghana has become the latest African country to reject the United States’ terms for bilateral health assistance, particularly the requirement to share sensitive health data, according to Reuters. Late last year, Zimbabwe rejected US terms for health assistance, particularly the demand to share pathogen data without any “corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data,” according to government spokesperson Nick Mangwana. Zambia has until 30 April to decide on whether to avail its minerals – primarily copper, cobalt and lithium – to US companies in exchange for health assistance. US aid supported antiretroviral treatment for an estimated 1,3 million Zambians. In the wake of disruptions since President Donald Trump assumed office last January, some Zambian hospitals are seeing an increase in AIDS cases, according to the New York Times. Back in December, the US announced Zambia had committed to a plan to unlock “a substantial grant package of US support in exchange for collaboration in the mining sector and clear business sector reforms that will drive economic growth and commercial investment that benefits both the United States and Zambia”. But this has never materialised amid renewed US pressure on Zambia to open its mineral wealth to the US. Meanwhile, South Africa has been frozen out of health aid by the Trump administration – in the main, for charging Israel with genocide at the International Criminal Court and for policies aimed at addressing apartheid-era discrimination that the US claims are anti-white. The loss of US funding has “damaged critical health services, dismantled HIV prevention programs, and disrupted world-class South Africa-U.S. research collaboration,” according to a report published last week by Physicians for Human Rights (PHR), Advocates for the Prevention of HIV in South Africa (APHA), and Emthonjeni Counselling and Training. ‘Trade over aid’ The terms of the Memorandums of Understanding (MOU) that the US is seeking with key countries, as part of its “America First Global Health Strategy” (AFGHSD), are overwhelmingly transactional. This week, the US entrenched this approach at the launch of its ‘Trade over Aid’ initiative at the New York Stock Exchange, asserting that the free market is the “surest route to economic prosperity” Ghana is Africa’s largest gold producer. It is unclear whether the US tried to use its aid offer to extract minerals, as it has in other countries. However, this is unlikely to have gone down well as Ghana is clamping down on foreign mining operations. In the past few weeks, the country’s Minerals Commission has given three international firms until the end of the year to transfer their gold mining operations to locals. Ghanaian President John Mahama is also championing the “Accra Reset”, launched last year to encourage African countries to invest more of their domestic budgets in their health and depend less on aid. At the same time, Ghana is heavily indebted and recently held off paying newly recruited nurses as it lacked the finances. US role in DRC conflict? President Donald Trump meets with DRC President Felix Tshisekedi and President Paul Kagame of the Republic of Rwanda, in the Oval Office in December 2025. The US held off signing an MOU with the DRC on 5 December, when it signed deals with Rwanda and Kenya on the sidelines of a peace accord between the DRC and Rwanda, allegedly the sponsor of the M23 rebels waging war inside the DRC. Instead, the US and DRC first signed a “strategic partnership agreement” to “promote secure, reliable, and mutually beneficial critical mineral flows for commercial and defense purposes”, according to the US State Department. The health MOU followed on 26 February. The DRC is one of the world’s most important sources of rare earth minerals, but China has dominated the purchasing and processing of its minerals. Following the agreement, the DRC offered US investors stakes in state-owned mineral assets. In late March, a US company, Virtus, bought a cobalt mine. Recently, it emerged that the DRC has offered mining opportunities to US companies in Rubaya, currently held by M23 rebels, indicating that the US would need to play a role in maintaining peace if it wants access to rare minerals. This week, the DRC announced the formation of a $100 million initiative to establish “mining guards” to secure mines, with investment from the US and the United Arab Emirates. However, lawyers in the DRC have challenged the MOU in court, while part of Kenya’s MOU has been suspended by a High Court in the face of an ongoing court challenge. South Africa in the cold South African HIV scientist Prof Linda-Gail Bekker received a standing ovation at the International AIDS Conference in 2022 when she announced the results of the lenacapavir clinical trial. South Africa has the biggest HIV population in the world, and was the largest international recipient of US National Institutes of Health (NIH) research funds, as well as getting funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR). “Our report illustrates what an ‘America First’ approach to global health looks like: Lifesaving programs shuttered, world-class research jettisoned, decades of progress against HIV/AIDS jeopardized. All to the harm of, not only South Africans, but to Americans and the global public as well,” said Thomas McHale, director of public health at PHR and a report co-author. Co-author Emily Bass warned: “Short-sighted, sudden withdrawal of funds for critical components of the HIV response will cause long-term harm to infants, children, adolescent girls and young women, and other groups at the highest risk of HIV.” The report mentions two scientific breakthroughs that came from US-South African research partnerships, namely the clinical trial of lenacapavir, an injectable pre-exposure prophylaxis (PrEP) that is almost 100% effective in preventing HIV, and updated global guidelines for treating drug-resistant tuberculosis (TB). These breakthroughs “directly benefit Americans”, the authors argue. “By freezing research funding to South Africa, the Trump administration is sabotaging the United States’ own future health and national security.” The report is based on interviews with South African doctors, researchers, people living with HIV, and others involved in South Africa’s HIV response efforts. Image Credits: Daniel Torok/ White House , Kerry Cullinan. Record European Heatwaves Shrink Glaciers and Diminish Snow Cover in 2025 29/04/2026 Disha Shetty Europe experienced record extremes in 2025, according to WMO’s latest assessment. Around 95% of Europe experienced above-average temperatures in 2025, with record heatwaves from the Mediterranean to the Arctic region. This caused rapid loss of glacier mass and snow cover, according to the latest State of the European Climate report by the World Meteorological Organization (WMO) released on Thursday. All of Europe’s glaciers saw a net mass loss, with Iceland recording its second-largest glacier loss on record. The continent experienced dangerously high air temperatures, drought, heatwaves and record ocean temperatures. This has translated into economic and biodiversity loss affecting countries and ecosystems across the continent. “Europe is the fastest-warming continent, and the impacts are already severe. Almost the whole region has seen above-average annual temperatures,” said Florian Pappenberger, Director-General of the European Centre for Medium-Range Weather Forecasts (ECMWF), an inter-governmental organisation that contributed to the report along with WMO. Also read: Europe is World’s Fastest Warming Continent With Record Temperatures in 2024 Europe is warming twice as fast as the global average Europe is now the fastest-warming continent, warming twice as fast as the global average. The impact of the temperature increases is most visible in the coldest regions, such as the Arctic and the Alps. Snow and ice play a critical role in slowing climate change by reflecting sunlight into space in what is known as the albedo effect. “In 2025, sub-Arctic Norway, Sweden and Finland recorded their worst heatwave on record with 21 straight days and temperatures exceeding 30°C within the Arctic Circle itself,” Pappenberger of ECMWF said. This also pushed up temperatures within and adjacent to the Arctic Circle to over 30°C, peaking at 34.9°C in Frosta, Norway. Ironically, low levels of air pollution in Europe allow more solar radiation to reach the surface, leading to a higher rate of warming. The number of cold stress days when temperatures drop below normal is also reducing. Nearly 90% of the continent experienced fewer cold stress days than average, and minimum temperatures remained above average for most of the year. Hot, dry conditions resulted in more wildfires. A record total area of around 1,034,000 hectares was burnt across Europe – an area larger than Cyprus. Spain, Cyprus, the United Kingdom, the Netherlands, and Germany recorded their highest wildfire emissions on record in 2025. Record loss of glacier mass Glaciers across Europe lost mass in 2025, with the highest loss recorded in Iceland. The Greenland Ice Sheet, which is the largest ice mass in the northern hemisphere and covers 80% of Greenland, lost 139 gigatonnes (139 billion tonnes) of ice. This is equivalent to 1.5 times the volume stored in all glaciers in the European Alps. Such ice loss contributes to rising global sea levels, with every centimetre increase exposing an additional six million people to coastal flooding. Overall, snow cover was 31% below average, affecting 1.32 million square kilometres, which is equivalent to the combined area of France, Italy, Germany, Switzerland, and Austria. “The ESOTC 2025 paints a stark picture: the pace of climate change demands more urgent action. With rising temperatures, and widespread wildfires and drought, the evidence is unequivocal; climate change is not a future threat, it is our present reality,” Samantha Burgess, Strategic Lead for Climate at ECMWF said. Rising ocean heat, reducing river flow Nearly 86% of European waters saw strong marine heatwaves in 2025. Oceans absorb 90% of the atmosphere’s excess heat due to the burning of fossil fuels. In 2025, Europe’s sea surface temperature was the highest on record. Around 86% of the region experienced strong marine heatwaves, disrupting fish and the ocean plants. Changes in rainfall and snowfall patterns have also affected the flow in 70% of Europe’s rivers. In May 2025, around half of Europe (53%) was affected by drought conditions. “Maintaining our own state-of-the-art, reliable data records of our Earth system is vital for making informed policy decisions in our rapidly changing climate. Copernicus is pivotal to help us preserve our sovereignty, our environment, food systems, safety, and economy,” said Mauro Facchini, Head of the European Commission’s Copernicus, is the European Union’s Earth Observation Programme. Renewable growth and actionable items for policymakers The share of renewables in Europe’s energy mix has gone up, supported by the growth in solar energy. A silver lining in the report is the growth of renewable energy, which in 2025 supplied nearly half (46.4%) of Europe’s electricity. Solar power contributed around 12.5% of this, a new regional record. Countries have begun to see energy security as a national security issue, and that appears to be one of the reasons driving the growth of renewables, including the adoption of nuclear energy at a higher rate compared to recent decades. Another positive was that by the end of 2025, around half of the European Biodiversity Strategy 2030’s recommended actions were in place or completed. The strategy is a European Union plan to restore the continent’s biodiversity. The report highlighted initiatives like Ireland’s network of marine protected areas, Armenia’s biodiversity finance plan, and Iceland’s funding to assist in recovering wetlands as examples of policy interventions that can help arrest biodiversity loss. Image Credits: Unsplash/Jochen Bückers, WMO. Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
No Pandemic Agreement Annex by World Health Assembly, Says Civil Society 30/04/2026 Kerry Cullinan (Left to right from top) Third World Network’s moderator and speakers Lauren Paremoer, KP Gopakumar and Tamara Prisenburg form AIDS Healthcare Foundation. The final missing piece of the Pandemic Agreement – a pathogen access and benefit-sharing (PABS) system – is unlikely to be agreed on by the World Health Assembly (WHA) later this month. This was the view of civil society observers of the talks taking place at the World Health Organisation (WHO) headquarters in Geneva, who briefed the media on Thursday. The sixth round of talks is scheduled to end late on Friday night (1 May). Earlier in the week, WHO Director General Dr Tedros Adhanom Ghebreyesus told a Geneva media briefing that “key differences remain on key issues”. “I still see a common will to reach consensus, which means I continue to believe there is a way to reach consensus,” Tedros added. Although the notion of a “hybrid” PABS system is being discussed informally, its proponent, the European Union (EU), has not presented any formal text, Third World Network’s (TWN) KM Gopakumar told the media briefing, which was hosted by TWN and the AIDS Healthcare Foundation. While Brazil and Botswana have apparently indicated that they might support a hybrid or “blended” compromise, the Africa Group is opposed to it, according to the civil society representatives. WHO member states are negotiating how to share both information about dangerous pathogens and some of the “benefits” that manufacturers may develop from that information – namely, vaccines, therapeutics and diagnostics (VTDs). The “hybrid” or “blended” proposal is a mix of mandatory and voluntary measures for sharing pathogen information and any benefits that flow from this information. It de-links information-sharing and benefit-sharing. Gopakumar said that, in terms of the blended agreements, countries that shared pathogens “will have the freedom to choose to attach certain conditions for sharing the data and the sample, including benefit sharing requirements” or share without any conditions. Kill the efficiency Shifting the choice to individual countries would undermine the efficiency of a single PABS system as users would need to negotiate with the individual countries instead of through a centralised system, he argued. “If you have a hybrid system, first of all, it kills the efficiency [of a single system], and second, it’s going to debase the access and benefit sharing norms set by the international instruments like the Convention on Biological Diversity and the Nagoya Protocol. Any attempt to dilute benefit-sharing obligations would be a “disaster” for equity, said AHF’s Tamara Prisenberg. Lauren Paremoer of the People’s Health Movement said that the blended model introduces “a two-track system for accessing pathogens” that violates access and benefit-sharing on an “equal footing” specified in Article 12 of the Pandemic Agreement. One track would allow anonymous users to access pathogen data without upfront commitments to benefit-sharing or legally binding contracts. The other was in line with Article 12, permitting access to pathogens through databases and laboratories that would require users to register and commit to specified benefit-sharing. Earlier in the day, the Intergovernmental Working Group (IGWG) briefed civil society on text-based negotiations, but very little of the text they shared had been “greened” to show agreement. EXCLUSIVE: WHO Opens Nominations for Next Director General; Germany May Advance Former Merkel Aide, Helge Braun 30/04/2026 Felix Sassmannshausen, Elaine Ruth Fletcher & Editorial team WHO DG Dr Tedros Adhanom Ghebreyesus issued a call for nominations for the DG elections. He recently travelled to Berlin, where he met with high-level politicians and the WHO’s Pandemic Intelligence team. As the World Health Organization (WHO) formally opens the nomination process for the next Director-General, Germany now appears likely to propose Helge Braun, Chief of Staff in former Chancellor Angela Merkel’s government, according to Berlin insiders. But after slashing its global health budget, sources question whether a German candidate can win wide support from other WHO member states. WHO Director-General Dr Tedros Adhanom Ghebreyesus has formally issued a call to WHO member states for nominations to the DG elections, scheduled for May 2027, in an invitation sent on 24 April to all WHO member states. WHO confirmed this in an email to Health Policy Watch. The invitations had been sent via private letters to countries’ Geneva missions. The period in which member states may nominate candidates will now run for six months, until 24 September. Contenders who have until now remained in the shadows are expected to begin coming forward publicly with their candidacies at the World Health Assembly in May. From the German perspective, Berlin wants its financial weight reflected in executive influence at the multilateral level as the largest global health donor following the US withdrawal from the WHO in January 2025. The withdrawal, combined with the US non-payment of dues owed, thrust WHO into a budget crisis, prompting layoffs of about 25% of the workforce in the past year. German Foreign Ministry neither confirms nor denies The German Foreign Ministry, formally responsible for the nomination, declined to confirm or comment on Braun’s potential candidacy when responding to a query by Health Policy Watch. Germany’s other potential candidates include the contested former Health Minister Karl Lauterbach and the lesser-known Paul Zubeil. In contrast, Braun’s dual profile as an accomplished politician, skilled financial manager, and trained physician and researcher who successfully built cross-party bridges offers a distinct advantage. But he is little known outside of Germany. Bridge-builder with executive and medical expertise Former Chair of the influential German Budget Committee, Helge Braun (right), and former French Chair of the Finance Committee, Claude Raynal (left), in the Bundestag. The current WHO leadership landscape demands a candidate capable of managing deep institutional fractures and uniting a divided global community. Despite him being largely unknown in the international community, Germany could be expected to emphasise Braun’s extensive fiscal and crisis management experience in any candidacy it mounts. As ‘Head of the Chancellery’, effectively Chief of Staff, in Angela Merkel’s last term as Chancellor, from 2018 to 2021, Braun operated at the nexus of scientific advice and political implementation during the COVID-19 pandemic, notably comparing the Chancellery to an intensive care unit where acute problems must be solved. Between 2021 and 2025, Braun then chaired the powerful Budget Committee of the German Bundestag (Parliament), overseeing the distribution and management of hundreds of billions of Euros with strict discipline This profound understanding of macroeconomic management, coupled with his pragmatic defence of Germany’s controversial debt ceiling alongside crisis-driven special funds, makes him an attractive prospect for donor nations currently demanding more financial accountability and restructuring at WHO in Geneva. Serving as a central mediator across government ministries, Braun built a reputation as a highly pragmatic problem solver whose past domestic political affiliations will not necessarily dictate his future approach to global health governance. This pragmatism complements his longstanding political advocacy for research into infectious diseases like Ebola and malaria. And unlike many career politicians, Braun’s foundational expertise lies in medicine, having worked for years as an intensive care physician and anaesthesiologist. He returned to these roots in April 2025 by assuming the presidency of the University of Lübeck, an institution renowned for its focus on life sciences and artificial intelligence. Why the candidacy might spark concerns WHO member states are currently negotiating a pathogen access and benefit-sharing (PABS) system in Geneva. While Braun championed early interventions and massive digitisation projects in his role as Merkel’s Head of the Chancellery during the COVID pandemic, severe bureaucratic delays hampered the rollout of vaccination campaigns and testing strategies. This tarnished his crisis management legacy just as he exited the federal government. His domestic political capital suffered further damage during the December 2021 Christian Democratic Union leadership election, where he lost heavily to conservative rival Friedrich Merz, now Chancellor. Party members largely rejected Braun as an establishment candidate, perceiving him as too closely aligned with the moderate legacy of former Chancellor Angela Merkel. Additionally, it is questionable whether Braun would wield the necessary diplomatic connections and familiarity with foreign health systems to be effective on Day One of a term as WHO head. The Director-General must immediately command trust and authority on the international stage, particularly when dealing with health ministries and stakeholders in the Global South. Most notably, the German government opposed the release of COVID-19 vaccine patents during his tenure, drawing sharp criticism from international health equity advocates. Defending this refusal in May 2021, Braun wrote in a guest article for the German newspaper Die Zeit that “patent protection as a driver of innovation is not the problem in this crisis, but an essential foundation for its solution.” In the Global South, this track record could thus reinforce the perception that Germany defends pharmaceutical interests over equitable technology transfer – especially in the face of current PABS Annex negotiations. Recent reports from Tagesspiegel Background indicating that the former minister was approached by Germany’s Association of Research-Based Pharmaceutical Companies to become their next president, when the post becomes vacant at the end of 2026, might further fuel these concerns. Finally, Germany has been cutting back its Official Development Assistance (ODA) in general, including contributions to the World Health Organization, where it has historically been the largest member state donor after the United States. On Wednesday, the Merz government announced its 2027 budget plans with further ODA cuts following last year’s drastic 17% reductions. The likelihood of Germany fulfilling its original 2024 financial pledge to WHO for the current biennium (2026-27) also remains in doubt. “They can put forward a candidate, but I don’t think it’s going to get a lot of traction from other member states,” said one informed WHO source. “At a time when Germany is reducing global health funding to member states, I don’t think they can go ahead and claim the top seat.” Step back and support allied candidates? Braun served as Head of Chancellery under then German Chancellor Angela Merkel, seen here with WHO Director General Dr Tedros in Berlin in 2021. Furthermore, domestic opinion remains highly divided on mounting a campaign amidst the geopolitical strains on Chancellor Friedrich Merz’s coalition and Tedros has reportedly urged Germany to back allied candidates instead. At the same time, the desire to seize more leadership in the UN system remains strong after Germany’s failed previous attempt to secure the top role at the UN High Commissioner for Refugees in 2025. Currently, Germany is also pushing for another attempt at a UN Security Council seat. Should Germany put forward a candidate, Foreign Minister Johann Wadephul, who will make the final decision, also faces a stark choice between Braun and the better-known Karl Lauterbach, as well as Paul Zubeil with his strong international health and technical background. Advancing a WHO outsider like Braun against established public health veterans is a highly calculated risk for Berlin, which must first convince other European countries to rally behind him. In case Berlin formally nominates Braun, the success of his candidacy will depend entirely on how effectively the government can reframe his perceived lack of field experience and global networks as delivery on fresh, badly needed fiscal expertise and perspectives. Grappling with WHO’s funding crisis As the race for the next Director-General opens for formal nominations, the names of over a dozen high-profile potential candidates are still circulating – from Indonesia to the United Kingdom. Want to Become the Next WHO Director-General? Get in Line And the list is still growing. Among the newer names being floated is that of Dr Hanan Mohamed al-Kuwari, who served as Qatar’s Minister of Public Health until November 2024 and chaired the 153rd Session of the WHO Executive Board. Before joining the Hamad Medical Corporation in 1996, where she ultimately rose to managing director, al-Kuwari worked for Reuters and as a freelance health reporter. Holding a PhD in healthcare management from Brunel University and bringing early career experience from the WHO, she represents a highly networked voice from the Arab world, celebrated for her crisis resilience and for shaping the WHO’s recent global work programme. Dr Maria Neira, WHO Director of Climate, Environment and Health Another candidate who has been mentioned is Spain’s Dr Maria Neira, who recently retired from WHO as the director of Climate, Environment and Health. An iconic spokesperson for the climate, environment and health movement, Neira is known as a telegenic personality and adroit politically. As a young medical doctor, she worked in emergency relief in Latin America and Africa, and later served as Spain’s Vice Minister of Health and Consumer Affairs as well as President of the Spanish Food Safety and Nutrition Agency. However, Spain also recently decided to nominate a candidate to head the UN Food and Agriculture Organization (FAO), when Qu Dongyu’s second term as Director General ends in July 2027, leaving doubts about whether it would want to mount yet another campaign, in parallel. Continuing decline in ODA and global health aid Drastic ODA cuts and reduced global health funding leave vulnerable populations in precarious conditions worldwide. Whoever is elected will have to continue grappling with the continuing long-term declines in donor-driven ODA, and particularly global health aid – directly to countries and to WHO. While WHO 2026-2027 $4.2 billion base budget is now 85% financed, according to Tedros’ comments on Wednesday, declines in ODA continue to cast uncertainty on how the remaining $630 million gap will be filled. It’s unlikely that the $260.6 million in assessed US contributions still due for years 2024-2025, before the withdrawal became official in January, will ever be repaid, conceded WHO’s Tedros at a Geneva press briefing on Wednesday. “We’re hoping to get the money, but no signals yet,” Tedros told journalists, adding: “No signals means maybe we may not be able to get the money. The likelihood could be not getting the money.” “We’re looking at nontraditional donors. We’re looking at international financial institutions and other ways to mobilize that 15%,” Tedros said, in terms of filling that gap. “It’s not that we won’t go to the traditional donors, but I think we’re expanding that donor base.” This article has been edited to reflect additional information regarding Dr Hanan Mohamed al-Kuwari’s early career as a freelance journalist. Image Credits: X/Dr Tedros, Deutscher Bundestag/Leon Kügeler, European Commission. African Leaders Declare End of Aid Era at Nairobi World Health Summit, But The Data Tell a More Complicated Story 29/04/2026 Stefan Anderson Delegates gather for the opening plenary of the World Health Summit Regional meeting in Nairobi, Kenya. African leaders opened the World Health Summit Regional Meeting at the United Nations complex in Nairobi this week with a unified declaration that two decades of dependence on foreign aid for health is over. “The challenge that I see is that many of the leaders in our continent believe that it is somebody else’s responsibility. It should be the World Health Organization, USAID, I don’t know who,” Kenyan President William Ruto told the summit. “The sooner we realise that it is our responsibility to raise especially domestic resources to fund our health, the better for all of us.” The Nairobi meeting, the first co-organised by the World Health Organization (WHO) and the World Health Summit, has positioned itself as the continent’s first high-level response to the collapse of official development assistance (ODA) for health, which fell by an estimated $31.1 billion in 2025, according to the Africa Centres for Disease Control and Prevention (Africa CDC). Over 2,000 delegates from more than 50 countries, including health and finance ministers from 17 nations, are convening in the Kenyan capital to coordinate a united African position ahead of next month’s World Health Assembly in Geneva. “I don’t want to see this continent being dependent. And we are dependent because we want it,” Ruto said. “Africa is manufacturing a number of products today, from Egypt, from Kenya, from South Africa, from a number of countries, but we are not buying our own product.” Africa carries more than 25% of the global disease burden but accounts for less than 3% of global health expenditure. The continent currently produces less than 2% of the medicines and vaccines it consumes, leaving its countries dependent on external supply chains for essential medical commodities. “Who’s asking us not to buy our own product, who’s asking us not to register to the African Medicines Agency for the regulatory aspect?” Ruto asked. “It’s not Germany, it’s not Europe, it’s ourselves. We need to change our mindset.” A break with the past African leaders led by Kenyan President William Ruto arrive in Nairobi for the summit. The urgency on display in Nairobi is driven by the most disruptive year for global health financing on record. For African governments, the pivot to self-reliance has become a fiscal necessity. The dismantling of the United States Agency for International Development (USAID), followed by aid cuts by the United Kingdom, Germany, France and the Netherlands, drove a 23.1% drop in total ODA from OECD donors in 2025. This is the largest single-year contraction since records began. The US, Germany, UK, Japan and France accounted for 95.7% of the total decline. The Boston University ImpactCounter estimates the US cuts have already led to more than 518,000 child and 263,000 adult deaths from preventable diseases such as HIV and tuberculosis. A further 14 million preventable deaths, including 4.5 million children, may occur by 2030 if USAID funding gaps are not filled, a major international study found. Africa CDC estimates the combined cuts from the US, UK, Germany and other major donors will kill an additional two to four million Africans annually. “The year 2025 marked the end of one era and the beginning of another,” Sulaiman Shahabuddin, President and Vice Chancellor of the Aga Khan University, told the opening plenary. “We are confronting a new reality, defined by funding constraints, the rise of technology and artificial intelligence, and a decisive shift towards local ownership.” “Climate change, chronic diseases, lack of financial resources, the digital divide, inequity and others are [challenges] we will have to overcome,” Shahabuddin added. What aid remains on the table increasingly comes with strings attached. Washington has begun rolling out bilateral “America First” global health agreements, with US President Donald Trump retaining the right to terminate any programme judged not to align with American interests. Conditionalities include sharing pathogen samples and genomic data with US authorities, prioritising faith-based health providers to prevent services such as abortions, channelling funding away from non-governmental organisations, and, in the case of Zambia, granting access to critical minerals in exchange for health funding. Lukoye Atwoli, Dean of the Aga Khan University Medical College East Africa and the summit’s international president, said this year’s gathering would mark a break with past meetings on African health. “Historically, meetings about Africa and Africa’s health have been about lamentations. Have been about framing the problems. Have been about basically begging and saying that we have a problem and we need help,” Atwoli told delegates. “This meeting will be different.” Reform body launched Africa CDC Director Dr Jean Kaseya speaking in Nairobi. On the sidelines of the summit, Africa CDC launched the African High-Level Ministerial Committee on Global Health Architecture Reform. The body brings together health and finance ministers from across the continent to coordinate African positions ahead of the World Health Assembly and broader UN reform processes. Convening both portfolios in the same room is a long-standing demand of global health advocates, who have struggled for decades to make the economic case for health investment to treasuries that hold the purse strings. The committee, chaired by former Liberian president Ellen Johnson Sirleaf, will produce coordinated African position papers on health architecture reform and a 2026–2030 reform roadmap focused on five axes: governance, financial sovereignty, data sovereignty, local manufacturing, and pandemic preparedness. “The old model is no longer fit for purpose. Africa cannot continue to be a passive recipient of global health decisions,” said Africa CDC Director General Dr Jean Kaseya. “We welcome our partners, but on a new basis: not as donors and recipients, but as equal partners aligned with Africa’s priorities.” Aspiration meets evidence Official development assistance fell by a historic 23.1% in 2025. African nations are among the hardest hit. The data on whether Africa can deliver on the vision laid out in Nairobi tell a more complicated story. A Centre for Global Development (CGD) audit of 442 government actions across all 54 African countries found a continental reaction to the historic aid cuts split in radically uneven ways, a story of inequality within Africa as much as between Africa and its donors. The countries that moved fastest are those with the deepest pockets and most diversified economies, including Nigeria, Ghana and Ethiopia. Lower-income, debt-burdened countries, many of which were the largest per-capita recipients of foreign assistance, have largely absorbed the loss in silence. “Governments with limited fiscal space and weaker administrative capacity have less room to cushion abrupt external shocks,” the analysis found. “What is slightly surprising is that they were not only doing little about the aid cuts, they are also saying little about them.” Global Health Leaders Urge Fewer Agencies Amid Funding Crisis A separate CGD study published in February examined the budget statements of 18 sub-Saharan African countries: among the world’s poorest, most heavily aid-dependent and exposed to the cuts. It found that only two, Tanzania and Sierra Leone, proposed new revenue measures to replace lost financing in their 2025 budgets. None reprioritised spending from other sectors to protect health. “With few exceptions, governments neither raised new revenues nor reallocated spending to compensate for lost external financing,” the analysis concluded. The burden of adjustment, it found, has instead fallen on the services patients receive, from disrupted HIV and tuberculosis treatment to delays in vaccination campaigns and the closure of clinics that depended on donor financing. “Health is not a cost, it is an investment,” Ruto said. “And it is important for us to invest.” Cascading crises Runaway climate change is colliding with constant economic shocks from war and the COVID-19 pandemic, shrinking Africa’s budgets and taking away the space to invest in health. The continent’s ability to absorb the aid shock and finance the pivot to support its own health systems is constrained by an unending sequence of external crises over the past decade that continue to batter government budgets, layered on top of the escalating climate crisis. The COVID-19 pandemic, during which wealthy nations hoarded vaccines, exposed Africa’s reliance on a foreign supply chain that produces 99% of the vaccines and 90% of the medical supplies it consumes. Pandemic response cost African governments an additional $154 billion in 2020 and 2021, according to the African Development Bank, pushing sub-Saharan public debt up by 8 percentage points of GDP in a single year. Russia’s invasion of Ukraine drove an inflationary spike that ballooned debt-service costs across the region, a pressure that has now snowballed into the global economic crisis triggered by the US-Israeli war on Iran, to which African economies are uniquely vulnerable. The closure of the Strait of Hormuz, a chokepoint for a fifth of the world’s oil and a third of its liquefied natural gas, is driving up fuel and fertiliser costs and deepening food insecurity across the continent. The resulting inflation, weaker currencies and tighter global financial conditions across Africa are inflating debt-servicing bills and forcing governments to divert money that could otherwise help absorb the aid shock. Climate change is compounding the pressure on every front. African countries are losing between 2% and 5% of GDP to climate extremes, the World Meteorological Organization estimates, with some governments diverting up to 9% of national budgets to respond. Health systems will bear a growing share of that cost. The World Bank estimates climate change could drive at least $21 trillion in excess health costs in low- and middle-income countries by 2050, with sub-Saharan Africa among the regions hit hardest. “What was considered reliable for decades is turning out to be fragile,” said Birgit Pickel, Director-General for Global Health at Germany’s Federal Ministry for Economic Cooperation and Development. “Cracks are appearing in the international order. Cracks that, in some cases, are already leading to its collapse.” Fiscal squeeze limits options African debt levels have more than doubled in the past decade, according to ONE Data figures. The cumulative damage has left African governments with little room to manoeuvre. Thirty-two African nations now spend more servicing external debt than funding healthcare. The continent paid almost $90 billion in external debt service in 2024 alone, with African governments now spending an average of 17% of state revenue on debt servicing, according to leading estimates. The IMF warned last week that more than a third of African countries are at high risk of, or already in, debt distress, with rising interest bills “crowding out essential development spending, healthcare above all.” “Official funding will probably shrink, at least internationally. Domestic funding will hopefully move up,” Pickel said. “But there are innovative instruments out there to also meet urgent funding needs in the health sector, especially for heavily indebted countries.” Pickel proposed debt-for-health swaps, an instrument under which creditor nations cancel debt in exchange for redirected health spending, as a route to fiscal space for highly indebted countries. Germany issued €100 million in such swaps last year, channelled to the Global Fund. The figure is substantial as a signal, but negligible against the scale of the African external debt service crisis. The IMF’s Africa Director, Abebe Selassie, told the Fund’s Spring Meetings in Washington this month that the 2025 foreign aid contraction marks a structural break – and the money is unlikely to come back. “Past aid shocks were largely cyclical; donors cut back and then returned. What we are seeing now appears more structural,” Selassie said. “And it is falling hardest on the region’s most vulnerable countries: fragile states and low-income economies that depend on aid not as a supplement, but as a critical source of budget financing, healthcare, and food assistance.” The summit runs through Wednesday, with the African Union expected to publish a position paper on global health architecture reform at its close. Image Credits: ONE Data. Ghana Rebuffs US Health Deal – But South Africa and Zambia Struggle Without Aid 29/04/2026 Kerry Cullinan US Ambassador to the UN Mike Waltz (left) at the launch of the ‘Trade over Aid’ event at the New York Stock Exchange this week. Ghana has become the latest African country to reject the United States’ terms for bilateral health assistance, particularly the requirement to share sensitive health data, according to Reuters. Late last year, Zimbabwe rejected US terms for health assistance, particularly the demand to share pathogen data without any “corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data,” according to government spokesperson Nick Mangwana. Zambia has until 30 April to decide on whether to avail its minerals – primarily copper, cobalt and lithium – to US companies in exchange for health assistance. US aid supported antiretroviral treatment for an estimated 1,3 million Zambians. In the wake of disruptions since President Donald Trump assumed office last January, some Zambian hospitals are seeing an increase in AIDS cases, according to the New York Times. Back in December, the US announced Zambia had committed to a plan to unlock “a substantial grant package of US support in exchange for collaboration in the mining sector and clear business sector reforms that will drive economic growth and commercial investment that benefits both the United States and Zambia”. But this has never materialised amid renewed US pressure on Zambia to open its mineral wealth to the US. Meanwhile, South Africa has been frozen out of health aid by the Trump administration – in the main, for charging Israel with genocide at the International Criminal Court and for policies aimed at addressing apartheid-era discrimination that the US claims are anti-white. The loss of US funding has “damaged critical health services, dismantled HIV prevention programs, and disrupted world-class South Africa-U.S. research collaboration,” according to a report published last week by Physicians for Human Rights (PHR), Advocates for the Prevention of HIV in South Africa (APHA), and Emthonjeni Counselling and Training. ‘Trade over aid’ The terms of the Memorandums of Understanding (MOU) that the US is seeking with key countries, as part of its “America First Global Health Strategy” (AFGHSD), are overwhelmingly transactional. This week, the US entrenched this approach at the launch of its ‘Trade over Aid’ initiative at the New York Stock Exchange, asserting that the free market is the “surest route to economic prosperity” Ghana is Africa’s largest gold producer. It is unclear whether the US tried to use its aid offer to extract minerals, as it has in other countries. However, this is unlikely to have gone down well as Ghana is clamping down on foreign mining operations. In the past few weeks, the country’s Minerals Commission has given three international firms until the end of the year to transfer their gold mining operations to locals. Ghanaian President John Mahama is also championing the “Accra Reset”, launched last year to encourage African countries to invest more of their domestic budgets in their health and depend less on aid. At the same time, Ghana is heavily indebted and recently held off paying newly recruited nurses as it lacked the finances. US role in DRC conflict? President Donald Trump meets with DRC President Felix Tshisekedi and President Paul Kagame of the Republic of Rwanda, in the Oval Office in December 2025. The US held off signing an MOU with the DRC on 5 December, when it signed deals with Rwanda and Kenya on the sidelines of a peace accord between the DRC and Rwanda, allegedly the sponsor of the M23 rebels waging war inside the DRC. Instead, the US and DRC first signed a “strategic partnership agreement” to “promote secure, reliable, and mutually beneficial critical mineral flows for commercial and defense purposes”, according to the US State Department. The health MOU followed on 26 February. The DRC is one of the world’s most important sources of rare earth minerals, but China has dominated the purchasing and processing of its minerals. Following the agreement, the DRC offered US investors stakes in state-owned mineral assets. In late March, a US company, Virtus, bought a cobalt mine. Recently, it emerged that the DRC has offered mining opportunities to US companies in Rubaya, currently held by M23 rebels, indicating that the US would need to play a role in maintaining peace if it wants access to rare minerals. This week, the DRC announced the formation of a $100 million initiative to establish “mining guards” to secure mines, with investment from the US and the United Arab Emirates. However, lawyers in the DRC have challenged the MOU in court, while part of Kenya’s MOU has been suspended by a High Court in the face of an ongoing court challenge. South Africa in the cold South African HIV scientist Prof Linda-Gail Bekker received a standing ovation at the International AIDS Conference in 2022 when she announced the results of the lenacapavir clinical trial. South Africa has the biggest HIV population in the world, and was the largest international recipient of US National Institutes of Health (NIH) research funds, as well as getting funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR). “Our report illustrates what an ‘America First’ approach to global health looks like: Lifesaving programs shuttered, world-class research jettisoned, decades of progress against HIV/AIDS jeopardized. All to the harm of, not only South Africans, but to Americans and the global public as well,” said Thomas McHale, director of public health at PHR and a report co-author. Co-author Emily Bass warned: “Short-sighted, sudden withdrawal of funds for critical components of the HIV response will cause long-term harm to infants, children, adolescent girls and young women, and other groups at the highest risk of HIV.” The report mentions two scientific breakthroughs that came from US-South African research partnerships, namely the clinical trial of lenacapavir, an injectable pre-exposure prophylaxis (PrEP) that is almost 100% effective in preventing HIV, and updated global guidelines for treating drug-resistant tuberculosis (TB). These breakthroughs “directly benefit Americans”, the authors argue. “By freezing research funding to South Africa, the Trump administration is sabotaging the United States’ own future health and national security.” The report is based on interviews with South African doctors, researchers, people living with HIV, and others involved in South Africa’s HIV response efforts. Image Credits: Daniel Torok/ White House , Kerry Cullinan. Record European Heatwaves Shrink Glaciers and Diminish Snow Cover in 2025 29/04/2026 Disha Shetty Europe experienced record extremes in 2025, according to WMO’s latest assessment. Around 95% of Europe experienced above-average temperatures in 2025, with record heatwaves from the Mediterranean to the Arctic region. This caused rapid loss of glacier mass and snow cover, according to the latest State of the European Climate report by the World Meteorological Organization (WMO) released on Thursday. All of Europe’s glaciers saw a net mass loss, with Iceland recording its second-largest glacier loss on record. The continent experienced dangerously high air temperatures, drought, heatwaves and record ocean temperatures. This has translated into economic and biodiversity loss affecting countries and ecosystems across the continent. “Europe is the fastest-warming continent, and the impacts are already severe. Almost the whole region has seen above-average annual temperatures,” said Florian Pappenberger, Director-General of the European Centre for Medium-Range Weather Forecasts (ECMWF), an inter-governmental organisation that contributed to the report along with WMO. Also read: Europe is World’s Fastest Warming Continent With Record Temperatures in 2024 Europe is warming twice as fast as the global average Europe is now the fastest-warming continent, warming twice as fast as the global average. The impact of the temperature increases is most visible in the coldest regions, such as the Arctic and the Alps. Snow and ice play a critical role in slowing climate change by reflecting sunlight into space in what is known as the albedo effect. “In 2025, sub-Arctic Norway, Sweden and Finland recorded their worst heatwave on record with 21 straight days and temperatures exceeding 30°C within the Arctic Circle itself,” Pappenberger of ECMWF said. This also pushed up temperatures within and adjacent to the Arctic Circle to over 30°C, peaking at 34.9°C in Frosta, Norway. Ironically, low levels of air pollution in Europe allow more solar radiation to reach the surface, leading to a higher rate of warming. The number of cold stress days when temperatures drop below normal is also reducing. Nearly 90% of the continent experienced fewer cold stress days than average, and minimum temperatures remained above average for most of the year. Hot, dry conditions resulted in more wildfires. A record total area of around 1,034,000 hectares was burnt across Europe – an area larger than Cyprus. Spain, Cyprus, the United Kingdom, the Netherlands, and Germany recorded their highest wildfire emissions on record in 2025. Record loss of glacier mass Glaciers across Europe lost mass in 2025, with the highest loss recorded in Iceland. The Greenland Ice Sheet, which is the largest ice mass in the northern hemisphere and covers 80% of Greenland, lost 139 gigatonnes (139 billion tonnes) of ice. This is equivalent to 1.5 times the volume stored in all glaciers in the European Alps. Such ice loss contributes to rising global sea levels, with every centimetre increase exposing an additional six million people to coastal flooding. Overall, snow cover was 31% below average, affecting 1.32 million square kilometres, which is equivalent to the combined area of France, Italy, Germany, Switzerland, and Austria. “The ESOTC 2025 paints a stark picture: the pace of climate change demands more urgent action. With rising temperatures, and widespread wildfires and drought, the evidence is unequivocal; climate change is not a future threat, it is our present reality,” Samantha Burgess, Strategic Lead for Climate at ECMWF said. Rising ocean heat, reducing river flow Nearly 86% of European waters saw strong marine heatwaves in 2025. Oceans absorb 90% of the atmosphere’s excess heat due to the burning of fossil fuels. In 2025, Europe’s sea surface temperature was the highest on record. Around 86% of the region experienced strong marine heatwaves, disrupting fish and the ocean plants. Changes in rainfall and snowfall patterns have also affected the flow in 70% of Europe’s rivers. In May 2025, around half of Europe (53%) was affected by drought conditions. “Maintaining our own state-of-the-art, reliable data records of our Earth system is vital for making informed policy decisions in our rapidly changing climate. Copernicus is pivotal to help us preserve our sovereignty, our environment, food systems, safety, and economy,” said Mauro Facchini, Head of the European Commission’s Copernicus, is the European Union’s Earth Observation Programme. Renewable growth and actionable items for policymakers The share of renewables in Europe’s energy mix has gone up, supported by the growth in solar energy. A silver lining in the report is the growth of renewable energy, which in 2025 supplied nearly half (46.4%) of Europe’s electricity. Solar power contributed around 12.5% of this, a new regional record. Countries have begun to see energy security as a national security issue, and that appears to be one of the reasons driving the growth of renewables, including the adoption of nuclear energy at a higher rate compared to recent decades. Another positive was that by the end of 2025, around half of the European Biodiversity Strategy 2030’s recommended actions were in place or completed. The strategy is a European Union plan to restore the continent’s biodiversity. The report highlighted initiatives like Ireland’s network of marine protected areas, Armenia’s biodiversity finance plan, and Iceland’s funding to assist in recovering wetlands as examples of policy interventions that can help arrest biodiversity loss. Image Credits: Unsplash/Jochen Bückers, WMO. Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
EXCLUSIVE: WHO Opens Nominations for Next Director General; Germany May Advance Former Merkel Aide, Helge Braun 30/04/2026 Felix Sassmannshausen, Elaine Ruth Fletcher & Editorial team WHO DG Dr Tedros Adhanom Ghebreyesus issued a call for nominations for the DG elections. He recently travelled to Berlin, where he met with high-level politicians and the WHO’s Pandemic Intelligence team. As the World Health Organization (WHO) formally opens the nomination process for the next Director-General, Germany now appears likely to propose Helge Braun, Chief of Staff in former Chancellor Angela Merkel’s government, according to Berlin insiders. But after slashing its global health budget, sources question whether a German candidate can win wide support from other WHO member states. WHO Director-General Dr Tedros Adhanom Ghebreyesus has formally issued a call to WHO member states for nominations to the DG elections, scheduled for May 2027, in an invitation sent on 24 April to all WHO member states. WHO confirmed this in an email to Health Policy Watch. The invitations had been sent via private letters to countries’ Geneva missions. The period in which member states may nominate candidates will now run for six months, until 24 September. Contenders who have until now remained in the shadows are expected to begin coming forward publicly with their candidacies at the World Health Assembly in May. From the German perspective, Berlin wants its financial weight reflected in executive influence at the multilateral level as the largest global health donor following the US withdrawal from the WHO in January 2025. The withdrawal, combined with the US non-payment of dues owed, thrust WHO into a budget crisis, prompting layoffs of about 25% of the workforce in the past year. German Foreign Ministry neither confirms nor denies The German Foreign Ministry, formally responsible for the nomination, declined to confirm or comment on Braun’s potential candidacy when responding to a query by Health Policy Watch. Germany’s other potential candidates include the contested former Health Minister Karl Lauterbach and the lesser-known Paul Zubeil. In contrast, Braun’s dual profile as an accomplished politician, skilled financial manager, and trained physician and researcher who successfully built cross-party bridges offers a distinct advantage. But he is little known outside of Germany. Bridge-builder with executive and medical expertise Former Chair of the influential German Budget Committee, Helge Braun (right), and former French Chair of the Finance Committee, Claude Raynal (left), in the Bundestag. The current WHO leadership landscape demands a candidate capable of managing deep institutional fractures and uniting a divided global community. Despite him being largely unknown in the international community, Germany could be expected to emphasise Braun’s extensive fiscal and crisis management experience in any candidacy it mounts. As ‘Head of the Chancellery’, effectively Chief of Staff, in Angela Merkel’s last term as Chancellor, from 2018 to 2021, Braun operated at the nexus of scientific advice and political implementation during the COVID-19 pandemic, notably comparing the Chancellery to an intensive care unit where acute problems must be solved. Between 2021 and 2025, Braun then chaired the powerful Budget Committee of the German Bundestag (Parliament), overseeing the distribution and management of hundreds of billions of Euros with strict discipline This profound understanding of macroeconomic management, coupled with his pragmatic defence of Germany’s controversial debt ceiling alongside crisis-driven special funds, makes him an attractive prospect for donor nations currently demanding more financial accountability and restructuring at WHO in Geneva. Serving as a central mediator across government ministries, Braun built a reputation as a highly pragmatic problem solver whose past domestic political affiliations will not necessarily dictate his future approach to global health governance. This pragmatism complements his longstanding political advocacy for research into infectious diseases like Ebola and malaria. And unlike many career politicians, Braun’s foundational expertise lies in medicine, having worked for years as an intensive care physician and anaesthesiologist. He returned to these roots in April 2025 by assuming the presidency of the University of Lübeck, an institution renowned for its focus on life sciences and artificial intelligence. Why the candidacy might spark concerns WHO member states are currently negotiating a pathogen access and benefit-sharing (PABS) system in Geneva. While Braun championed early interventions and massive digitisation projects in his role as Merkel’s Head of the Chancellery during the COVID pandemic, severe bureaucratic delays hampered the rollout of vaccination campaigns and testing strategies. This tarnished his crisis management legacy just as he exited the federal government. His domestic political capital suffered further damage during the December 2021 Christian Democratic Union leadership election, where he lost heavily to conservative rival Friedrich Merz, now Chancellor. Party members largely rejected Braun as an establishment candidate, perceiving him as too closely aligned with the moderate legacy of former Chancellor Angela Merkel. Additionally, it is questionable whether Braun would wield the necessary diplomatic connections and familiarity with foreign health systems to be effective on Day One of a term as WHO head. The Director-General must immediately command trust and authority on the international stage, particularly when dealing with health ministries and stakeholders in the Global South. Most notably, the German government opposed the release of COVID-19 vaccine patents during his tenure, drawing sharp criticism from international health equity advocates. Defending this refusal in May 2021, Braun wrote in a guest article for the German newspaper Die Zeit that “patent protection as a driver of innovation is not the problem in this crisis, but an essential foundation for its solution.” In the Global South, this track record could thus reinforce the perception that Germany defends pharmaceutical interests over equitable technology transfer – especially in the face of current PABS Annex negotiations. Recent reports from Tagesspiegel Background indicating that the former minister was approached by Germany’s Association of Research-Based Pharmaceutical Companies to become their next president, when the post becomes vacant at the end of 2026, might further fuel these concerns. Finally, Germany has been cutting back its Official Development Assistance (ODA) in general, including contributions to the World Health Organization, where it has historically been the largest member state donor after the United States. On Wednesday, the Merz government announced its 2027 budget plans with further ODA cuts following last year’s drastic 17% reductions. The likelihood of Germany fulfilling its original 2024 financial pledge to WHO for the current biennium (2026-27) also remains in doubt. “They can put forward a candidate, but I don’t think it’s going to get a lot of traction from other member states,” said one informed WHO source. “At a time when Germany is reducing global health funding to member states, I don’t think they can go ahead and claim the top seat.” Step back and support allied candidates? Braun served as Head of Chancellery under then German Chancellor Angela Merkel, seen here with WHO Director General Dr Tedros in Berlin in 2021. Furthermore, domestic opinion remains highly divided on mounting a campaign amidst the geopolitical strains on Chancellor Friedrich Merz’s coalition and Tedros has reportedly urged Germany to back allied candidates instead. At the same time, the desire to seize more leadership in the UN system remains strong after Germany’s failed previous attempt to secure the top role at the UN High Commissioner for Refugees in 2025. Currently, Germany is also pushing for another attempt at a UN Security Council seat. Should Germany put forward a candidate, Foreign Minister Johann Wadephul, who will make the final decision, also faces a stark choice between Braun and the better-known Karl Lauterbach, as well as Paul Zubeil with his strong international health and technical background. Advancing a WHO outsider like Braun against established public health veterans is a highly calculated risk for Berlin, which must first convince other European countries to rally behind him. In case Berlin formally nominates Braun, the success of his candidacy will depend entirely on how effectively the government can reframe his perceived lack of field experience and global networks as delivery on fresh, badly needed fiscal expertise and perspectives. Grappling with WHO’s funding crisis As the race for the next Director-General opens for formal nominations, the names of over a dozen high-profile potential candidates are still circulating – from Indonesia to the United Kingdom. Want to Become the Next WHO Director-General? Get in Line And the list is still growing. Among the newer names being floated is that of Dr Hanan Mohamed al-Kuwari, who served as Qatar’s Minister of Public Health until November 2024 and chaired the 153rd Session of the WHO Executive Board. Before joining the Hamad Medical Corporation in 1996, where she ultimately rose to managing director, al-Kuwari worked for Reuters and as a freelance health reporter. Holding a PhD in healthcare management from Brunel University and bringing early career experience from the WHO, she represents a highly networked voice from the Arab world, celebrated for her crisis resilience and for shaping the WHO’s recent global work programme. Dr Maria Neira, WHO Director of Climate, Environment and Health Another candidate who has been mentioned is Spain’s Dr Maria Neira, who recently retired from WHO as the director of Climate, Environment and Health. An iconic spokesperson for the climate, environment and health movement, Neira is known as a telegenic personality and adroit politically. As a young medical doctor, she worked in emergency relief in Latin America and Africa, and later served as Spain’s Vice Minister of Health and Consumer Affairs as well as President of the Spanish Food Safety and Nutrition Agency. However, Spain also recently decided to nominate a candidate to head the UN Food and Agriculture Organization (FAO), when Qu Dongyu’s second term as Director General ends in July 2027, leaving doubts about whether it would want to mount yet another campaign, in parallel. Continuing decline in ODA and global health aid Drastic ODA cuts and reduced global health funding leave vulnerable populations in precarious conditions worldwide. Whoever is elected will have to continue grappling with the continuing long-term declines in donor-driven ODA, and particularly global health aid – directly to countries and to WHO. While WHO 2026-2027 $4.2 billion base budget is now 85% financed, according to Tedros’ comments on Wednesday, declines in ODA continue to cast uncertainty on how the remaining $630 million gap will be filled. It’s unlikely that the $260.6 million in assessed US contributions still due for years 2024-2025, before the withdrawal became official in January, will ever be repaid, conceded WHO’s Tedros at a Geneva press briefing on Wednesday. “We’re hoping to get the money, but no signals yet,” Tedros told journalists, adding: “No signals means maybe we may not be able to get the money. The likelihood could be not getting the money.” “We’re looking at nontraditional donors. We’re looking at international financial institutions and other ways to mobilize that 15%,” Tedros said, in terms of filling that gap. “It’s not that we won’t go to the traditional donors, but I think we’re expanding that donor base.” This article has been edited to reflect additional information regarding Dr Hanan Mohamed al-Kuwari’s early career as a freelance journalist. Image Credits: X/Dr Tedros, Deutscher Bundestag/Leon Kügeler, European Commission. African Leaders Declare End of Aid Era at Nairobi World Health Summit, But The Data Tell a More Complicated Story 29/04/2026 Stefan Anderson Delegates gather for the opening plenary of the World Health Summit Regional meeting in Nairobi, Kenya. African leaders opened the World Health Summit Regional Meeting at the United Nations complex in Nairobi this week with a unified declaration that two decades of dependence on foreign aid for health is over. “The challenge that I see is that many of the leaders in our continent believe that it is somebody else’s responsibility. It should be the World Health Organization, USAID, I don’t know who,” Kenyan President William Ruto told the summit. “The sooner we realise that it is our responsibility to raise especially domestic resources to fund our health, the better for all of us.” The Nairobi meeting, the first co-organised by the World Health Organization (WHO) and the World Health Summit, has positioned itself as the continent’s first high-level response to the collapse of official development assistance (ODA) for health, which fell by an estimated $31.1 billion in 2025, according to the Africa Centres for Disease Control and Prevention (Africa CDC). Over 2,000 delegates from more than 50 countries, including health and finance ministers from 17 nations, are convening in the Kenyan capital to coordinate a united African position ahead of next month’s World Health Assembly in Geneva. “I don’t want to see this continent being dependent. And we are dependent because we want it,” Ruto said. “Africa is manufacturing a number of products today, from Egypt, from Kenya, from South Africa, from a number of countries, but we are not buying our own product.” Africa carries more than 25% of the global disease burden but accounts for less than 3% of global health expenditure. The continent currently produces less than 2% of the medicines and vaccines it consumes, leaving its countries dependent on external supply chains for essential medical commodities. “Who’s asking us not to buy our own product, who’s asking us not to register to the African Medicines Agency for the regulatory aspect?” Ruto asked. “It’s not Germany, it’s not Europe, it’s ourselves. We need to change our mindset.” A break with the past African leaders led by Kenyan President William Ruto arrive in Nairobi for the summit. The urgency on display in Nairobi is driven by the most disruptive year for global health financing on record. For African governments, the pivot to self-reliance has become a fiscal necessity. The dismantling of the United States Agency for International Development (USAID), followed by aid cuts by the United Kingdom, Germany, France and the Netherlands, drove a 23.1% drop in total ODA from OECD donors in 2025. This is the largest single-year contraction since records began. The US, Germany, UK, Japan and France accounted for 95.7% of the total decline. The Boston University ImpactCounter estimates the US cuts have already led to more than 518,000 child and 263,000 adult deaths from preventable diseases such as HIV and tuberculosis. A further 14 million preventable deaths, including 4.5 million children, may occur by 2030 if USAID funding gaps are not filled, a major international study found. Africa CDC estimates the combined cuts from the US, UK, Germany and other major donors will kill an additional two to four million Africans annually. “The year 2025 marked the end of one era and the beginning of another,” Sulaiman Shahabuddin, President and Vice Chancellor of the Aga Khan University, told the opening plenary. “We are confronting a new reality, defined by funding constraints, the rise of technology and artificial intelligence, and a decisive shift towards local ownership.” “Climate change, chronic diseases, lack of financial resources, the digital divide, inequity and others are [challenges] we will have to overcome,” Shahabuddin added. What aid remains on the table increasingly comes with strings attached. Washington has begun rolling out bilateral “America First” global health agreements, with US President Donald Trump retaining the right to terminate any programme judged not to align with American interests. Conditionalities include sharing pathogen samples and genomic data with US authorities, prioritising faith-based health providers to prevent services such as abortions, channelling funding away from non-governmental organisations, and, in the case of Zambia, granting access to critical minerals in exchange for health funding. Lukoye Atwoli, Dean of the Aga Khan University Medical College East Africa and the summit’s international president, said this year’s gathering would mark a break with past meetings on African health. “Historically, meetings about Africa and Africa’s health have been about lamentations. Have been about framing the problems. Have been about basically begging and saying that we have a problem and we need help,” Atwoli told delegates. “This meeting will be different.” Reform body launched Africa CDC Director Dr Jean Kaseya speaking in Nairobi. On the sidelines of the summit, Africa CDC launched the African High-Level Ministerial Committee on Global Health Architecture Reform. The body brings together health and finance ministers from across the continent to coordinate African positions ahead of the World Health Assembly and broader UN reform processes. Convening both portfolios in the same room is a long-standing demand of global health advocates, who have struggled for decades to make the economic case for health investment to treasuries that hold the purse strings. The committee, chaired by former Liberian president Ellen Johnson Sirleaf, will produce coordinated African position papers on health architecture reform and a 2026–2030 reform roadmap focused on five axes: governance, financial sovereignty, data sovereignty, local manufacturing, and pandemic preparedness. “The old model is no longer fit for purpose. Africa cannot continue to be a passive recipient of global health decisions,” said Africa CDC Director General Dr Jean Kaseya. “We welcome our partners, but on a new basis: not as donors and recipients, but as equal partners aligned with Africa’s priorities.” Aspiration meets evidence Official development assistance fell by a historic 23.1% in 2025. African nations are among the hardest hit. The data on whether Africa can deliver on the vision laid out in Nairobi tell a more complicated story. A Centre for Global Development (CGD) audit of 442 government actions across all 54 African countries found a continental reaction to the historic aid cuts split in radically uneven ways, a story of inequality within Africa as much as between Africa and its donors. The countries that moved fastest are those with the deepest pockets and most diversified economies, including Nigeria, Ghana and Ethiopia. Lower-income, debt-burdened countries, many of which were the largest per-capita recipients of foreign assistance, have largely absorbed the loss in silence. “Governments with limited fiscal space and weaker administrative capacity have less room to cushion abrupt external shocks,” the analysis found. “What is slightly surprising is that they were not only doing little about the aid cuts, they are also saying little about them.” Global Health Leaders Urge Fewer Agencies Amid Funding Crisis A separate CGD study published in February examined the budget statements of 18 sub-Saharan African countries: among the world’s poorest, most heavily aid-dependent and exposed to the cuts. It found that only two, Tanzania and Sierra Leone, proposed new revenue measures to replace lost financing in their 2025 budgets. None reprioritised spending from other sectors to protect health. “With few exceptions, governments neither raised new revenues nor reallocated spending to compensate for lost external financing,” the analysis concluded. The burden of adjustment, it found, has instead fallen on the services patients receive, from disrupted HIV and tuberculosis treatment to delays in vaccination campaigns and the closure of clinics that depended on donor financing. “Health is not a cost, it is an investment,” Ruto said. “And it is important for us to invest.” Cascading crises Runaway climate change is colliding with constant economic shocks from war and the COVID-19 pandemic, shrinking Africa’s budgets and taking away the space to invest in health. The continent’s ability to absorb the aid shock and finance the pivot to support its own health systems is constrained by an unending sequence of external crises over the past decade that continue to batter government budgets, layered on top of the escalating climate crisis. The COVID-19 pandemic, during which wealthy nations hoarded vaccines, exposed Africa’s reliance on a foreign supply chain that produces 99% of the vaccines and 90% of the medical supplies it consumes. Pandemic response cost African governments an additional $154 billion in 2020 and 2021, according to the African Development Bank, pushing sub-Saharan public debt up by 8 percentage points of GDP in a single year. Russia’s invasion of Ukraine drove an inflationary spike that ballooned debt-service costs across the region, a pressure that has now snowballed into the global economic crisis triggered by the US-Israeli war on Iran, to which African economies are uniquely vulnerable. The closure of the Strait of Hormuz, a chokepoint for a fifth of the world’s oil and a third of its liquefied natural gas, is driving up fuel and fertiliser costs and deepening food insecurity across the continent. The resulting inflation, weaker currencies and tighter global financial conditions across Africa are inflating debt-servicing bills and forcing governments to divert money that could otherwise help absorb the aid shock. Climate change is compounding the pressure on every front. African countries are losing between 2% and 5% of GDP to climate extremes, the World Meteorological Organization estimates, with some governments diverting up to 9% of national budgets to respond. Health systems will bear a growing share of that cost. The World Bank estimates climate change could drive at least $21 trillion in excess health costs in low- and middle-income countries by 2050, with sub-Saharan Africa among the regions hit hardest. “What was considered reliable for decades is turning out to be fragile,” said Birgit Pickel, Director-General for Global Health at Germany’s Federal Ministry for Economic Cooperation and Development. “Cracks are appearing in the international order. Cracks that, in some cases, are already leading to its collapse.” Fiscal squeeze limits options African debt levels have more than doubled in the past decade, according to ONE Data figures. The cumulative damage has left African governments with little room to manoeuvre. Thirty-two African nations now spend more servicing external debt than funding healthcare. The continent paid almost $90 billion in external debt service in 2024 alone, with African governments now spending an average of 17% of state revenue on debt servicing, according to leading estimates. The IMF warned last week that more than a third of African countries are at high risk of, or already in, debt distress, with rising interest bills “crowding out essential development spending, healthcare above all.” “Official funding will probably shrink, at least internationally. Domestic funding will hopefully move up,” Pickel said. “But there are innovative instruments out there to also meet urgent funding needs in the health sector, especially for heavily indebted countries.” Pickel proposed debt-for-health swaps, an instrument under which creditor nations cancel debt in exchange for redirected health spending, as a route to fiscal space for highly indebted countries. Germany issued €100 million in such swaps last year, channelled to the Global Fund. The figure is substantial as a signal, but negligible against the scale of the African external debt service crisis. The IMF’s Africa Director, Abebe Selassie, told the Fund’s Spring Meetings in Washington this month that the 2025 foreign aid contraction marks a structural break – and the money is unlikely to come back. “Past aid shocks were largely cyclical; donors cut back and then returned. What we are seeing now appears more structural,” Selassie said. “And it is falling hardest on the region’s most vulnerable countries: fragile states and low-income economies that depend on aid not as a supplement, but as a critical source of budget financing, healthcare, and food assistance.” The summit runs through Wednesday, with the African Union expected to publish a position paper on global health architecture reform at its close. Image Credits: ONE Data. Ghana Rebuffs US Health Deal – But South Africa and Zambia Struggle Without Aid 29/04/2026 Kerry Cullinan US Ambassador to the UN Mike Waltz (left) at the launch of the ‘Trade over Aid’ event at the New York Stock Exchange this week. Ghana has become the latest African country to reject the United States’ terms for bilateral health assistance, particularly the requirement to share sensitive health data, according to Reuters. Late last year, Zimbabwe rejected US terms for health assistance, particularly the demand to share pathogen data without any “corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data,” according to government spokesperson Nick Mangwana. Zambia has until 30 April to decide on whether to avail its minerals – primarily copper, cobalt and lithium – to US companies in exchange for health assistance. US aid supported antiretroviral treatment for an estimated 1,3 million Zambians. In the wake of disruptions since President Donald Trump assumed office last January, some Zambian hospitals are seeing an increase in AIDS cases, according to the New York Times. Back in December, the US announced Zambia had committed to a plan to unlock “a substantial grant package of US support in exchange for collaboration in the mining sector and clear business sector reforms that will drive economic growth and commercial investment that benefits both the United States and Zambia”. But this has never materialised amid renewed US pressure on Zambia to open its mineral wealth to the US. Meanwhile, South Africa has been frozen out of health aid by the Trump administration – in the main, for charging Israel with genocide at the International Criminal Court and for policies aimed at addressing apartheid-era discrimination that the US claims are anti-white. The loss of US funding has “damaged critical health services, dismantled HIV prevention programs, and disrupted world-class South Africa-U.S. research collaboration,” according to a report published last week by Physicians for Human Rights (PHR), Advocates for the Prevention of HIV in South Africa (APHA), and Emthonjeni Counselling and Training. ‘Trade over aid’ The terms of the Memorandums of Understanding (MOU) that the US is seeking with key countries, as part of its “America First Global Health Strategy” (AFGHSD), are overwhelmingly transactional. This week, the US entrenched this approach at the launch of its ‘Trade over Aid’ initiative at the New York Stock Exchange, asserting that the free market is the “surest route to economic prosperity” Ghana is Africa’s largest gold producer. It is unclear whether the US tried to use its aid offer to extract minerals, as it has in other countries. However, this is unlikely to have gone down well as Ghana is clamping down on foreign mining operations. In the past few weeks, the country’s Minerals Commission has given three international firms until the end of the year to transfer their gold mining operations to locals. Ghanaian President John Mahama is also championing the “Accra Reset”, launched last year to encourage African countries to invest more of their domestic budgets in their health and depend less on aid. At the same time, Ghana is heavily indebted and recently held off paying newly recruited nurses as it lacked the finances. US role in DRC conflict? President Donald Trump meets with DRC President Felix Tshisekedi and President Paul Kagame of the Republic of Rwanda, in the Oval Office in December 2025. The US held off signing an MOU with the DRC on 5 December, when it signed deals with Rwanda and Kenya on the sidelines of a peace accord between the DRC and Rwanda, allegedly the sponsor of the M23 rebels waging war inside the DRC. Instead, the US and DRC first signed a “strategic partnership agreement” to “promote secure, reliable, and mutually beneficial critical mineral flows for commercial and defense purposes”, according to the US State Department. The health MOU followed on 26 February. The DRC is one of the world’s most important sources of rare earth minerals, but China has dominated the purchasing and processing of its minerals. Following the agreement, the DRC offered US investors stakes in state-owned mineral assets. In late March, a US company, Virtus, bought a cobalt mine. Recently, it emerged that the DRC has offered mining opportunities to US companies in Rubaya, currently held by M23 rebels, indicating that the US would need to play a role in maintaining peace if it wants access to rare minerals. This week, the DRC announced the formation of a $100 million initiative to establish “mining guards” to secure mines, with investment from the US and the United Arab Emirates. However, lawyers in the DRC have challenged the MOU in court, while part of Kenya’s MOU has been suspended by a High Court in the face of an ongoing court challenge. South Africa in the cold South African HIV scientist Prof Linda-Gail Bekker received a standing ovation at the International AIDS Conference in 2022 when she announced the results of the lenacapavir clinical trial. South Africa has the biggest HIV population in the world, and was the largest international recipient of US National Institutes of Health (NIH) research funds, as well as getting funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR). “Our report illustrates what an ‘America First’ approach to global health looks like: Lifesaving programs shuttered, world-class research jettisoned, decades of progress against HIV/AIDS jeopardized. All to the harm of, not only South Africans, but to Americans and the global public as well,” said Thomas McHale, director of public health at PHR and a report co-author. Co-author Emily Bass warned: “Short-sighted, sudden withdrawal of funds for critical components of the HIV response will cause long-term harm to infants, children, adolescent girls and young women, and other groups at the highest risk of HIV.” The report mentions two scientific breakthroughs that came from US-South African research partnerships, namely the clinical trial of lenacapavir, an injectable pre-exposure prophylaxis (PrEP) that is almost 100% effective in preventing HIV, and updated global guidelines for treating drug-resistant tuberculosis (TB). These breakthroughs “directly benefit Americans”, the authors argue. “By freezing research funding to South Africa, the Trump administration is sabotaging the United States’ own future health and national security.” The report is based on interviews with South African doctors, researchers, people living with HIV, and others involved in South Africa’s HIV response efforts. Image Credits: Daniel Torok/ White House , Kerry Cullinan. Record European Heatwaves Shrink Glaciers and Diminish Snow Cover in 2025 29/04/2026 Disha Shetty Europe experienced record extremes in 2025, according to WMO’s latest assessment. Around 95% of Europe experienced above-average temperatures in 2025, with record heatwaves from the Mediterranean to the Arctic region. This caused rapid loss of glacier mass and snow cover, according to the latest State of the European Climate report by the World Meteorological Organization (WMO) released on Thursday. All of Europe’s glaciers saw a net mass loss, with Iceland recording its second-largest glacier loss on record. The continent experienced dangerously high air temperatures, drought, heatwaves and record ocean temperatures. This has translated into economic and biodiversity loss affecting countries and ecosystems across the continent. “Europe is the fastest-warming continent, and the impacts are already severe. Almost the whole region has seen above-average annual temperatures,” said Florian Pappenberger, Director-General of the European Centre for Medium-Range Weather Forecasts (ECMWF), an inter-governmental organisation that contributed to the report along with WMO. Also read: Europe is World’s Fastest Warming Continent With Record Temperatures in 2024 Europe is warming twice as fast as the global average Europe is now the fastest-warming continent, warming twice as fast as the global average. The impact of the temperature increases is most visible in the coldest regions, such as the Arctic and the Alps. Snow and ice play a critical role in slowing climate change by reflecting sunlight into space in what is known as the albedo effect. “In 2025, sub-Arctic Norway, Sweden and Finland recorded their worst heatwave on record with 21 straight days and temperatures exceeding 30°C within the Arctic Circle itself,” Pappenberger of ECMWF said. This also pushed up temperatures within and adjacent to the Arctic Circle to over 30°C, peaking at 34.9°C in Frosta, Norway. Ironically, low levels of air pollution in Europe allow more solar radiation to reach the surface, leading to a higher rate of warming. The number of cold stress days when temperatures drop below normal is also reducing. Nearly 90% of the continent experienced fewer cold stress days than average, and minimum temperatures remained above average for most of the year. Hot, dry conditions resulted in more wildfires. A record total area of around 1,034,000 hectares was burnt across Europe – an area larger than Cyprus. Spain, Cyprus, the United Kingdom, the Netherlands, and Germany recorded their highest wildfire emissions on record in 2025. Record loss of glacier mass Glaciers across Europe lost mass in 2025, with the highest loss recorded in Iceland. The Greenland Ice Sheet, which is the largest ice mass in the northern hemisphere and covers 80% of Greenland, lost 139 gigatonnes (139 billion tonnes) of ice. This is equivalent to 1.5 times the volume stored in all glaciers in the European Alps. Such ice loss contributes to rising global sea levels, with every centimetre increase exposing an additional six million people to coastal flooding. Overall, snow cover was 31% below average, affecting 1.32 million square kilometres, which is equivalent to the combined area of France, Italy, Germany, Switzerland, and Austria. “The ESOTC 2025 paints a stark picture: the pace of climate change demands more urgent action. With rising temperatures, and widespread wildfires and drought, the evidence is unequivocal; climate change is not a future threat, it is our present reality,” Samantha Burgess, Strategic Lead for Climate at ECMWF said. Rising ocean heat, reducing river flow Nearly 86% of European waters saw strong marine heatwaves in 2025. Oceans absorb 90% of the atmosphere’s excess heat due to the burning of fossil fuels. In 2025, Europe’s sea surface temperature was the highest on record. Around 86% of the region experienced strong marine heatwaves, disrupting fish and the ocean plants. Changes in rainfall and snowfall patterns have also affected the flow in 70% of Europe’s rivers. In May 2025, around half of Europe (53%) was affected by drought conditions. “Maintaining our own state-of-the-art, reliable data records of our Earth system is vital for making informed policy decisions in our rapidly changing climate. Copernicus is pivotal to help us preserve our sovereignty, our environment, food systems, safety, and economy,” said Mauro Facchini, Head of the European Commission’s Copernicus, is the European Union’s Earth Observation Programme. Renewable growth and actionable items for policymakers The share of renewables in Europe’s energy mix has gone up, supported by the growth in solar energy. A silver lining in the report is the growth of renewable energy, which in 2025 supplied nearly half (46.4%) of Europe’s electricity. Solar power contributed around 12.5% of this, a new regional record. Countries have begun to see energy security as a national security issue, and that appears to be one of the reasons driving the growth of renewables, including the adoption of nuclear energy at a higher rate compared to recent decades. Another positive was that by the end of 2025, around half of the European Biodiversity Strategy 2030’s recommended actions were in place or completed. The strategy is a European Union plan to restore the continent’s biodiversity. The report highlighted initiatives like Ireland’s network of marine protected areas, Armenia’s biodiversity finance plan, and Iceland’s funding to assist in recovering wetlands as examples of policy interventions that can help arrest biodiversity loss. Image Credits: Unsplash/Jochen Bückers, WMO. Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
African Leaders Declare End of Aid Era at Nairobi World Health Summit, But The Data Tell a More Complicated Story 29/04/2026 Stefan Anderson Delegates gather for the opening plenary of the World Health Summit Regional meeting in Nairobi, Kenya. African leaders opened the World Health Summit Regional Meeting at the United Nations complex in Nairobi this week with a unified declaration that two decades of dependence on foreign aid for health is over. “The challenge that I see is that many of the leaders in our continent believe that it is somebody else’s responsibility. It should be the World Health Organization, USAID, I don’t know who,” Kenyan President William Ruto told the summit. “The sooner we realise that it is our responsibility to raise especially domestic resources to fund our health, the better for all of us.” The Nairobi meeting, the first co-organised by the World Health Organization (WHO) and the World Health Summit, has positioned itself as the continent’s first high-level response to the collapse of official development assistance (ODA) for health, which fell by an estimated $31.1 billion in 2025, according to the Africa Centres for Disease Control and Prevention (Africa CDC). Over 2,000 delegates from more than 50 countries, including health and finance ministers from 17 nations, are convening in the Kenyan capital to coordinate a united African position ahead of next month’s World Health Assembly in Geneva. “I don’t want to see this continent being dependent. And we are dependent because we want it,” Ruto said. “Africa is manufacturing a number of products today, from Egypt, from Kenya, from South Africa, from a number of countries, but we are not buying our own product.” Africa carries more than 25% of the global disease burden but accounts for less than 3% of global health expenditure. The continent currently produces less than 2% of the medicines and vaccines it consumes, leaving its countries dependent on external supply chains for essential medical commodities. “Who’s asking us not to buy our own product, who’s asking us not to register to the African Medicines Agency for the regulatory aspect?” Ruto asked. “It’s not Germany, it’s not Europe, it’s ourselves. We need to change our mindset.” A break with the past African leaders led by Kenyan President William Ruto arrive in Nairobi for the summit. The urgency on display in Nairobi is driven by the most disruptive year for global health financing on record. For African governments, the pivot to self-reliance has become a fiscal necessity. The dismantling of the United States Agency for International Development (USAID), followed by aid cuts by the United Kingdom, Germany, France and the Netherlands, drove a 23.1% drop in total ODA from OECD donors in 2025. This is the largest single-year contraction since records began. The US, Germany, UK, Japan and France accounted for 95.7% of the total decline. The Boston University ImpactCounter estimates the US cuts have already led to more than 518,000 child and 263,000 adult deaths from preventable diseases such as HIV and tuberculosis. A further 14 million preventable deaths, including 4.5 million children, may occur by 2030 if USAID funding gaps are not filled, a major international study found. Africa CDC estimates the combined cuts from the US, UK, Germany and other major donors will kill an additional two to four million Africans annually. “The year 2025 marked the end of one era and the beginning of another,” Sulaiman Shahabuddin, President and Vice Chancellor of the Aga Khan University, told the opening plenary. “We are confronting a new reality, defined by funding constraints, the rise of technology and artificial intelligence, and a decisive shift towards local ownership.” “Climate change, chronic diseases, lack of financial resources, the digital divide, inequity and others are [challenges] we will have to overcome,” Shahabuddin added. What aid remains on the table increasingly comes with strings attached. Washington has begun rolling out bilateral “America First” global health agreements, with US President Donald Trump retaining the right to terminate any programme judged not to align with American interests. Conditionalities include sharing pathogen samples and genomic data with US authorities, prioritising faith-based health providers to prevent services such as abortions, channelling funding away from non-governmental organisations, and, in the case of Zambia, granting access to critical minerals in exchange for health funding. Lukoye Atwoli, Dean of the Aga Khan University Medical College East Africa and the summit’s international president, said this year’s gathering would mark a break with past meetings on African health. “Historically, meetings about Africa and Africa’s health have been about lamentations. Have been about framing the problems. Have been about basically begging and saying that we have a problem and we need help,” Atwoli told delegates. “This meeting will be different.” Reform body launched Africa CDC Director Dr Jean Kaseya speaking in Nairobi. On the sidelines of the summit, Africa CDC launched the African High-Level Ministerial Committee on Global Health Architecture Reform. The body brings together health and finance ministers from across the continent to coordinate African positions ahead of the World Health Assembly and broader UN reform processes. Convening both portfolios in the same room is a long-standing demand of global health advocates, who have struggled for decades to make the economic case for health investment to treasuries that hold the purse strings. The committee, chaired by former Liberian president Ellen Johnson Sirleaf, will produce coordinated African position papers on health architecture reform and a 2026–2030 reform roadmap focused on five axes: governance, financial sovereignty, data sovereignty, local manufacturing, and pandemic preparedness. “The old model is no longer fit for purpose. Africa cannot continue to be a passive recipient of global health decisions,” said Africa CDC Director General Dr Jean Kaseya. “We welcome our partners, but on a new basis: not as donors and recipients, but as equal partners aligned with Africa’s priorities.” Aspiration meets evidence Official development assistance fell by a historic 23.1% in 2025. African nations are among the hardest hit. The data on whether Africa can deliver on the vision laid out in Nairobi tell a more complicated story. A Centre for Global Development (CGD) audit of 442 government actions across all 54 African countries found a continental reaction to the historic aid cuts split in radically uneven ways, a story of inequality within Africa as much as between Africa and its donors. The countries that moved fastest are those with the deepest pockets and most diversified economies, including Nigeria, Ghana and Ethiopia. Lower-income, debt-burdened countries, many of which were the largest per-capita recipients of foreign assistance, have largely absorbed the loss in silence. “Governments with limited fiscal space and weaker administrative capacity have less room to cushion abrupt external shocks,” the analysis found. “What is slightly surprising is that they were not only doing little about the aid cuts, they are also saying little about them.” Global Health Leaders Urge Fewer Agencies Amid Funding Crisis A separate CGD study published in February examined the budget statements of 18 sub-Saharan African countries: among the world’s poorest, most heavily aid-dependent and exposed to the cuts. It found that only two, Tanzania and Sierra Leone, proposed new revenue measures to replace lost financing in their 2025 budgets. None reprioritised spending from other sectors to protect health. “With few exceptions, governments neither raised new revenues nor reallocated spending to compensate for lost external financing,” the analysis concluded. The burden of adjustment, it found, has instead fallen on the services patients receive, from disrupted HIV and tuberculosis treatment to delays in vaccination campaigns and the closure of clinics that depended on donor financing. “Health is not a cost, it is an investment,” Ruto said. “And it is important for us to invest.” Cascading crises Runaway climate change is colliding with constant economic shocks from war and the COVID-19 pandemic, shrinking Africa’s budgets and taking away the space to invest in health. The continent’s ability to absorb the aid shock and finance the pivot to support its own health systems is constrained by an unending sequence of external crises over the past decade that continue to batter government budgets, layered on top of the escalating climate crisis. The COVID-19 pandemic, during which wealthy nations hoarded vaccines, exposed Africa’s reliance on a foreign supply chain that produces 99% of the vaccines and 90% of the medical supplies it consumes. Pandemic response cost African governments an additional $154 billion in 2020 and 2021, according to the African Development Bank, pushing sub-Saharan public debt up by 8 percentage points of GDP in a single year. Russia’s invasion of Ukraine drove an inflationary spike that ballooned debt-service costs across the region, a pressure that has now snowballed into the global economic crisis triggered by the US-Israeli war on Iran, to which African economies are uniquely vulnerable. The closure of the Strait of Hormuz, a chokepoint for a fifth of the world’s oil and a third of its liquefied natural gas, is driving up fuel and fertiliser costs and deepening food insecurity across the continent. The resulting inflation, weaker currencies and tighter global financial conditions across Africa are inflating debt-servicing bills and forcing governments to divert money that could otherwise help absorb the aid shock. Climate change is compounding the pressure on every front. African countries are losing between 2% and 5% of GDP to climate extremes, the World Meteorological Organization estimates, with some governments diverting up to 9% of national budgets to respond. Health systems will bear a growing share of that cost. The World Bank estimates climate change could drive at least $21 trillion in excess health costs in low- and middle-income countries by 2050, with sub-Saharan Africa among the regions hit hardest. “What was considered reliable for decades is turning out to be fragile,” said Birgit Pickel, Director-General for Global Health at Germany’s Federal Ministry for Economic Cooperation and Development. “Cracks are appearing in the international order. Cracks that, in some cases, are already leading to its collapse.” Fiscal squeeze limits options African debt levels have more than doubled in the past decade, according to ONE Data figures. The cumulative damage has left African governments with little room to manoeuvre. Thirty-two African nations now spend more servicing external debt than funding healthcare. The continent paid almost $90 billion in external debt service in 2024 alone, with African governments now spending an average of 17% of state revenue on debt servicing, according to leading estimates. The IMF warned last week that more than a third of African countries are at high risk of, or already in, debt distress, with rising interest bills “crowding out essential development spending, healthcare above all.” “Official funding will probably shrink, at least internationally. Domestic funding will hopefully move up,” Pickel said. “But there are innovative instruments out there to also meet urgent funding needs in the health sector, especially for heavily indebted countries.” Pickel proposed debt-for-health swaps, an instrument under which creditor nations cancel debt in exchange for redirected health spending, as a route to fiscal space for highly indebted countries. Germany issued €100 million in such swaps last year, channelled to the Global Fund. The figure is substantial as a signal, but negligible against the scale of the African external debt service crisis. The IMF’s Africa Director, Abebe Selassie, told the Fund’s Spring Meetings in Washington this month that the 2025 foreign aid contraction marks a structural break – and the money is unlikely to come back. “Past aid shocks were largely cyclical; donors cut back and then returned. What we are seeing now appears more structural,” Selassie said. “And it is falling hardest on the region’s most vulnerable countries: fragile states and low-income economies that depend on aid not as a supplement, but as a critical source of budget financing, healthcare, and food assistance.” The summit runs through Wednesday, with the African Union expected to publish a position paper on global health architecture reform at its close. Image Credits: ONE Data. Ghana Rebuffs US Health Deal – But South Africa and Zambia Struggle Without Aid 29/04/2026 Kerry Cullinan US Ambassador to the UN Mike Waltz (left) at the launch of the ‘Trade over Aid’ event at the New York Stock Exchange this week. Ghana has become the latest African country to reject the United States’ terms for bilateral health assistance, particularly the requirement to share sensitive health data, according to Reuters. Late last year, Zimbabwe rejected US terms for health assistance, particularly the demand to share pathogen data without any “corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data,” according to government spokesperson Nick Mangwana. Zambia has until 30 April to decide on whether to avail its minerals – primarily copper, cobalt and lithium – to US companies in exchange for health assistance. US aid supported antiretroviral treatment for an estimated 1,3 million Zambians. In the wake of disruptions since President Donald Trump assumed office last January, some Zambian hospitals are seeing an increase in AIDS cases, according to the New York Times. Back in December, the US announced Zambia had committed to a plan to unlock “a substantial grant package of US support in exchange for collaboration in the mining sector and clear business sector reforms that will drive economic growth and commercial investment that benefits both the United States and Zambia”. But this has never materialised amid renewed US pressure on Zambia to open its mineral wealth to the US. Meanwhile, South Africa has been frozen out of health aid by the Trump administration – in the main, for charging Israel with genocide at the International Criminal Court and for policies aimed at addressing apartheid-era discrimination that the US claims are anti-white. The loss of US funding has “damaged critical health services, dismantled HIV prevention programs, and disrupted world-class South Africa-U.S. research collaboration,” according to a report published last week by Physicians for Human Rights (PHR), Advocates for the Prevention of HIV in South Africa (APHA), and Emthonjeni Counselling and Training. ‘Trade over aid’ The terms of the Memorandums of Understanding (MOU) that the US is seeking with key countries, as part of its “America First Global Health Strategy” (AFGHSD), are overwhelmingly transactional. This week, the US entrenched this approach at the launch of its ‘Trade over Aid’ initiative at the New York Stock Exchange, asserting that the free market is the “surest route to economic prosperity” Ghana is Africa’s largest gold producer. It is unclear whether the US tried to use its aid offer to extract minerals, as it has in other countries. However, this is unlikely to have gone down well as Ghana is clamping down on foreign mining operations. In the past few weeks, the country’s Minerals Commission has given three international firms until the end of the year to transfer their gold mining operations to locals. Ghanaian President John Mahama is also championing the “Accra Reset”, launched last year to encourage African countries to invest more of their domestic budgets in their health and depend less on aid. At the same time, Ghana is heavily indebted and recently held off paying newly recruited nurses as it lacked the finances. US role in DRC conflict? President Donald Trump meets with DRC President Felix Tshisekedi and President Paul Kagame of the Republic of Rwanda, in the Oval Office in December 2025. The US held off signing an MOU with the DRC on 5 December, when it signed deals with Rwanda and Kenya on the sidelines of a peace accord between the DRC and Rwanda, allegedly the sponsor of the M23 rebels waging war inside the DRC. Instead, the US and DRC first signed a “strategic partnership agreement” to “promote secure, reliable, and mutually beneficial critical mineral flows for commercial and defense purposes”, according to the US State Department. The health MOU followed on 26 February. The DRC is one of the world’s most important sources of rare earth minerals, but China has dominated the purchasing and processing of its minerals. Following the agreement, the DRC offered US investors stakes in state-owned mineral assets. In late March, a US company, Virtus, bought a cobalt mine. Recently, it emerged that the DRC has offered mining opportunities to US companies in Rubaya, currently held by M23 rebels, indicating that the US would need to play a role in maintaining peace if it wants access to rare minerals. This week, the DRC announced the formation of a $100 million initiative to establish “mining guards” to secure mines, with investment from the US and the United Arab Emirates. However, lawyers in the DRC have challenged the MOU in court, while part of Kenya’s MOU has been suspended by a High Court in the face of an ongoing court challenge. South Africa in the cold South African HIV scientist Prof Linda-Gail Bekker received a standing ovation at the International AIDS Conference in 2022 when she announced the results of the lenacapavir clinical trial. South Africa has the biggest HIV population in the world, and was the largest international recipient of US National Institutes of Health (NIH) research funds, as well as getting funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR). “Our report illustrates what an ‘America First’ approach to global health looks like: Lifesaving programs shuttered, world-class research jettisoned, decades of progress against HIV/AIDS jeopardized. All to the harm of, not only South Africans, but to Americans and the global public as well,” said Thomas McHale, director of public health at PHR and a report co-author. Co-author Emily Bass warned: “Short-sighted, sudden withdrawal of funds for critical components of the HIV response will cause long-term harm to infants, children, adolescent girls and young women, and other groups at the highest risk of HIV.” The report mentions two scientific breakthroughs that came from US-South African research partnerships, namely the clinical trial of lenacapavir, an injectable pre-exposure prophylaxis (PrEP) that is almost 100% effective in preventing HIV, and updated global guidelines for treating drug-resistant tuberculosis (TB). These breakthroughs “directly benefit Americans”, the authors argue. “By freezing research funding to South Africa, the Trump administration is sabotaging the United States’ own future health and national security.” The report is based on interviews with South African doctors, researchers, people living with HIV, and others involved in South Africa’s HIV response efforts. Image Credits: Daniel Torok/ White House , Kerry Cullinan. Record European Heatwaves Shrink Glaciers and Diminish Snow Cover in 2025 29/04/2026 Disha Shetty Europe experienced record extremes in 2025, according to WMO’s latest assessment. Around 95% of Europe experienced above-average temperatures in 2025, with record heatwaves from the Mediterranean to the Arctic region. This caused rapid loss of glacier mass and snow cover, according to the latest State of the European Climate report by the World Meteorological Organization (WMO) released on Thursday. All of Europe’s glaciers saw a net mass loss, with Iceland recording its second-largest glacier loss on record. The continent experienced dangerously high air temperatures, drought, heatwaves and record ocean temperatures. This has translated into economic and biodiversity loss affecting countries and ecosystems across the continent. “Europe is the fastest-warming continent, and the impacts are already severe. Almost the whole region has seen above-average annual temperatures,” said Florian Pappenberger, Director-General of the European Centre for Medium-Range Weather Forecasts (ECMWF), an inter-governmental organisation that contributed to the report along with WMO. Also read: Europe is World’s Fastest Warming Continent With Record Temperatures in 2024 Europe is warming twice as fast as the global average Europe is now the fastest-warming continent, warming twice as fast as the global average. The impact of the temperature increases is most visible in the coldest regions, such as the Arctic and the Alps. Snow and ice play a critical role in slowing climate change by reflecting sunlight into space in what is known as the albedo effect. “In 2025, sub-Arctic Norway, Sweden and Finland recorded their worst heatwave on record with 21 straight days and temperatures exceeding 30°C within the Arctic Circle itself,” Pappenberger of ECMWF said. This also pushed up temperatures within and adjacent to the Arctic Circle to over 30°C, peaking at 34.9°C in Frosta, Norway. Ironically, low levels of air pollution in Europe allow more solar radiation to reach the surface, leading to a higher rate of warming. The number of cold stress days when temperatures drop below normal is also reducing. Nearly 90% of the continent experienced fewer cold stress days than average, and minimum temperatures remained above average for most of the year. Hot, dry conditions resulted in more wildfires. A record total area of around 1,034,000 hectares was burnt across Europe – an area larger than Cyprus. Spain, Cyprus, the United Kingdom, the Netherlands, and Germany recorded their highest wildfire emissions on record in 2025. Record loss of glacier mass Glaciers across Europe lost mass in 2025, with the highest loss recorded in Iceland. The Greenland Ice Sheet, which is the largest ice mass in the northern hemisphere and covers 80% of Greenland, lost 139 gigatonnes (139 billion tonnes) of ice. This is equivalent to 1.5 times the volume stored in all glaciers in the European Alps. Such ice loss contributes to rising global sea levels, with every centimetre increase exposing an additional six million people to coastal flooding. Overall, snow cover was 31% below average, affecting 1.32 million square kilometres, which is equivalent to the combined area of France, Italy, Germany, Switzerland, and Austria. “The ESOTC 2025 paints a stark picture: the pace of climate change demands more urgent action. With rising temperatures, and widespread wildfires and drought, the evidence is unequivocal; climate change is not a future threat, it is our present reality,” Samantha Burgess, Strategic Lead for Climate at ECMWF said. Rising ocean heat, reducing river flow Nearly 86% of European waters saw strong marine heatwaves in 2025. Oceans absorb 90% of the atmosphere’s excess heat due to the burning of fossil fuels. In 2025, Europe’s sea surface temperature was the highest on record. Around 86% of the region experienced strong marine heatwaves, disrupting fish and the ocean plants. Changes in rainfall and snowfall patterns have also affected the flow in 70% of Europe’s rivers. In May 2025, around half of Europe (53%) was affected by drought conditions. “Maintaining our own state-of-the-art, reliable data records of our Earth system is vital for making informed policy decisions in our rapidly changing climate. Copernicus is pivotal to help us preserve our sovereignty, our environment, food systems, safety, and economy,” said Mauro Facchini, Head of the European Commission’s Copernicus, is the European Union’s Earth Observation Programme. Renewable growth and actionable items for policymakers The share of renewables in Europe’s energy mix has gone up, supported by the growth in solar energy. A silver lining in the report is the growth of renewable energy, which in 2025 supplied nearly half (46.4%) of Europe’s electricity. Solar power contributed around 12.5% of this, a new regional record. Countries have begun to see energy security as a national security issue, and that appears to be one of the reasons driving the growth of renewables, including the adoption of nuclear energy at a higher rate compared to recent decades. Another positive was that by the end of 2025, around half of the European Biodiversity Strategy 2030’s recommended actions were in place or completed. The strategy is a European Union plan to restore the continent’s biodiversity. The report highlighted initiatives like Ireland’s network of marine protected areas, Armenia’s biodiversity finance plan, and Iceland’s funding to assist in recovering wetlands as examples of policy interventions that can help arrest biodiversity loss. Image Credits: Unsplash/Jochen Bückers, WMO. Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Ghana Rebuffs US Health Deal – But South Africa and Zambia Struggle Without Aid 29/04/2026 Kerry Cullinan US Ambassador to the UN Mike Waltz (left) at the launch of the ‘Trade over Aid’ event at the New York Stock Exchange this week. Ghana has become the latest African country to reject the United States’ terms for bilateral health assistance, particularly the requirement to share sensitive health data, according to Reuters. Late last year, Zimbabwe rejected US terms for health assistance, particularly the demand to share pathogen data without any “corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data,” according to government spokesperson Nick Mangwana. Zambia has until 30 April to decide on whether to avail its minerals – primarily copper, cobalt and lithium – to US companies in exchange for health assistance. US aid supported antiretroviral treatment for an estimated 1,3 million Zambians. In the wake of disruptions since President Donald Trump assumed office last January, some Zambian hospitals are seeing an increase in AIDS cases, according to the New York Times. Back in December, the US announced Zambia had committed to a plan to unlock “a substantial grant package of US support in exchange for collaboration in the mining sector and clear business sector reforms that will drive economic growth and commercial investment that benefits both the United States and Zambia”. But this has never materialised amid renewed US pressure on Zambia to open its mineral wealth to the US. Meanwhile, South Africa has been frozen out of health aid by the Trump administration – in the main, for charging Israel with genocide at the International Criminal Court and for policies aimed at addressing apartheid-era discrimination that the US claims are anti-white. The loss of US funding has “damaged critical health services, dismantled HIV prevention programs, and disrupted world-class South Africa-U.S. research collaboration,” according to a report published last week by Physicians for Human Rights (PHR), Advocates for the Prevention of HIV in South Africa (APHA), and Emthonjeni Counselling and Training. ‘Trade over aid’ The terms of the Memorandums of Understanding (MOU) that the US is seeking with key countries, as part of its “America First Global Health Strategy” (AFGHSD), are overwhelmingly transactional. This week, the US entrenched this approach at the launch of its ‘Trade over Aid’ initiative at the New York Stock Exchange, asserting that the free market is the “surest route to economic prosperity” Ghana is Africa’s largest gold producer. It is unclear whether the US tried to use its aid offer to extract minerals, as it has in other countries. However, this is unlikely to have gone down well as Ghana is clamping down on foreign mining operations. In the past few weeks, the country’s Minerals Commission has given three international firms until the end of the year to transfer their gold mining operations to locals. Ghanaian President John Mahama is also championing the “Accra Reset”, launched last year to encourage African countries to invest more of their domestic budgets in their health and depend less on aid. At the same time, Ghana is heavily indebted and recently held off paying newly recruited nurses as it lacked the finances. US role in DRC conflict? President Donald Trump meets with DRC President Felix Tshisekedi and President Paul Kagame of the Republic of Rwanda, in the Oval Office in December 2025. The US held off signing an MOU with the DRC on 5 December, when it signed deals with Rwanda and Kenya on the sidelines of a peace accord between the DRC and Rwanda, allegedly the sponsor of the M23 rebels waging war inside the DRC. Instead, the US and DRC first signed a “strategic partnership agreement” to “promote secure, reliable, and mutually beneficial critical mineral flows for commercial and defense purposes”, according to the US State Department. The health MOU followed on 26 February. The DRC is one of the world’s most important sources of rare earth minerals, but China has dominated the purchasing and processing of its minerals. Following the agreement, the DRC offered US investors stakes in state-owned mineral assets. In late March, a US company, Virtus, bought a cobalt mine. Recently, it emerged that the DRC has offered mining opportunities to US companies in Rubaya, currently held by M23 rebels, indicating that the US would need to play a role in maintaining peace if it wants access to rare minerals. This week, the DRC announced the formation of a $100 million initiative to establish “mining guards” to secure mines, with investment from the US and the United Arab Emirates. However, lawyers in the DRC have challenged the MOU in court, while part of Kenya’s MOU has been suspended by a High Court in the face of an ongoing court challenge. South Africa in the cold South African HIV scientist Prof Linda-Gail Bekker received a standing ovation at the International AIDS Conference in 2022 when she announced the results of the lenacapavir clinical trial. South Africa has the biggest HIV population in the world, and was the largest international recipient of US National Institutes of Health (NIH) research funds, as well as getting funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR). “Our report illustrates what an ‘America First’ approach to global health looks like: Lifesaving programs shuttered, world-class research jettisoned, decades of progress against HIV/AIDS jeopardized. All to the harm of, not only South Africans, but to Americans and the global public as well,” said Thomas McHale, director of public health at PHR and a report co-author. Co-author Emily Bass warned: “Short-sighted, sudden withdrawal of funds for critical components of the HIV response will cause long-term harm to infants, children, adolescent girls and young women, and other groups at the highest risk of HIV.” The report mentions two scientific breakthroughs that came from US-South African research partnerships, namely the clinical trial of lenacapavir, an injectable pre-exposure prophylaxis (PrEP) that is almost 100% effective in preventing HIV, and updated global guidelines for treating drug-resistant tuberculosis (TB). These breakthroughs “directly benefit Americans”, the authors argue. “By freezing research funding to South Africa, the Trump administration is sabotaging the United States’ own future health and national security.” The report is based on interviews with South African doctors, researchers, people living with HIV, and others involved in South Africa’s HIV response efforts. Image Credits: Daniel Torok/ White House , Kerry Cullinan. Record European Heatwaves Shrink Glaciers and Diminish Snow Cover in 2025 29/04/2026 Disha Shetty Europe experienced record extremes in 2025, according to WMO’s latest assessment. Around 95% of Europe experienced above-average temperatures in 2025, with record heatwaves from the Mediterranean to the Arctic region. This caused rapid loss of glacier mass and snow cover, according to the latest State of the European Climate report by the World Meteorological Organization (WMO) released on Thursday. All of Europe’s glaciers saw a net mass loss, with Iceland recording its second-largest glacier loss on record. The continent experienced dangerously high air temperatures, drought, heatwaves and record ocean temperatures. This has translated into economic and biodiversity loss affecting countries and ecosystems across the continent. “Europe is the fastest-warming continent, and the impacts are already severe. Almost the whole region has seen above-average annual temperatures,” said Florian Pappenberger, Director-General of the European Centre for Medium-Range Weather Forecasts (ECMWF), an inter-governmental organisation that contributed to the report along with WMO. Also read: Europe is World’s Fastest Warming Continent With Record Temperatures in 2024 Europe is warming twice as fast as the global average Europe is now the fastest-warming continent, warming twice as fast as the global average. The impact of the temperature increases is most visible in the coldest regions, such as the Arctic and the Alps. Snow and ice play a critical role in slowing climate change by reflecting sunlight into space in what is known as the albedo effect. “In 2025, sub-Arctic Norway, Sweden and Finland recorded their worst heatwave on record with 21 straight days and temperatures exceeding 30°C within the Arctic Circle itself,” Pappenberger of ECMWF said. This also pushed up temperatures within and adjacent to the Arctic Circle to over 30°C, peaking at 34.9°C in Frosta, Norway. Ironically, low levels of air pollution in Europe allow more solar radiation to reach the surface, leading to a higher rate of warming. The number of cold stress days when temperatures drop below normal is also reducing. Nearly 90% of the continent experienced fewer cold stress days than average, and minimum temperatures remained above average for most of the year. Hot, dry conditions resulted in more wildfires. A record total area of around 1,034,000 hectares was burnt across Europe – an area larger than Cyprus. Spain, Cyprus, the United Kingdom, the Netherlands, and Germany recorded their highest wildfire emissions on record in 2025. Record loss of glacier mass Glaciers across Europe lost mass in 2025, with the highest loss recorded in Iceland. The Greenland Ice Sheet, which is the largest ice mass in the northern hemisphere and covers 80% of Greenland, lost 139 gigatonnes (139 billion tonnes) of ice. This is equivalent to 1.5 times the volume stored in all glaciers in the European Alps. Such ice loss contributes to rising global sea levels, with every centimetre increase exposing an additional six million people to coastal flooding. Overall, snow cover was 31% below average, affecting 1.32 million square kilometres, which is equivalent to the combined area of France, Italy, Germany, Switzerland, and Austria. “The ESOTC 2025 paints a stark picture: the pace of climate change demands more urgent action. With rising temperatures, and widespread wildfires and drought, the evidence is unequivocal; climate change is not a future threat, it is our present reality,” Samantha Burgess, Strategic Lead for Climate at ECMWF said. Rising ocean heat, reducing river flow Nearly 86% of European waters saw strong marine heatwaves in 2025. Oceans absorb 90% of the atmosphere’s excess heat due to the burning of fossil fuels. In 2025, Europe’s sea surface temperature was the highest on record. Around 86% of the region experienced strong marine heatwaves, disrupting fish and the ocean plants. Changes in rainfall and snowfall patterns have also affected the flow in 70% of Europe’s rivers. In May 2025, around half of Europe (53%) was affected by drought conditions. “Maintaining our own state-of-the-art, reliable data records of our Earth system is vital for making informed policy decisions in our rapidly changing climate. Copernicus is pivotal to help us preserve our sovereignty, our environment, food systems, safety, and economy,” said Mauro Facchini, Head of the European Commission’s Copernicus, is the European Union’s Earth Observation Programme. Renewable growth and actionable items for policymakers The share of renewables in Europe’s energy mix has gone up, supported by the growth in solar energy. A silver lining in the report is the growth of renewable energy, which in 2025 supplied nearly half (46.4%) of Europe’s electricity. Solar power contributed around 12.5% of this, a new regional record. Countries have begun to see energy security as a national security issue, and that appears to be one of the reasons driving the growth of renewables, including the adoption of nuclear energy at a higher rate compared to recent decades. Another positive was that by the end of 2025, around half of the European Biodiversity Strategy 2030’s recommended actions were in place or completed. The strategy is a European Union plan to restore the continent’s biodiversity. The report highlighted initiatives like Ireland’s network of marine protected areas, Armenia’s biodiversity finance plan, and Iceland’s funding to assist in recovering wetlands as examples of policy interventions that can help arrest biodiversity loss. Image Credits: Unsplash/Jochen Bückers, WMO. Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Record European Heatwaves Shrink Glaciers and Diminish Snow Cover in 2025 29/04/2026 Disha Shetty Europe experienced record extremes in 2025, according to WMO’s latest assessment. Around 95% of Europe experienced above-average temperatures in 2025, with record heatwaves from the Mediterranean to the Arctic region. This caused rapid loss of glacier mass and snow cover, according to the latest State of the European Climate report by the World Meteorological Organization (WMO) released on Thursday. All of Europe’s glaciers saw a net mass loss, with Iceland recording its second-largest glacier loss on record. The continent experienced dangerously high air temperatures, drought, heatwaves and record ocean temperatures. This has translated into economic and biodiversity loss affecting countries and ecosystems across the continent. “Europe is the fastest-warming continent, and the impacts are already severe. Almost the whole region has seen above-average annual temperatures,” said Florian Pappenberger, Director-General of the European Centre for Medium-Range Weather Forecasts (ECMWF), an inter-governmental organisation that contributed to the report along with WMO. Also read: Europe is World’s Fastest Warming Continent With Record Temperatures in 2024 Europe is warming twice as fast as the global average Europe is now the fastest-warming continent, warming twice as fast as the global average. The impact of the temperature increases is most visible in the coldest regions, such as the Arctic and the Alps. Snow and ice play a critical role in slowing climate change by reflecting sunlight into space in what is known as the albedo effect. “In 2025, sub-Arctic Norway, Sweden and Finland recorded their worst heatwave on record with 21 straight days and temperatures exceeding 30°C within the Arctic Circle itself,” Pappenberger of ECMWF said. This also pushed up temperatures within and adjacent to the Arctic Circle to over 30°C, peaking at 34.9°C in Frosta, Norway. Ironically, low levels of air pollution in Europe allow more solar radiation to reach the surface, leading to a higher rate of warming. The number of cold stress days when temperatures drop below normal is also reducing. Nearly 90% of the continent experienced fewer cold stress days than average, and minimum temperatures remained above average for most of the year. Hot, dry conditions resulted in more wildfires. A record total area of around 1,034,000 hectares was burnt across Europe – an area larger than Cyprus. Spain, Cyprus, the United Kingdom, the Netherlands, and Germany recorded their highest wildfire emissions on record in 2025. Record loss of glacier mass Glaciers across Europe lost mass in 2025, with the highest loss recorded in Iceland. The Greenland Ice Sheet, which is the largest ice mass in the northern hemisphere and covers 80% of Greenland, lost 139 gigatonnes (139 billion tonnes) of ice. This is equivalent to 1.5 times the volume stored in all glaciers in the European Alps. Such ice loss contributes to rising global sea levels, with every centimetre increase exposing an additional six million people to coastal flooding. Overall, snow cover was 31% below average, affecting 1.32 million square kilometres, which is equivalent to the combined area of France, Italy, Germany, Switzerland, and Austria. “The ESOTC 2025 paints a stark picture: the pace of climate change demands more urgent action. With rising temperatures, and widespread wildfires and drought, the evidence is unequivocal; climate change is not a future threat, it is our present reality,” Samantha Burgess, Strategic Lead for Climate at ECMWF said. Rising ocean heat, reducing river flow Nearly 86% of European waters saw strong marine heatwaves in 2025. Oceans absorb 90% of the atmosphere’s excess heat due to the burning of fossil fuels. In 2025, Europe’s sea surface temperature was the highest on record. Around 86% of the region experienced strong marine heatwaves, disrupting fish and the ocean plants. Changes in rainfall and snowfall patterns have also affected the flow in 70% of Europe’s rivers. In May 2025, around half of Europe (53%) was affected by drought conditions. “Maintaining our own state-of-the-art, reliable data records of our Earth system is vital for making informed policy decisions in our rapidly changing climate. Copernicus is pivotal to help us preserve our sovereignty, our environment, food systems, safety, and economy,” said Mauro Facchini, Head of the European Commission’s Copernicus, is the European Union’s Earth Observation Programme. Renewable growth and actionable items for policymakers The share of renewables in Europe’s energy mix has gone up, supported by the growth in solar energy. A silver lining in the report is the growth of renewable energy, which in 2025 supplied nearly half (46.4%) of Europe’s electricity. Solar power contributed around 12.5% of this, a new regional record. Countries have begun to see energy security as a national security issue, and that appears to be one of the reasons driving the growth of renewables, including the adoption of nuclear energy at a higher rate compared to recent decades. Another positive was that by the end of 2025, around half of the European Biodiversity Strategy 2030’s recommended actions were in place or completed. The strategy is a European Union plan to restore the continent’s biodiversity. The report highlighted initiatives like Ireland’s network of marine protected areas, Armenia’s biodiversity finance plan, and Iceland’s funding to assist in recovering wetlands as examples of policy interventions that can help arrest biodiversity loss. Image Credits: Unsplash/Jochen Bückers, WMO. Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Posts navigation Older posts